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“But I don’t want to go among mad people," Alice remarked. 
"Oh, you can’t help that," said the Cat: "we’re all mad here. I’m mad. You’re mad." 
"How do you know I’m mad?" said Alice. 
"You must be," said the Cat, "or you wouldn’t have come here.”  
― Lewis Carroll, Alice in Wonderland 
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 ABSTRACT  
 
Glioblastoma is an aggressive brain cancer with a median survival rate of 14.6 
months post diagnosis. Treatments for glioblastoma include surgery, radiotherapy, and 
chemotherapy with the alkylating agent temozolomide (TMZ). In 50% of patients, TMZ 
treatment is ineffective due to the reparative action of the protein O6- MeG DNA 
methyltransferase (MGMT). The base excision repair (BER) pathway repairs the most 
common lesions caused by TMZ. 
 
This work reports the characterization of several glioblastoma cell lines in terms 
of their repair status and sensitivity to traditional therapy of X-ray irradiation and TMZ. 
We find that the expression of BER proteins differed between cell lines, with alkyladenine-
DNA-glycosylase (AAG) showing the greatest variation in expression. Sensitivity to TMZ 
and X-rays was MGMT dependent. Moreover, our results suggest that cell lines expressing 
higher AAG levels display increased sensitivity to X-rays and TMZ combination treatment 
in an MGMT independent fashion.  
 
Pharmacological inhibition of BER enzymes AP-endonuclease (APE) and 
polymerase  (PolB) was examined, intending to enhance sensitivity of the glioblastoma 
cell lines to TMZ and X-ray or proton treatment. Methoxyamine (MX), an inhibitor of AP-
endonuclease (APE) activity, leads to a modest increase in TMZ sensitivity. The 
combination of X-rays, MX and TMZ sensitised MGMT-negative cell lines, this was not seen 
in proton radiation. PolB inhibition greatly increased TMZ toxicity in conjunction with 
radiation in glioblastoma cell lines.  
 
Proton irradiation systems were analysed and developed within this work, 
leading to a high-throughput broadbeam irradiation system. These methodologies lead to 
differences being detected in response to proton irradiation depending on the method 
used. This might in future, lead to further understanding of low-dose hypersensitivity.   
 
In conclusion, the modulation of BER can enhance glioblastoma sensitivity to 
current treatment modalities, however, this is in an MGMT dependent fashion. These 
studies could provide insight for current clinical trials.  
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1 INTRODUCTION TO 
ACCELERATORS IN MEDICINE 
1.1 Development of cancer 
Cancer can be defined as a disease caused by an uncontrolled division of 
abnormal cells causing a malignant growth or tumour(Hanahan, R. a Weinberg, et al. 
2000). The cause of this unregulated cell division can be multifactorial but one of the 
major causes are from carcinogenic: reagents, chemicals,  and agents which leads to 
mutations in the DNA, to either oncogenes or tumour suppressor genes, which can 
dysregulate the cell cycle pathways and cell death pathways (Hanahan & Weinberg 2011).  
1.2 X-rays, DNA damage and strand breaks 
 X-rays were discovered in 1895 by Roentgen and the therapeutic potential for 
them was quickly realised (Kemp 1998). From the discovery, and the biological 
therapeutic advantages being understood X-rays were first used to treat cancer in America 
by Emil Grubbe in 1896.  
 
There is debate over who invented the X-ray tube and and whether Coolidge or 
Grubbe conducted the first irradiations. X-ray tubes are vacuum tubes that convert 
electrical energy into X-rays, the invention of which is highly debated (Grubbé 1933). The 
tube contains an anode and cathode which the electrons (electron beam) flow between, 
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with X-rays being generated from the electrons bombarding into the anode, normally 
tungsten or copper. This continuous release of X-rays is due to bremsstrahlung.  
 
1.2.1 Types of DNA damage 
X-rays form many different types of DNA damage, these include; double strand 
breaks (DSBs), single strand breaks (SSBs) and crosslinks. A SSB is defined as a break in 
the backbone of the DNA on one side only and the strands have not separated. A cleavage 
on both sides of the DNA, within 10 bas pairs is characterised as a DSB, however the 
strands have not separated. These are often a direct effect of ionising irradiation. However 
Base methylation and crosslinking of bases are often caused by indirect effects; which is 
the creation of reactive oxygen species which then interact and damage the DNA.  
The damage that occurs to DNA during X-ray irradiation repairs at different rates 
depending on the cell type. In rat splenic lymphocytes it is shown that the repair kinetics 
after irradiation with X-rays repair by 80% after 1 hr(Coogan et al. 1992). When human 
peripheral lymphocytes were irradiated with 4 Gy the repair kinetics were similar to rat 
lymphocytes and after 1 hr 80-90% of breaks were repaired (Boerrigter 1991). After 
100 Gy dose of X-rays over 60% of single strand breaks (SSBs) can repair 
in drosophilia (Oliveri et al. 1990).  These show fast repair kinetics, but does take into 
account both double strand breaks (DSBs) and SSBs.   
 
However, other studies have shown that for DSBs in particular that 30 minutes 
after irradiation DSBs are 14 times higher than 24 hours later (Fleckenstein et al. 2011). In 
human lymphocytes, X-rays cause DSB foci of 11.66 foci per Gy per cell (Mandina et al. 
2011).  Different techniques of applying traditional radiotherapy, such as Intensity 
modulated radiotherapy (IMRT) and intensity modulated arc therapy (IMAT) produce a 
different number of DSB foci developing. Foci yields are higher in IMRT that in 
IMAT(Werbrouck et al. 2013).   
 
1.3 Applications of accelerators in medicine 
Since the development of accelerators there have been many other applications 
than just nuclear physics that they have been used for. One use of the utmost importance 
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is in health care. As will be discussed in detail below accelerators are used in medicine for  
many different applications. These include; radioisotope production, imaging and 
radiotherapy treatment. In this chapter we will focus on radiotherapy treatment.  
 
1.4 History of accelerators 
Accelerators were originally developed due to a lacking in understanding in 
nuclear physics. Ernest Rutherford urged the Royal Society in 1927 to develop a source of 
positive particles with higher energies. In 1929, in the Cambridge Cavendish laboratories, 
Cockcroft and Walton built the first accelerator and in 1932 they reported a nuclear 
reaction produced by a particle accelerator (Martins & Silva 2012). The accelerator used 
was an ion accelerating column connected to a voltage multiplying column, which was 
used to accelerate protons to 600 kV. The voltage multiplying circuits used in the design 
by Cockcroft and Walton were originally developed in 1920, they adapted this and it is 
called the Cockcroft-Walton machine (Livingston, 1980). The circuit works by charging 
capacitors in a parallel system and discharging them in series. The circuit used gave a four-
fold voltage multiplication. The Cockcroft-Walton machine design was built all over the 
world, for example the one built in Rome by Amaldi which eventually managed to reach 
1.1 MeV (Amaldi 2012). 
 
1.4.1 Cyclotrons 
A cyclotron works by providing a constant magnetic field, with a set of D-shaped 
electrodes driven by an RF source that alternates the fields constantly. This  in turn speeds 
the particles in a spiralling outward motion. The kinetic energy of the particles can only 
increase when they are between the gaps of the two D shaped magnets/electrodes, the 
radius increases as the particle travels round the accelerator. As the particles accelerate 
their orbit increases as shown in figure 1-1. Lawrence realized that the cyclotron could be 
of use in the production of radioactive isotopes (Amaldi et al. 2010). 
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Figure 1-1 of a cyclotron Taken from (Redfine Knowledge, 2018) 
 
In 1938 a cyclotron was used to treat patients with cancer; the machine was 37 
inches, produced neutrons and was run by Lawrence (Stone et al. 1940). The cyclotron ran 
8 MV deuterons into a beryllium target producing the neutrons. Unfortunately when a 
machine was built which reacted 16 MV deuterons with beryllium, the effect on the 
healthy tissue was so severe that the approach was abandoned (Amaldi et al. 2010).  
Radioisotopes were initially used in diagnostics with iodine  (131I) for imaging 
purposes (Silberstein 2012).  In 2007 there were approximately 250 cyclotrons in use for 
the production of radioisotopes. These radioisotopes include C11, N13, O15 and F18 and are 
regularly used in PET scans (Denker et al. 2007). PET scans work by the radioisotopes 
emitting gamma rays within the body. The radioisotopes accumulate in the target tissue 
due to metabolism and bloody flow. The decay of the radioisotope results in the 
simultaneous release of an electron and gamma ray in opposite directions. Fluorine 18 is 
the most common tracer in oncology.  
 
 
1.4.2 Synchrotrons 
The design of the synchrotron accelerator came after the cyclotron, with the 
beam travelling in a circular motion. However, with a synchrotron the circular size is fixed. 
The magnetic field is applied externally at set points with the magnetic field strength 
increasing, leading to an increase in the acceleration of the particles. An example of a 
synchrotron is the large hadron collider at CERN.   
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Figure 1-2 A synchrotron diagram taken from (Machine Design, 2018) 
The first synchrotrons were built for the purpose of studies in nuclear and 
particle physics. Two synchrotrons were built around the same time, from 1952-1954 
Brookhaven built a 3 GeV synchrotron and Berkeley built a 6 GeV, both had different sized 
magnet apertures (Amaldi 2012).  
 
Synchrotron radiation was also a problem for high speed synchrotrons. 
Synchrotron radiation was first observed in 1946 by John Blewett using a betatron of 100 
MeV. The further uses of this radiation were realised, allowing it to be used for other 
applications in science such as by the Stanford Synchrotron Radiation Laboratory. 
 
Synchrotrons in radiotherapy are used for the production of carbon ions. These 
synchrotrons are roughly 20-25 m diameter. Synchrotrons are also used for proton 
therapy, the size of these synchrotrons is around 6-8 m diameter (Amaldi et al. 2010).  
1.4.3 Linear Accelerators 
In the 1930s klystrons were invented by the Varian brothers which were 
improved upon by Ginzton (Freeman & Morris 2015). The magnetron was invented by 
Randall and Boot at the University of Birmingham (BOOT 1961). Both magnetrons and 
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klystrons are RF cavities, with magnetrons having a broader spectrum. These inventions 
allowed linear accelerators to progress and be RF driven (Martins & Silva 2012).  
 
In 1946, a linear accelerator (LinAcc) was built and tested by Fry at the 
Telecommunications Research Establishment, it was a 45 cm long 0.5 MeV linear 
accelerator. Further construction of these accelerators led to Fry building a 3 m long 
accelerator which reached 6 MeV (Martins & Silva 2012). Fry went on further to develop a 
LinAcc for medical x-ray use which was able to reach 8 MeV. The ministry of health 
decided that 4 MeV LinAccs for radiotherapy would be used. This was designed by 
Howard-Flanders, who developed the gantry in 1949. Ginzton and Kaplan built a medical 
LinAcc at Standford in 1954 which reached 6 MeV and was 1.65 m long (Martins & Silva 
2012).  
 
There are far more electron linear accelerators than proton accelerators, as 
cyclotrons are capable of accelerating protons for a lower price. The cost consideration is 
why many proton therapy centres use cyclotrons over LinAccs. 
 
 
1.5 Hadron therapy 
 
Hadron therapy is a type of radiotherapy involving the acceleration of hadrons 
which are particles formed from quarks, anti-quarks and gluons.  Hadrontherapy has been 
considered as a new approach, however, in 1945 Lawrence and Wilson measured the 
stopping process in protons off the cyclotron in Berkeley and realised the potential it 
would have in therapy (Amaldi et al. 2010). The accelerators used in proton therapy are 
around 3-4 m diameter cyclotrons. Other than the initial findings of a proton beam’s 
stopping distances, hadron therapy has been a new development in radiotherapy. Proton 
therapy was originally used to treat the pituitary gland for breast cancer, with the work 
being conducted at the Berkeley facilities (Amaldi et al. 2010).   
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1.5.1 Proton centres  
Currently there are 33 proton therapy centres in the world, with more currently 
in construction (Anderung 2012). Protons are advantageous to treating tumours due to 
the deposition of the dose within the target area, with a small tail of irradiation exiting the 
target area leading to a lower exit dose and less healthy tissue irradiated.  
 
Proton therapy is further advantageous in comparison to X-ray irradiation due to 
the difference in energy deposition along the path, or track. X-rays deposit high levels of 
energy along the track, lowering the energy deposition the further through material it 
travels, the higher the energy deposition within tissue the higher the direct damage which 
occurs to the DNA due to the irradiation (Jäkel 2008). Direct DNA damage from high 
energy irradiation causes a clustering of damage at the Bragg peak, where the track is 
slowing and releasing the energy. This clustered damage causes a higher proportion of 
DSBs which if the damage is high enough, the cell cannot repair leading to cell death (Hill 
1999). However, as the damage is deposited mainly in the Bragg peak (due to the stopping 
ions and energy deposition) for protons, this level of damage should not occur so greatly 
upon entry of the patient. It has been suggested that the track structure caused by the 
varying levels of linear energy transfer (LET), which is higher for slower moving particles 
like protons, is not a sufficient description of how radiation affects the DNA (Ballarini et al. 
2008).   
 
The relative biological effectiveness (RBE) is a measure for how different types 
and energies of irradiation produce a different biological effect. It is generally seen that the 
higher the LET the higher the RBE (Frankenberg 1994). However, the ion is important too, 
as heavy ions have a wider track structure. Heavy ions have high levels of energy 
deposition clustering in the DNA as well as being able to produce high-energy secondary 
electrons which can travel micrometres away from the main track causing additional 
damage to the DNA (Ballarini et al. 2008). Because of the combined effects of LET and how 
heavy the ion is, the RBE is the best explanation of how much damage a type of irradiation 
causes.   
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1.6 Microbeams  
The first microbeam was set up by Zirkle and Bloom using 2 MeV protons 
produced in a Van Der Graaff accelerator. Microappertures were manually positioned to 
be able to focus the beam to 0.5 µm to 5 mm. The beam was capable of depositing energy 
into the cells upto 2.5 µm. The first experiment looked at mitotic amphibian heart cells 
(Zirkle & Bloom 1953).  This study shows how a microbeam can be used to focus on a 
small area of a cell, even in the 50’s to study the effects of radiation on just that area. 
Microbeam studies are mostly used for 3 reasons; irradiating specific parts of a cell to 
compare cellular response to damage, elucidating the role of Bystander effect, and to 
ensure each cell is irradiated rather than in broadbeam irradiation, where a cell being hit 
is reliant on poisson statistics (Prise et al. 2010). Microbeam studies can now focus on the 
difference in cellular response to radiation to the nucleus compared to the mitochondria, 
where the mitochondria spontaneously bursts and disappears (Walsh et al. 2017), and the 
long term effect of this can be elucidated. Studies looking into the bystander effect are also 
of importance. These studies ask if you miss a tumour cell with the irradiation, or a healthy 
one, can signalling cause the cell to die regardless i.e. does the non-hit cell also undergo 
damage from cellular signalling? (Bonner 2004) 
1.6.1 Surrey Microbeam 
Surrey University is home to the Ion Beam Centre, which hosts a 2 MV Tandetron 
accelerator with 5 beamlines. The accelerator itself is well described by Simon and 
colleagues (Simon et al. 2004), with two beamlines described, the microbeam line and the 
millibeam line, which are currently used for MeV single ion Mass Spectroscopy (SIMs), 
Rutherford backscattering (RBS) and proton induced x-ray emissions (PIXE). The 
scanning capabilities of the microbeam for RBS and PIXE was described and evaluated by 
Merchant for the in air rather than vacuum system (Merchant et al. 2005).  
 
The current system for cell irradiation in place at the university of surrey is a 
scanning vertical microbeam line, where the design was first described by Kirkby and 
colleagues in 2007 (Kirkby et al. 2007). The system was designed to come off of the 
tandem accelerator in a lab 3 stories below and the beam bent at a 90o angle and focussed 
until it exits the beam line into the end-station where cell dishes are available to be 
irradiated. The initial design assumed that ion species ranging from protons and helium as 
well as O, C, N and Ar could be accelerated this distance. Since the conceptual ideas were 
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published, further work was completed on this beamline and cell irradiation systems were 
designed. The beamline is described in detail by Merchant and co-workers, where they 
describe the object and collimator aperture positions and capabilities along the beamline. 
To ensure the correct dose is being given and no extra, a “beam switch” is used to deflect 
the beam and scattered ions and stop further particles from entering the cells (Merchant 
et al. 2009). The beam exits the line via a silicon nitride window and the stage controlling 
the cells can be employed to insert the cells under the beam line remotely. Cells are placed 
on polypropylene and fixed into metal dishes, as described by Jeynes and co-workers 
(Jeynes et al. 2013). The physical limitations of a vertical beam that could be affected by 
ground vibrations were dealt with by using a tripod stand, with sand as an insulator and 
absorber (Merchant et al. 2012). Many of the studies successfully using this beam line look 
into glioblastoma cell lines which are irradiated with both protons and alpha particles 
(Barazzuol et al. 2012). As this system is set up to not only perform broadbeam 
irradiation, but also single cell irradiation, studies using V79 Chinese hamster cells looked 
into survival after irradiation on “broadbeam” or single cell targeting (Prakrajanga et al. 
2013).  
1.7 Dosimetry 
When working with radiation for medical research the units Dosimetric 
parameters of interest are the Gray (Gy) and Sievert (Sv). The absorbed dose is … Sieverts 
are the SI unit of radiation for the biological effect and refers to the effect of a joule of 
energy to the receiver’s mass in kilograms. This is a measurement of stochastic health 
risks from radiation and are generally used in accidental exposure to radiation. This is the 
same for Gy, except it is the absorbed dose, rather than the effect of the dose. Gy are used 
to measure the absorbed dose when treating a patient with radiotherapy in treatment 
settings. 
 
To work out the dose given in Gy from an accelerator, be it a medical device or 
research, Equation 1 Dose rate;   
Dose rate (Gy/s) = 1.6 * 10-9 
L

 
 
Where L is the LET (keV m-1),  is the particle flux (particles per second) and  
is the density of the medium (g cm-3). There are a multitude of ways to measure this 
through simulations for the LET and for particle flux measuring devices include; ionisation 
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chambers, P-N diodes and calorimeters. The vertical microbeam beam tests the 
homogeneity with a scintillator, and beam flux is measured with a PIN diode (silicon p-i-n 
device) before the irradiation of cells (Jeynes et al. 2013). 
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2 GLIOBLASTOMA AND DNA 
REPAIR  
 
2.1 Introduction  
This chapter will focus on the brain cancer glioblastoma and current treatments 
for this devastating disease. This will explore specifically, the damage which is caused to 
the cancer cell by the treatments and the way the cells repair this damage. There will be a 
particular focus on the DNA repair pathway base excision repair (BER), and how BER has 
been manipulated in current studies, as well as discussing drugs/inhibitors to modulate 
BER which are being tested as potential therapeutic tools in cancer treatment.  
2.2 Glioblastoma 
Glioblastoma multiforme is the most common form of brain cancer. The 
prognosis is poor with a 2 year survival rate of 7.7% as found by recent studies (Ahmadloo 
et al. 2013). Survival rates in the elderly are far more pessimistic with median survival 
being approximately 4-5 months (Scott et al. 2012). Recurrent glioblastoma has a median 
survival rate between 3-6 months (Vredenburgh et al. 2007). Surgical resection of this 
tumour is difficult due to its infiltrative nature and therefore the damage which could 
occur due to possible neural damage (Louis et al. 2007).  
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2.2.1 Glioblastoma Morphology 
Glioblastoma is a brain cancer originating in glial cells; oligodendrocytes or 
astrocytes. Glioblastoma is most commonly found in men with a ratio of 3:2, male to 
female occurrence, from the ages of 40-70 years old (Jellinger 1978). It can occur 
anywhere within the CNS, but is most commonly found in the frontal and temporal lobes 
(Jellinger 1978). Glioblastomas can be primary or secondary by either developing 
spontaneously into a glioblastoma or from a recurring form of glioma tumour.  
 
The hallmarks of cancer were defined by Hanahan and Weinberg who laid out 6 
and then 11 traits common in all cancers (Hanahan, R. A. Weinberg, et al. 2000; Hanahan & 
Weinberg 2011). These include; evasion of apoptosis and cell death, self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potential and sustained angiogenesis. In glioblastoma, tumours go 
through substantial angiogenesis, keeping the tumours with a high oxygen and nutrient 
supply. Ring growth structures are visualised in neuroimaging of glioblastoma due to 
heavy angiogenesis and distortion of the vasculature. Necrotic pseudopalisades are 
associated with an increase in micro vascularisation and are signs for a poor prognosis. 
The formation of pseudopalisades with microvasculature in glomeruloid appearance, 
signal a high growth phase within the tumour formation (Whittle et al. 2010). The 
pseudopalisades are often linked to high levels of necrosis (Jellinger 1978). The cells 
regularly have ill-defined cytoplasm and there are many mitotic figures (Jellinger 1978). 
The vasculature cells around the tumour tissues have sometimes been found to have 
higher levels of mitochondria than the cells in the blood vessels in normal areas 
(Coomberl et al. 1987). They also found that the junctions between cells in the 
interendothelial layer of the vasculature around some tumours were wide and distorted 
(Coomberl et al. 1987).  
2.2.2 Glioblastoma Subtypes 
As shown in one small case study of patients, the genetics of the DNA defects are 
very diverse for different patients and so treatment is hard to personalise (Hassler et al. 
2006). Glioblastoma Multiforme have a number of subgroup divisions. These subgroups 
are proneural, mesenchymal, classical and neural, as identified by Pal (Pal et al. 2014). 
Proneural group occurred in much younger patients than the other groups and survived 
the longest, however, treatment saw no benefit to the survival rates. In the group 
Chapter 2: Glioblastoma and DNA repair 
Natalie Mayhead - August 2018   13 
Proneural, it was found that the tp53 gene is a tumour suppressor protein which has roles 
in activating DNA repair proteins, cell cycle and apoptosis (Romano et al. 2016).  
Proneural glioblastoma also regularly have mutations in other genes such as: IDH1, 
isocitrate dehydrogenase, changes the function of enzymes in the KREBs cycle to produce 
a mutogenic chemical which binds to the DNA and leads to abnormal cell growth (Cohen et 
al. 2013) and platelet derived growth factor receptor A (PDGFRA) which also leads to 
uncontrolled growth and invasion when heavily mutated(Pathania et al. 2017).   
 
The mesenchymal group responded well to aggressive treatment. Mesenchymal 
glioblastoma had mutations in phosphatase and tensin homolog (PTEN), 
neurofibromatosis type 1(NF1) and TP53. PTEN is a tumour suppressor gene which 
catalyses the dephosphorylation of the 3’ phosphate on the inositol ring in PIP3 during 
signal cascades, for example in cell cycle (Chu & Tarnawski 2004). NF1 regulates cell 
proliferation, differentiation, survival and growth through a signalling pathway common 
to them all (Helfferich et al. 2016).  
 
Classical glioblastoma group of patients respond well to aggressive treatment 
and survive the longest due to the treatment given. Classical glioblastoma has high 
expression levels of EGFR which is a growth factor receptor, which leads to increased cell 
growth.  
 
Neural glioblastoma was categorised as expressing gene types found on normal, 
noncancerous neurons. This type of glioblastoma was seen more commonly in the older 
patients and were found to respond well to treatments (Pal et al. 2014).  These gene 
mutations show how the cancers hide from the immune system by disguising as neurons, 
neural type, or lead to excessive cell growth and proliferation.   
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Glioblastoma 
subtype 
Gene 
regulation changes 
Cellular 
advantage 
Effect of 
treatment 
Proneural p53, IDH1, 
PDGFRA 
removal 
of cell cycle 
checks and 
inhibition to 
apoptosis, 
increased 
abnormal cell 
growth and 
increased 
invasion 
No benefit 
from treatment. 
Mesenchymal PTEN, NF1, 
TP53 
increase
d signalling to 
pass through the 
cell cycle, 
increased cell 
proliferation and 
differentiation, 
resistance to 
apoptosis 
Responsive 
Classical EGFR cell 
growth increased 
Responsive 
and longest survival 
Neural  NEFL, 
GABRA1 
Neuron 
projection and 
filaments and 
GABA receptor 
(inhibitory 
signalling 
receptor) 
Responsive
  
Table 1 A summary of gene expression changes in subtypes of glioblastoma 
(Verhaak et al., 2010). 
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2.2.3 Glioblastoma treatment 
Although the morphology and the subtypes for glioblastoma is diverse a standard 
treatment regime is used. As can be expected the survival rate varies depending on patient 
age and treatment regimens (Stupp et al. 2005a). The standard treatment regimen as 
outlined by Stupp for glioblastoma includes surgery, radiotherapy and temozolomide 
(TMZ). The dose of radiotherapy traditionally used is 60 Gy administered in fractions of 2 
Gy per day, 5 days per week, delivered by a linear accelerator (LinAcc). TMZ is 
concomitantly administered over a 4-week period at a dose of 200 mg/m2 orally for 5 days 
(Stupp et al. 2001). Concomitant therapy such as this has increased the median survival 
rate from 12.1 months to 14.6 months (Stupp et al. 2005a)(Stupp et al. 2005b). 
 
As the survival rate is still so low, different radiotherapy fractionation regimens 
have been examined, including an increase in the daily radiotherapy dose, or a reduction 
in the dosage per irradiation event whilst increasing the number of daily irradiation 
events administered (Balducci et al. 2014; Miwa et al. 2014; Kulshrestha et al. 2008). 
Neither of these made a significant difference to survival rates. It is of great importance to 
elucidate the best treatment delivery schedule for radiotherapy. This can be done via in 
silico, in vitro, in vivo or using epidemiological studies.  
 
The majority of glioblastomas are treated with radiotherapy, for elderly patients 
trials involving radiotherapy, in comparison to resection alone, showed an increase in 
median survival by approximately 3.6 months (Arvold & Reardon 2014). However, few 
patients, about 30%, get the full prescribed dose often due to patients poor compliance 
(Ahmadloo et al. 2013). Small studies just looking at curative rates from radiotherapy 
show that median survival rates are 12 months  (Lin et al. 2003). Temozolomide with 
radiotherapy provides the most effective care. Temozolomide alone in elderly patients has 
been shown to increase median survival from 3 months to 6.3 months (Gállego Pérez-
Larraya et al. 2011). 
 
Treatment with TMZ has also been extensively investigated as some patients 
show resistance to the cytotoxic effects of this chemotherapeutic. It has been shown that 
resistance to TMZ is due to the expression of the DNA repair protein O6-methylguanine-
DNA methyltransferase (MGMT) in some patients. MGMT repairs O6-methylguanine (O6-
MeG), a toxic lesion caused by TMZ within the DNA, therefore preventing apoptosis from 
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occurring (Explained further in section: 2.4.3). Due to this resistance it is imperative to 
manipulate the treatment plan, personalising the medicine for these patients. This has 
been suggested to be brought into hospitals in some countries (Wick & Platten 2014; 
McNamara et al. 2013).  
 
2.3 The effects of radiation 
2.3.1 The importance of RBE and LET 
As cancers are currently being treated with different types of radiation to shrink 
the tumour mass it is useful to compare the different effects these radiation types have on 
the cells and specifically the DNA. Radiation types can be compared by looking at the 
linear energy transfer (LET). LET, as a rule of thumb, increases as the particle increases in 
atomic number. The LET deﬁnes the average energy locally imparted to the medium by a 
particle traversing a given distance (unit, keV/µm). The path that the particle travels is 
known as the track and the track structure is compared for different types of radiation and 
their energies (Hill 1999).  
 
When treating patients with X-rays and protons the energy with which the 
particles are directed towards the tumour changes depending on how much material the 
particles have to travel through before hitting the tumour. In traditional X-ray therapy the 
treatment plan is often designed so the X-rays travel through the body at a multitude of 
angles to intersect and give a greater dose at the tumour and to minimise damage to the 
surrounding healthy tissue (Saunders 1985). This is important for X-rays as the energy 
deposition for X-rays is at its greatest within the first few cm of tissue, this then drops 
exponentially as it travels through, causing lower amounts of damage to the cell and 
specifically the DNA the further the X-ray travels (Saunders 1985). However, protons 
travel through material differently. A proton beam releases lower amounts of energy 
whilst travelling fast through material, however, as it slows, greater amounts of ionising 
energy are released in the material; this is seen as a sharp peak in energy deposition 
curves. This characteristic shape is known as the Bragg peak (Amaldi et al. 2010).  
 
The LET, although very informative for the quality of the radiation, does not 
describe the biological effects of radiation (Waligórski et al. 2004). Particle therapy has 
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been shown to have a great biological effectiveness in comparison to traditional photon, X-
ray, therapy. This change, due to the LET, has been termed the relative biological 
effectiveness (RBE). The RBE is defined as the ratio of absorbed dose of a reference 
radiation over the dose of a radiation under test to produce the same biological effect.  
 
Although increasing LET is seen to give a higher RBE due to the deposition of 
energy, there is a point, 100 KeV/µM, where the increase in LET no longer affects the RBE 
as the energy deposited cannot cause any greater damage due to the intervals in which the 
energy is deposited is smaller than the size of the DNA and so a waste of energy 
expenditure (Paganetti et al. 2002).  
 
2.3.2 The case for proton therapy 
According to WHO 7.6 million people died of cancer in 2008 (World health 
organisation 2013). With statistics like this the importance of accelerators in medicine is 
understandable. Accelerators are used for radiotherapy which over 50% of cancer 
patients undergo (Delaney & Barton 2015; Barton et al. 2014). Linear accelerators are 
currently the standard for UK hospital radiotherapy, however, microtrons can be used also 
to provide x-rays and electrons(Amaldi 2012; Miwa et al. 2014). The x-rays are formed 
from an electron beam due to Bremsstrahlung, which is the production of a photon when 
an electron loses energy, as the electrons hit a heavy metal target. The accelerators used 
are often around 5-30 MeV capable accelerators with around 5000 in use around the 
world (Cleary et al. 2015). Other than the initial findings of proton beam’s stopping 
distances, hadron therapy has been a relatively new development in radiotherapy. Proton 
therapy was originally used to treat the pituitary gland for breast cancer, with the work 
being conducted at the Berkeley facilities (Amaldi et al. 2010).  
 
The advantage of a proton beams is that  far less energy is released until it 
reaches the target area, unlike x-rays as can be seen in Figure 2-1. This means that the 
tissue in front of the tumour has a lower amount of radiation deposited there and only the 
tumour is affected by the damage of the protons(McDonald & Fitzek 2010). In traditional 
radiotherapy, x-ray energy is deposited along the tissue until the wave stops, as the energy 
released through the tissue is similarly high until it comes to a stop, damage to healthy 
tissue occurs which can increase side effects such as secondary cancers. Where the proton 
beam stops is called the Bragg peak, as shown in Figure 2-1, this Bragg peak occurs due to 
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coulomb interactions within the target tissue (Liauw et al. 2013). The coulomb interaction 
causes the proton beam to slow down, as it does so more energy can be imparted to the 
atoms surrounding it, increasing the radiation which is why proton beams impart the 
majority of their energy at the target tissue.  
 
Figure 2-1 Spread-out Bragg peak a) it can be seen that x-rays start to move 
through tissue with a higher energy that decreases as it reaches the target depth. However, 
proton beams have a Bragg peak that shows an increase in radiation dose/energy at the target 
depth, where the wave stops. In b) it can be seen that due to the lower radiation through the 
tissue and the Bragg peak seen at the target where the wave ends less radiation is seen in the 
healthy tissue past the tumour.  
2.3.3 Types of damage caused by radiation  
 
Traditional X-ray photons cause more single strand breaks (SSBs) than double 
strand breaks (DSBs) by direct and indirect interaction with the DNA within the cell. 
Indirect actions are mainly due to the formation of free radicals which damage the DNA 
(Yokoya et al. 2008). Direct mechanisms of DNA damage have been linked to the photo-
electric effect, where electrons are produced within the cell along the track structure 
releasing energy onto the bonds of the DNA, breaking them and causing damage (Roots & 
Okada 1975). Further damage by radiation can be caused by the production of free 
radicals which can proteins proteins and other molecules, binding them to atoms on the 
DNA damaging either the sugar, base or phosphate backbone(Azzam et al. 2012). The 
amount of DSBs, which are more toxic than SSBs, formed from radiation depends on the 
cell type and nucleus size (Wéra et al. 2014). DSBs can be visualised and measured 
through an assay which binds to the DNA at H2AX histone which is phosphorylated at the 
site of damage (Yokoya et al. 2008), this is explained further later in this chapter. It has 
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been shown that as the level of LET increases the efficiency of SSB induction lowers (Jäkel 
2008). It has however also been shown that with higher LET the rate of SSB repair is 
decreased in CHO cells (Olive & Banáth 1993). DSB formation has been measured to 
increase linearly with dose. DSB formation is lower than the formation of SSBs by a factor 
of 25 (Frankenberg 1994). Unlike SSBs, DSBs increase with increasing LET. Different 
studies report different amounts for the number of DSBs that are formed per Gy. Studies 
using the γ-H2AX assay show that between 11.6 and 14.7 foci form per Gy (Rogakou 1998; 
Redon et al. 2012; Mandina et al. 2011). This can be the difference of LET as well as 
limitations of the methodology to analyse DSBs. 
 
2.3.4 Double strand break signalling 
 
Histones play a crucial role in DNA structure, allowing the DNA to be super coiled 
or unwound. DNA is ravelled 1.7 times around the histone core, which is made up of 8 
histones, repeating histone H2A, H2B, H3 and H4, this forms the nucleosome (Suto et al. 
2003). The DNA is further compacted by a linker histone which compresses the 
nucleosome, this histone is H1.  
 
There are 10 genes that code for the human H2A histones. The histone H2AX 
makes up 2-25% of the total H2A histones in the nucleosome (Fernandez-Capetillo et al. 
2004).  H2AX is considered a minor variant of the H2A histones due to the rarity of this 
polypeptide and it was discovered in the 1980s (Musgrave et al. 1991). Where H2AX 
differs from other histones in the H2A family is on the COOH- tail which becomes rapidly 
phosphorylated on Ser 139 upon DNA damage (Rogakou 1998), this post translational 
modification is highly conserved from yeast to humans (Redon et al. 2002).  
 
H2AX has an important role in DNA repair signalling; DNA damage triggers a 
signalling cascade known as the DNA damage response (DDR) (Paull et al. 2000). The 
kinase family involved in the DDR is the phosphatidylinositol-3-kinase (PIKK) family of 
kinases, composed of ataxia telangiectasia mutated (ATM), ATM and Rad3-related (ATR), 
ATM related kinase (ATX) and DNA dependent protein kinase (DNA-PK), all being 
important during DNA damage signalling(Golding et al. 2012; Srivastava et al. 2009; 
Schultz et al. 2000; Burma et al. 2001; Riballo et al. 2004). It has been shown that H2AX is 
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phosphorylated by ATM after DSB (Burma et al. 2001) whereas ATR phosphorylates H2AX 
after a single strand break and during replication stress, DNA-PK phosphorylates H2AX 
when DNA fragments during apoptosis (Srivastava et al. 2009).  
 
The γ-H2AX foci disappears as the repair pathways take place. The disappearance 
occurs as the H2AX histones becomes dephosphorylated by protein phosphatase-2A 
(Svetlova et al. 2010) and the nucleosome becomes reassembled (Suto et al. 2003). This 
gives a good representation of the repair kinetics within a cell after DSBs have occurred.  
As γ-H2AX foci appear at 1:1 at DSB locations, the foci start to appear a few seconds after 
damage but it can take up to 1 hour for foci to be fully visualised using 
immunohistochemistry (Hall 1985).  
 
2.3.5 Repair pathways involved in radiation damage  
There are two well recognised repair pathways which are of specific interest to 
radiotherapy, due to the importance of DSBs formed by radiotherapy; these pathways are 
non-homologous end joining (NHEJ) and homologous recombination (HR) (Kavanagh et 
al. 2013). These repair pathways are shown in Figure 2-2 and Figure 2-3. It has been 
shown that H2AX has a role in modulating non-homologous end joining (NHEJ) and 
homologous recombination (HR), although H2AX is not essential for these processes to 
occur (Petersen et al. 2001).  The DSB is recognised by a complex of proteins known as 
MRN. MRN complex involves MRE11 , RAD50 and Nijmegen breakage syndrome 1 (NBS1) 
proteins (Lavin 2007). It has been noted that depending on the phase of the cell cycle 
NHEJ or HR may or may not be used. HR is predominantly used to repair DSB damage 
during S and G2 phase(Allen et al. 2003; Aymard et al. 2014).   
 
The major form of DSB repair can be utilised throughout all phases of the cell 
cycle. Non-homologous end joining is initiated when a heterodimer, formed by Ku70 and 
Ku80, bind to either end of the breakage site(Iyama & Wilson 2013). This binding recruits 
the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and the resulting protein 
complex at the breakage site allows the strands to stabilise and align.  Once the DNA is 
aligned and stable the DNA-PKcs autophosphorylates and dissociates from the complex, 
starting a signalling cascade which recruits the endonuclease artemis(Weterings & van 
Gent 2004). Artemis trims the 3’ and 5’ ends of the break creating an overhang to help 
Chapter 2: Glioblastoma and DNA repair 
Natalie Mayhead - August 2018   21 
ligate the ends. PNKP and XRCC4-ligase IV remove phosphate groups attached to the 
overhangs before ligation takes place. DNA polymerases fill in any gaps that are missing in 
the homology of the overhangs, the DSB is ligated back together when XLF complexes with 
XRCC4-ligase IV and the DNA is sown back up (Iyama & Wilson 2013).  
 
Figure 2-2 Non-homologous End Joining double strand break repair, low accuracy 
as joins two damaged ends together, without checking they match. taken from (Mladenov & 
Iliakis 2011) 
 
Homologous recombination is utilised by the cell to repair DSBs during S and G2 
phases of the cell cycle. Homologous recombination is an efficient repair mechanism as it 
employs the sister chromatid to accurately repair the lesion. The DSB is recognised by a 
complex of proteins known as MRN. MRN complex involves MREII , RAD50 and Nijmegan 
breakage syndrome 1 (NBS1) proteins (Lavin 2007). MRE11 is the main catalytic 
component of this complex and acts as a sensor, as mentioned above, this complex also 
signals for protein kinase activation phosphorylating  ATM at the site of the DSB (Lavin 
2008; Iyama & Wilson 2013), and can act as a exo- and endomuclease (Dudás & Chovanec 
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2004).  Single strand DNA (ssDNA) is created from 5’-3’ DNA end trimming by C-terminal 
binding protein-interacting protein (CtIP) and MRN when they associate (Sartori et al. 
2008). During this step further trimming occurs due to exonucleases.  
 
The next steps in HR is stabilisation of the ssDNA and signalling for checkpoint 
response. These steps are initiated by the binding of RPA stabilising the DNA and 
signalling for ATR and ATR-interacting protein to create the signal. BRCA2 promotes the 
replacement of RPA with RAD51. RAD51 is an essential part of the DSB repair as RAD51 
filaments (from five RAD51 types) search for homology and strand invasion (Karpenshif & 
Bernstein 2012). Homologous recombination, after DNA stabilisation, forms a D-loop of 
DNA which is formed from the DNA being extended by polymerases. This D-loop is formed 
from the RAD51 filaments seeking homologous sequence with the ssDNA overhang 
invading the homologous double stranded DNA displacing the DNA and allowing the 
damaged DNA to be repaired correctly (Karpenshif & Bernstein 2012).  
 
After the formation of the D-loop, homologous repair has two mechanisms that it 
can use to repair the DSB. A Holliday junction can be formed, or alternatively synthesis-
dependent strand annealing (SDSA). A Holliday junction is formed when the second end of 
the damaged DNA is captured within the D-loop. This complex requires DNA nucleases 
and DNA helicases to be resolved. In SDSA the DNA is displaced and re-annealed to the 
other broken chromosome.  
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Figure 2-3 Homologous Recombination. Double strand break repair using the sister 
chromatid to ensure highly accurate repair. Taken from (Mladenov & Iliakis 2011) 
 
Radiation damage is also recognised by poly(ADP-ribose) polymerase 1 (PARP1) 
which ribosylates ATM to activate ATM in remodelling the chromatin (Haince et al. 2007). 
In human lymphoblasts PARP inhibition has been demonstrated to delay repair of DSBs 
(Haince et al. 2007). PARP is important in the recognition of breaks where alternative end-
joining can be employed as a repair mechanism by the cell. PARP1 recognises the broken 
ends of the DNA in alternative end joining and through ribosylation can recruit ligase 3 to 
rejoin the breaks(Thompson 2012; Simsek, Brunet, et al. 2011). It has been shown that 
during this process the breaks are treated as single strand breaks during repair (Metzger 
et al. 2013). This can then lead on to late BER which involves DNA ligase 3 and XRCC1 to 
repair the nick in the DNA(Audebert et al. 2004). With this pathway, alternative end-
joining is not as well studied as HR and NHEJ, however, it is vital to understand for this 
study. 
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2.4 Temozolomide and the DNA 
2.4.1 Alkylating agents 
Alkylating agents are chemicals that react with biological molecules transferring 
an alkyl group. Alkylating agents can react with O- and N- groups on DNA bases which can 
disrupt the cell cycle due to the adducts caused (Kondo et al. 2010). There are different 
types of alkylating agents which describes the chemical structure and how it reacts with 
the DNA. There can be mono- and bifunctional alkylating reagents, which are named after 
how many reactive sites the alkylating agent has this can account for how many lesions 
will occur. Bi-functional alkylating agents can bind across the DNA and cause cross links 
(Fu, J. a. Calvo, et al. 2012). Alkylating agents can also have different types of nucleophilic 
substitution, this is denoted as either SN1 or SN2. SN2 alkylating reagents mainly interact 
with the nitrogen in a carbon ring. However, the SN1 reacts with not only the nitrogen in 
the ring, but also extra cyclic oxygen atoms. As alkylating agents interfere with the DNA 
they can be mutagenic, but, they can also be used as chemotherapeutics as they can put 
cells into cell cycle arrest (Wyatt & Pittman 2006).   
2.4.2 Temozolomide discovery 
Temozolomide (TMZ) is a derivate from imidiazotetrazinone and is pro-
drug which is converted to the active metabolite 5-(3-methyl)1-triazen-1-yl-
imidazole- 4-carboxamide (MTIC) (Denny et al. 1994).  Studies showed that 
temozolomide has good bioavailability after oral consumption to all tissues, 
including the brain (Newlands et al. 1992). The good bioavailability can be 
explained due to the chemical properties of TMZ.  TMZ is stable in acidic pH but 
becomes unstable from neutral to basic pH. This change in pH is what allows the 
drug to be taken orally and become active in the body, due to the change in pH 
from the stomach to other areas once absorbed. Conversely MTIC degrades into 
the reactive methyl agent in a pH which is more acidic than basic. This difference 
in stability and reactivity allows TMZ to not be destroyed by stomach acid, but only 
have a small window of reaction due to the pH changes (Newlands et al. 1997).  
 
It has been shown that TMZ targets specific areas of the DNA. This 
unstable methylating agent is a major-groove methylating agent which reacts with 
the DNA in a base selective manor choosing the central guanine in a GGG 
sequence(Denny et al. 1994; Newlands et al. 1992). The methyl adducts occur here 
Chapter 2: Glioblastoma and DNA repair 
Natalie Mayhead - August 2018   25 
due to being the most electron dense area of DNA, which correlates to being the 
most basic. TMZ is a monofunctional alkylating agent, so does not cause cross links 
(Newlands et al. 1997). But it is an SN1 alkylating agent and the methyl adducts 
occur on the N7 atoms on guanine (70%), N3 on adenine (9.2%), and O6 on guanine 
(5%) (Chakravarti et al. 1991) as these functional groups are more accessible in 
the DNA’s major groove (Newlands et al. 1997).  
 
Phase I and II studies run by Cancer Research Campaign showed that 
intravenous administration of TMZ had little effect whilst oral consumption gave 
good bioavailability at a dose of 200 mg/m2 (Newlands et al. 1992). However, in 
practice the first dose is given at 150 mg/m2 and if no toxicity through 
myelosuppresion is noted then the dose is increased to 200 mg/m2. The toxicity of 
TMZ is evident in the myelosuprression with a nadir on the 22nd day of the 4 week 
cycle and through sickness and nausea. In in vitro studies it has been shown that 
TMZ has a half life of 1.24 hours in phosphate buffer solution (Newlands et al. 
1997).  
 
2.4.3 Repair of lesions caused by temozolomide 
The most toxic TMZ-induced lesion, as mentioned above, is the O6-MeG lesion. 
This lesion is the most toxic because it can lead to apoptosis induction(Newlands et al. 
1992; Happold et al. 2012). In order to understand how the unrepaired O6-MeG lesion 
leads to apoptosis induction, one needs to understand the DNA repair pathway mismatch 
repair (MMR) (Liu et al. 1999). MMR initiates by the recognition of a mismatched base and 
the pathway can be seen in Figure 2-4.  The lesion is recognised by the mismatch repair 
(MMR) proteins in a heterodimeric complex; MSH2 with either MSH6 for MutSα 
(Drummond et al. 1995) or MSH3 for MutSβ. MutSα recognises base-base mismatches and 
insertion-deletion loops, therefore is the important complex for recognition of O6-MeG. 
The MutSα complex recognises that due to the methylation of guanine it can no longer 
provide 3 hydrogen bonds, but 2, and so should not be paired with cytosine. MutSα protein 
recognises the mismatch pair due to a contortion in the DNA and Van der Waal forces 
(Lamers et al. 2000). PCNA interacts with MSH2 to aide in DNA mispairing recognition 
(Lau & Kolodner 2003). EXO1 further interacts with MSH2, but to aid in excising the DNA 
in the 5'position (Zhang et al. 2005). RPA protects the gap in the DNA whilst polymerase 
delta is recruited to fill the gap with the correct base. The DNA is then ligated and sealed.  
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However, MMR proteins recognise that modified guanine should not be paired to 
thymine and recruit polymerases to the site for replacement of the mismatch with the 
correct base, cytosine. This cytosine is then replaced with thymine resulting in a futile 
mismatch repair loop leading to multiple breaks in the DNA strands and MutSα, part of the 
MMR pathway, signals for apoptosis (Hickman & Samson 1999). 
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Figure 2-4 Mismtach Repair pathway repair of incorrect DNA base matching 
preventing point mutations. Taken from (Jiricny 2006) 
 
2.4.3.1 Base excision Repair  
The additional lesions caused by TMZ are repaired by the base excision repair 
pathway (BER), shown in Figure 2-5. There is long patch BER (lp BER) or short patch BER 
(sp BER) which refers to the number of bases which need to be cleaved and replaced; sp 
BER refers to one base alone, but lp BER is when more than one nucleotide needs to be 
removed (Larsen et al. 2007). TMZ induced DNA damage is recognised by the enzyme 
alkyladenine-DNA-glycosylase (AAG) which is an initial enzyme in the BER cascade (Fishel 
et al. 2007; Zhang et al. 2012). AAG removes the lesions by rotating and cleaving the base 
leaving an apurinic/apyrimidinic (AP) site (Lau et al. 2000). This AP site is then 
hydrolysed at the phosphodiester backbone by an AP endonuclease which generates DNA 
ends as a 3’OH and a 5’ deoxyribose-5-phosphate (5’dRP) (Masuda et al. 1998). The 5’dRP 
is removed by the lyase activity of DNA polymerase β which also then replaces the missing 
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nucleotide (Sobol et al. 1996). DNA ligase I or III then ligates the new nucleotide leaving 
the DNA fully repaired.  
 
Each intermediate step in BER can cause cytotoxic effects if left unrepaired so the 
enzymes have to be in close proximity to each other once the repair has been initiated (Fu, 
J. a. Calvo, et al. 2012). Studies on a scaffolding protein known as X-ray repair cross-
complementing protein-1 (XRCC1) have shown that each enzyme in BER can bind to 
XRCC1, increasing their activity (Dianova et al. 2004)  and keeping them in close proximity 
to lower the risk of interrupting the repair pathway (Mutamba et al. 2011). PARP is also 
important in BER as it acts as a sensor for SSBs, this makes PARP important also for 
radiation damage. PARP1 PARylates proteins and histones to signal a damaged site which 
allows the DNA to uncoil and the repair proteins are brought to the SSB (Campalans et al. 
2013).  
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Figure 2-5 DNA damage repair pathways initialised by temozolomide damage. 
O
6
MeG adducts are repaired by MGMT if the protein is present, Otherwise mismatch repair 
is utilised. Base excision repair repairs the other adducts formed by TMZ.   
2.4.4 Limiting factors for efficacy of temozolomide 
Temozolomide is not effective for all patients. As previously stated, the most toxic 
lesion is O6-MeG which can be removed by the protein MGMT. The repair mechanism 
works by the O6-MeG being transferred into the active site of MGMT where it interacts 
with cysteine 145, repairing the base and inactivating MGMT. Methylated MGMT is then 
flipped out of the DNA via the substrate bound minor groove, this releases MGMT so that it 
can be ubiquitinated and degraded via the proteasome (Srivenugopal et al. 1996). This 
reduces the cytotoxicity of TMZ and therefore can lead to resistance in some patients.  
 
MGMT expression varies throughout different tissues and is controlled through 
epigenetic modification; the methylation of the promoter region of the gene transcribing 
MGMT. The MGMT gene is located on chromosome 10, 10q26. The promoter region can be 
hypermethylated at the CpG islands specifically on the cytosine and this inhibits the 
binding of transcription factors (Baylin et al. 2001). It has been shown that between 45-
70% of high grade glioblastoma patients have the MGMT promoter methylated (Zhang et 
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al. 2012) which conveys sensitivity to TMZ. This resistance needs to be addressed, as well 
as the efficiency of GBM treatment, perhaps by manipulating other repair pathways.  
2.4.4.1 AAG 
Human alkyladenine DNA glycosylase (AAG) is a glycosylase within the BER 
repair pathway, which as described above, is one of the first enzymes within this pathway 
(Engelward et al. 1997). AAG is also known as methylpurine DNA glycosylase (MPG) and 
alkylpurine-N-DNA-glycosylase (APNG), these names are associated with the adducts 
which the glycosylase recognise. AAG can excise many lesions; N3-MeA, N7-MeG, 1,N6- ethA 
(εA), 2,N3-ethG and hypoxanthine, but with different efficiencies.  
 
Figure 2-6 AAG. AAG 3-Dimensional structure and it’s interaction with DNA 
(Rubinson et al. 2016) 
The ease with which AAG can remove the lesions differs depending on placement 
and specificity.  For example hypoxanthine opposite thymine is removed faster than if 
opposite cytosine (Asaeda et al. 2000). Whereas, more specifically for adducts which are 
caused by SN1 alkylating agents, N7-MeG is removed 100 fold less efficiently than N3-MeA 
(Miao et al. 1998). Lau showed that once AAG has recognised its specific substrates, a Tyr-
162 side chain of the protein is β-hairpin inserts into the minor groove of the DNA which 
slips the nucleotide into the enzymes active site (Lau et al. 2000).   
 
The active site of AAG has been shown to be inhibited by magnesium (Lau et al. 
2000). Some studies have looked at the repair kinetics of AAG for certain substrates have 
shown that they are consistent throughout the first 24 hours for the base removal of N7-
MeG, with a half-life of 18 hours. But this study also showed that if AAG is knocked out 
then other enzymes will repair the lesions which AAG normally repairs, however the 
repair is at a slower rate (Smith & Engelward 2000). 
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 AAG has been shown to be brought to the site of damage by methylated DNA-
binding domain 1 (MBD1) which then represses transcription of the damaged gene by 
associating with the promoter of the gene. It was further shown that after alkylation 
damage by MMS this transcription repressing complex would be present on the damaged 
promoter, but MBD1 would dissociate after 3 hours, presumably for damage repair to 
ensue by AAG (Watanabe et al. 2003).  
 
2.4.4.2 AAG and BER 
The potential importance of AAG in the repair of TMZ lesions has been well 
acknowledged and hence studied. A study where AAG was overexpressed in breast cancer 
cell lines and subsequently treated with TMZ and a BER inhibitor, methoxyamine found 
that sensitivity to TMZ occurred when AAG was overexpressed by 4.8 fold (Rinne et al. 
2004). However, the concentrations of TMZ used are not comparable to the concentration 
of drug found at the tumour site as (Ostermann et al. 2004) found that the concentration 
at the tumour site should be approximately 25-50 µM not 2 mM or more as used in this 
study (Rinne et al. 2004). Another study demonstrated that the overexpression of AAG in 
GBM caused a slight increase in sensitivity to TMZ; this effect was also potentiated by a 
BER inhibitor methoxyamine (MX), concluding high levels of AAG coupled with BER 
interruption can increase the efficacy of temozolomide through DNA glycosylation (Tang 
et al. 2011). Conflicting evidence for the role of AAG has also been elucidated in cells over 
expressing AAG as an increase in resistance to TMZ was found (Agnihotri et al. 2012). 
These studies bring into question the role of AAG expression.   
 
These conflicting results can be hard to explain further in terms of AAG 
expression within GBM patients. It has been shown in many patient based experiments 
that the overexpression of AAG is related to the increasing grade of GBM and can be 
related to poor treatment outcome (Liu et al. 2012). Therefore, it may not be the 
expression levels of AAG which should be manipulated to enhance TMZ sensitivity if AAG 
is high in all GBM tumours.  
 
The effects of BER and MGMT as well as the effects of the inhibitors can be 
summarised in Figure 2-5. It is also necessary to remember the importance of the DSB 
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repair pathways for this study. Cell survival may also be decreased if DSB pathways are 
imbalanced for cell lines with certain repair protein expression profiles.  
 
2.5 Synthetic Lethality 
Synthetic lethality is when two genes, which normally do not lead to embryonic 
lethality when knocked out, do lead to lethality when combined. This can include genetic 
variations leading to lethality when combined. This was first described by Calvin Bridges 
(1922 the origin of variation) and then termed by Theodore Dobzhansky when working 
on Drosophilia (1946). In cancer cell development often DNA damage response and repair 
enzymes become silenced, increasing the viability of the cancer cell as well as genomic 
instability (Hanahan and Weinberg 2011).  PARP inhibitors have been found to be more 
effective in cancer cells with BRCA defects (Bryant 2005 and Turner et al 2004). This 
shows that inhibitors and genetic variation can be used together to increase toxicity in 
cancer cells. This is favourable to a combination of 2 inhibitors as it may be less selective 
to cancer cells. 
 
2.6 Pharmacological control of BER 
2.6.1 APE in the BER pathway 
APE is a globular enzyme consisting of α/β folds with two domains and can be 
seen in Error! Reference source not found.. As stated before, AP endonuclease (APE) is the 
second enzyme utilised in the BER after alkylation damage to N7G and N3A. APE is 
activated after apurinic/apyrimidinic site has been formed by a glycosylase enzyme, or a 
spontaneous event, has hydrolysed the N-glycosyl bond which attaches the base to the 
phosphate sugar backbone(Chohan et al. 2015; Talpaert-Borlè 1987). APE cleaves the 
backbone at the 5' leaving a deoxyribose phosphate and a 3'OH group. This is then the 
substrate which PolB interacts with continuing repair. It has been shown that APE can 
increase the binding affinity of PolB and accelerate the removal of the 5'dRP (Bennett et al. 
1997). The C-terminus of the protein deals with repair activity, however the N-terminus 
deals with redox reactions with other proteins.  
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APE can also remove the 3'-phosphate damage produced by ionising radiation 
and reactive oxygen species through a phosphodiesterase activity (Barzilay et al. 1995). 
The activities of APE, endonuclease activity, phosphodiesterase and RNAse H activity are 
all dependent on Mg+ ion in the active site (Barzilay & Hickson 1995). Due to these 
different roles, APE is also utilised after damage repaired by 8-oxoguanine glycosylase 
(OGG1). OGG1 is different to AAG as it not only has the glycolytic activity, but also an AP 
lyase activity which cuts the backbone at the 3' position (Hedglin & O’Brien 2010). To 
allow the functional repair by POLβ APE utilises the phosphodiesterase activity removing 
the 3' residues.  
 
APE binds to either the 5' or 3' (for phosphodiesterase activity) of the AP site 
(Masuda et al. 1998; Strauss et al. 1997). APE binds to the DNA at both the major and the 
minor groove, forming an extrahelical structure allowing for the exclusion of normal DNA 
(Mol et al. 2000). APE stabilises the extrahelical structure and widens the minor groove 
(Mol et al. 2000).  
 
2.6.1.1 The link of APE to cancer 
APE expression levels have been shown to be elevated in some cancers including; 
cervical cancer, ovarian cancer, prostate cancers and germ cell tumours (Lu et al. 2001; 
Fishel et al. 2007; Herring et al. 1998; Kelley et al. 2001). Studies have found 18 
polymorphisms of APE (Xi et al. 2004) with only 6 of the variants below 50% binding 
affinity (Xi et al. 2004). In a study by Kelley, they showed from tissue resection that within 
the tumour area there was an increase in the expression of APE, but not in the benign 
healthy tissue from the prostate (Kelley et al. 2001).  
 
2.6.1.2 APE expression and resistance to treatment  
Low APE1 levels measured in studies with mouse lymphoblastoid cells have 
shown a radioresistant trend (Chen et al. 1991). Ono et al., also found a non-significant 
correlation between APE levels and radioresistance (Ono et al. 1994). However, this 
finding was not replicated in human astrocytomas (Hughes-Davies et al., 1995). 
Furthermore, Herring and co-workers found no correlation with APE expression and 
radiosensitivity in cervical cancer (Herring et al. 1998). More recently siRNA for APE has 
been used to sensitise colorectal cancer cells both in vitro and in vivo, showing a good link 
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between APE and radiation sensitivity in these cells (Xiang et al. 2008). This strengthens 
the argument to look into the protein expression levels for repair pathways in 
glioblastoma cells as part of treatment development. In head and neck cancers it has been 
shown that high expression of APE not only is associated with radioresistance, but also 
chemoresistance, when patients were treated with a range of chemotherapeutics. High 
APE expression lead to a very poor survival with all patients having passed at 60 months, 
however, mild expression of APE lead to 40% of patients surviving until 110 months, the 
end of the study (Koukourakis et al. 2001).  
 
Chemo resistance due to APE expression has been seen in many different tumour 
types, with a variety of drugs. In non-small cell lung cancer it was shown that cisplatin 
resistance is associated with high expression of APE (Wang et al. 2009). Silber et al found 
that in glioma cell lines expression of APE lead to an increase in resistance to TMZ and 
BCNU, however, they also found that reactive oxygen species created during treatment 
lead to an increase in cell expression and activity of APE (Silber et al. 2002). In an 
experiment by Ono, using transfected rat glioma cells showed increased sensitivity to MMS 
and hydrogen peroxide in knockdown cells (Ono et al. 1994). 
 
In an initial study into glial cell tumours, it was found that APE expression is 
increased in glial tumours (Bobola et al. 2001). AP activity levels were measured in glioma 
patients and correlated the activity to the overall survival and sensitivity to chemotherapy 
and radiotherapy. Bobola and coworkers found that an increase in activity lead to an 
increased hazard of tumour progression in grade III gliomas, however, this association 
was not found in grade IV (Bobola et al. 2004). To prove their theory, but using 
medulloblastoma and primitive neuroectodermal tumours they used tumour resected 
cells and knocked down APE. These knockdown APE cells were more sensitive to TMZ and 
BCNU, than cells transfected with antisense siRNA. They also linked APE expression in 
cells to time to tumour progression, however, this link was not statistically significant 
(Bobola et al. 2005).  
2.6.2 How methoxyamine works 
Methoxyamine (MX) is an APE inhibitor which is a small organic amine which 
reacts with the aldehyde group present on the deoxyribose after the base has been excised 
by a glycosylase or spontaneously removed (Talpaert-Borl & Liuzzi 1983). Liuzzi also 
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found in further studies that MX does not inhibit the base excision performed by 
glycosylases, specifically uracil-DNA-glycosylase. As the AP-site then becomes stable MX 
has been tested to potentiate the effects of TMZ and other chemotherapeutics.  
 
In vitro studies with MX have shown that it can impair the growth of 
osteosarcoma tumours and potentiate radiation and cisplatin effects in cell killing 
(Montaldi et al. 2014). In colon cancer cell lines it was shown that the addition of 
methoxyamine with temozolomide increased early apoptotic signs from TMZ treatment of 
DNA fragmentation 24 hours earlier than treatment with TMZ alone (Taverna et al. 2001). 
Specifically to this project it has also been used in the glioblastoma cell line LN428, which 
is resistant to TMZ due to positive expression of MGMT. Tang et al., found that as they 
increased the expression of AAG in LN428 cells, they became more sensitive to MX and 
TMZ combined (Tang et al. 2011). However, the LN428 cells were not sensitive at 
chemotherapeutically relevant doses of TMZ or MX. Although this study measured the 
levels of polymerase beta, MPG and PARP in an attempt to establish a link between efficacy 
of TMZ, MX and PARP inhibitors, however, these studies are interesting but do not help to 
establish feasible chemotherapeutic links and are so not applicable to clinic.  
 
MX was brought into clinical trials for solid tumours and the first published 
results were in 2010 of the levels of methoxyamine found in plasma levels once treated 
orally daily for 5 days in 28 day cycles. It was found that the plasma levels increased over 
the days and cycles so that if given 100 mg/m2 the plasma levels would increase from 152 
ng/mL, 247 ng/mL to 225 ng/mL for day 1 of cycle, day 4 of cycle 1 and day 1 of cycle two 
respectively. All doses given orally leant to at least 50 ng/mL (Weiss et al. 2010). This for 
an in vitro experiment would correlate to concentrations between 0.6 µM and 3 µM. 
Therefore, all experiments conducted in this study will be around these limits. Final 
results of the clinical trials were supposed to be correlated in April 2015, but no further 
results have been published as of yet.  
 
A study to establish the AP site blocking function of MX and its role in combined 
toxicity with temozolomide was conducted by Yan and co workers (Yan et al. 2007). In 
this study, oligonucleotides were designed with uracil incorporated into the strands and 
treated with uracil DNA-glycosylase. The AP sites generated were then treated with 
methoxyamine and APE was added to find out how many AP sites were further processed, 
leading to a single strand break (SSB). They found that treatment of TMZ and MX (12.5 
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mmol/L) together mildly reduced the number of AP sites formed, however not 
significantly. They also showed that the addition of methoxyamine to treatment with 
temozolomide had an effect in cytotoxicity for the colon cancer cell line; SW480, however, 
did not have an effect on either human or mouse bone marrow cells (Yan et al. 2007). 
  
To understand how methoxyamine and temozolomide work together a study was 
performed where Montaldi and Sakamoto-Hojo (2013) found that out of a cell panel 
including U87, U251 and T98G, only T98G was sensitized by methoxyamine in the 
presence of temozolomide. The effect was so dramatic it reduced the IC50 from 
approximately 3000 µM to 450 µM. Interestingly, they found that the increase in cell death 
due to the combination treatment was not due to apoptosis (Montaldi & Sakamoto-Hojo 
2013).  
2.6.3 Introduction to polymerase  
Polymerase β (POLB) is an enzyme in the polymerase family and as such inserts 
nucleotides into DNA specifically in BER (Sobol et al. 1996). It is also the third enzyme in 
the short-patch base excision repair pathway (sp-BER). It is a protein made up of 335 
residues and it is 39kDa in weight. Polβ is formed from two sub units, an 8kDA subunit 
and a 31 kDa subunit. In vitro APE, the APsite and POLB form a ternery structure until the 
DNA is cleaved by APE, when POLB can bind to the DNA (Bennett et al. 1997). POLB can 
exhibit two enzymatic activities, traditional polymerase synthesis of DNA and a 5'dRp 
Lyase activity. It has been shown that these activities are performed by the two different 
subunits (Matsumoto & Kim 1995). The smaller 8 kDa subunit has the deoxyribose 
phosphate (dRP) lyase activity. Whereas the larger subunit consists of 3 subdomains; 
thumb, palm and fingers. The thumb domain binds to the DNA and connects to the smaller 
subunit. The palm domain contains the active site for polymerase activity and the fingers 
bind and select nucleotides (Beard & Wilson 2006). In the base excision repair pathway 
this enzyme is the penultimate enzyme which allows the DNA to be fully complimentary 
and just needs to be ligated, sealing the nicks where the new nucleotide has been inserted.  
 
Kinetic studies have shown that the lyase activity of PolB is far more rapid than 
the nucleotide insertion (Prasad et al. 2010). In a study looking at enzyme kinetics it was 
found that in 10 seconds 37% of 5'dRP lesions were removed, this was analysed using gel 
electrophoresis and radiolabeling. However, in 20 seconds only 25% of nucleotides were 
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inserted into specially designed oligomers. This shows that the 5'dRP lyase function is 
faster. When they were measured in the same reaction after pre-treatment with UDG, 
leaving a 3'OH and a 5'dRP they found that after 10 seconds 46% of the lyase activity had 
occurred and 26% of the nucleotide insertion (Prasad et al. 2010).   
 
 The polymerization mechanism of POLB consists of four basic steps (Beard & 
Wilson 2006). First, POLB binds to one base gapped DNA to form a polymerase-DNA 
binary complex. These binary complex next binds a nucleotide, forming an enzyme-DNA-
dNTP ternary complex. Once dNTP is bound in the active site, there is a rapid 
conformational change wherein the fingers domain rotates through the hydrophobic hinge 
region to close around the nucleotide. This movement initiates the nucleotidyl transferase 
activity in the active site, adding the nucleotide to the DNA strand. Lastly, in a likely rate-
limiting step, the DNA product extended by one nucleotide is released from the 
polymerase generating an apo-enyzme that can complete the cycle again (Kim & Wilson 
2012).      
 
2.6.3.1 Polymerase  in cancer  
POLB variants are linked to increasing likelihood of certain cancers, with 30% of 
tumours containing a mutated POLB (Starcevic et al. 2004). Some colon and prostate 
cancers have been linked to a mutated POLB (Dalal et al. 2005). In work on a gastric 
carcinoma cell line it was found that POLB mutations can lead to genomic instability (Lang 
et al. 2007), which can then lead to colon cancer progression (Nemec et al. 2012). Hong 
and co-workers found that an overexpression of POLB was correlated with poor prognosis 
in oesophageal cancers (Zhao et al. 2005). These studies show the importance of PolB in 
cancer progression due to an error prone pathway de-regulation and how it could be 
important as a method of inhibition for increased treatment sensitivity.  
 
2.6.4 XRCC1 
X-ray cross complementing group 1 (XRCC1) is a scaffolding protein which is 
recruited during BER (Caldecott 2003). XRCC1 was originally thought to be activated by 
PARP, which in turn brings Polymerase β and DNA ligase I/IIIα to the site of repair(El-
Khamisy 2003), however, there is evidence that XRCC1 binds glycosylases (Campalans et 
al. 2005) and POLB (Dianova et al. 2004).   Cells and organisms missing or with mutant 
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XRCC1 are more sensitive to ionising radiation, ROS, and alkylating agents. These cells 
with missing functional XRCC1 have an increased propensity for chromosomal 
aberrations, deletions and in null mice embryonic lethality (Tebbs et al. 1999). XRCC1 has 
been shown to have many single nucleotide polymorphisms, many of which are being 
linked to a high frequency of cancers such as breast cancer (Duell et al. 2001).  
 
XRCC1 has no enzymatic activity, but has binding domains specific for the 
proteins within BER. The first binding domains found were for Polymerase β, PARP and 
DNA ligase III (Caldecott et al. 1996). XRCC1 also can be phosphorylated by Chk2, near the 
nuclear localisation signal (Goode et al. 2002). Dianova et al., found that the XRCC1 binds 
polymerase β at a site near the N-terminal and binds PARP at the BRCT1 and DNA ligase at 
the BRCT2 (Dianova et al. 2004). Recently, studies have shown that XRCC1 may also bind 
to the glycosylases in BER, which can increase the catalytic activity, in the case of AAG by 
five-fold (Campalans et al. 2005). These studies make the role of XRCC1 one which needs 
to be considered during this project.  
 
2.7 Research Question 
Can repair proteins within GBM cell lines specific for TMZ and radiotherapy DNA 
repair pathways be quantified? Can this quantification be used to create an imbalance 
through the use of inhibitors to increase the effect of cell killing by TMZ and radiotherapy? 
And what are the optimum doses of radiotherapy to use? 
2.7.1 Aims and objectives 
 To measure the levels of DNA repair proteins by either PCR or western blot 
relative to each other in established GBM cell lines.  
 To measure cell survival of GBM after standard treatment with temozolomide and 
irradiation, specifically correlating the involvement of BER.  
 To compare the survival of cells after treatment with inhibitors for BER. 
Specifically; Methoxyamine (MX) inhibiting AP Endonuclease and Pamoic acid 
(PA) inhibiting polymerase beta. 
 Measure dosimetry of the proton beam accelerator to give the correct dose of 
radiation to compare with X-rays.  
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Hypothesis  
An imbalance in base excision repair will sensitise glioblastoma cells to 
chemotherapy and radiotherapy. Proton therapy will produce a higher cell killing effect, 
however, the sensitisation from BER inhibitors will be greatest with X-ray therapy due to 
the SSB DNA damage created.  
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3 METHODS 
3.1 Introduction  
This chapter discusses the experimental design and the protocols employed to 
explore the DNA repair protein expression profiles in glioblastoma cell lines. The DNA 
repair pathway named base excision repair (BER) is of particular interest as the main 
treatment strategies for glioblastoma are the chemotherapeutic drug temozolomide and 
radiotherapy, which causes DNA damage that is repaired by BER. To further elucidate the 
role of BER in the treatment of glioblastoma, drugs/inhibitors that unbalance this pathway 
and are either already in clinical trials or being tested at the pre-clinical stage, were tested 
in an attempt to exploit genetic differences in cancer tumours to improve outcome after 
chemotherapy.  
 
These results were then used to develop a model specific to the linear quadratic 
model for cells being treated with temozolomide in conjunction with radiotherapy.  The 
different equations produced may be explained by the repair misbalances within the 
tumour.  
 
This chapter further goes on to give details in cell culture, drug treatment and 
end-point assays used and finally data analysis methods are described. 
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3.2 Methods 
3.2.1 Cell culture 
Five established human glioblastoma cell lines (T98G, LN18, A172, U251, U87) 
were obtained from ATCC and grown in culture medium consisting of Dulbecco’s 
Minimum Essential Media (DMEM) (Sigma Aldrich- high glucose (4500g/L)) 
supplemented with 10% foetal bovine serum, 1 % penicillin/streptomycin, 4 mM L-
glutamine, (Lonza). Cells were incubated at 37oC and 5% CO2, with media changes every 
day. Once cells were 80% confluent they were passaged by exposing cells to 0.25% trypsin 
in 0.05 mM EDTA (Sigma Aldrich) until detached and then neutralised in media. These cell 
lines were chosen for their previous characterisation to different LETs by Barazzuol 
(2012). As well as being a mix of both oligodendrocyte and astrocyte derivatives.  
 
3.2.2 Western Blot  
Western blots were used to measure the amount of protein being expressed 
directly in the cells and could be normalised to loading controls and therefore comparable 
to each of the cell lines. The proteins are separated by size through a gel and then the 
protein of interest is specifically detected and visualised by using antibodies. 
3.2.2.1 Preparation of protein  
Cells were frozen in a pellet and stored at -20oC. Cells were lysed with a 1 x 
glycosylase buffer made of; 20 mM Tris at pH 7.6, 100 mM KCl, 5 mM EDTA, 1 mM EGTA 
and 5 mM β-mercaptoethanol using a 21g needle and syringe. Lysates were frozen and 
thawed 3 consecutive times to enhance cell lysis. Cells were then exposed to sonication for 
4 pulses, each lasting 30 seconds. The samples were then centrifuged at 14000 rpm at 4oC 
and the supernatant was kept as -20oC. 
 
 The amount of protein per sample was determined using the Bradford assay 
(Bio-Rad) following the standard 96 well protocol. The plate was read at 595 nm.  
3.2.2.2 Detection of protein  
Standardised Bio-Rad gels, (mini-protean precast wells, 10 wells at 30 µl/well, 
BioRad) were loaded with 20µg of protein per well. The gels were electrophoresed for an 
hour at a voltage of 150 V with running buffer (Tris-base 3.0 g, Glycine 14.4 g, 10 mL of 
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10% SDS and ddH2O to 1 L). Proteins were transferred from the gels onto transfer 
membranes (mini nitrocellulose and PVDF,  BioRad) using a Trans-Blot Turbo Transfer 
System (BioRad) for 30 minutes. The membranes were incubated for 2 hours at room 
temperature in 1% TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 0.05% Tween-20) 
with 0.1% non-fat dry milk powder. The membranes were washed 3 times with 1% TBST. 
The concentration of primary antibody is shown in the below table which were made up in 
1% TBST with 0.1% milk powder and incubated overnight at 4oC. Membranes were 
washed before a 1:10000 dilution of goat anti-mouse infrared dye labelled 800CW and 
goat anti-rabbit infrared dye labelled 650 CW (Li-Cor) was added for 30 minutes and 
incubated at room temperature, membranes were then washed before being read on the 
LiCor Odyssey which used lasers to detect the infrared fluorescence.  
 
Primary Ab Dilution  Control Ab Dilution 
AAG Mouse (Santa 
Cruz 
biotechnology, 
INC. sc-101237) 
1:250 Beta-Actin 
Mouse (Abcam, 
ab6276) 
1:5000 
APE1 Rabbit (Cell 
Signalling 
Technology, 
#4128) 
1:1000 Beta-actin 
Rabbit (Sigma, 
A2066) 
1:5000 
MGMT Rabbit 
(Cell Signalling 
Technology, 
#27395) 
1:500   
Table 2 Antibodies used in western blots 
3.2.3 Polymerase Chain Reaction  
Quantitative polymerase chain reaction (qPCR) was used to measure the amount 
of mRNA being transcribed for a particular gene during protein synthesis. This should give 
us a comparison between the transcribed levels and the translated, full protein, levels.  
 
3.2.3.1 RNA extraction and first strand synthesis 
Cell pellets were lysed using 5 ml of TRIzol (Invitrogen) and chloroform to 
produce phase separation and to extract the RNA following the manufacturers protocol.  
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Total RNA was measured for purity and RNA content using a “NanoDrop”. The 
RNA extracted from the cells was converted to complementary DNA (cDNA) using first 
strand synthesis kit SuperScript II Reverse Transcriptase (Life Technologies) following the 
standard protocol recommended by the manufacturer.  
The following chemicals were added to a 0.5 mL Eppendorf tube: 
Components for Primer mix Amount 
RNA n L 
Primers (forward and reverse) 1 µL of each 
10 mM dNTPs 1 µL 
DEPC water Upto 10 µL 
Table 3 SuperScript II reverse transcriptase reagent amounts - 1 
For the control 1 µL of DEPC water was added instead of RNA. This was then 
heated to 65oC for 5 minutes, then cooled at 4oC for at least a minute using a thermo cycler.  
 
The “reaction” mix was made following the instructions of the product, as shown 
in the table below. 9 µL was added of the reaction mix to the samples containing primers. 
This mixture was then heated to 42oC for 2 minutes before 1 µL of the reverse 
transcriptase was added and the mixture is then heated to 42oC for 50 minutes, 70oC for 
15 minutes and then it is chilled at 4oC. At this point 1 µL of RNAase H can be added and 
incubated with the mixture for 20 minutes at 37oC. A further control was made which did 
not include any reverse transcriptase.  
 
Components for Reaction Mix  Amount 
10 X Reverse Transcriptase Buffer 2 µL 
25 mM Mg2Cl 4 µL 
0.1 M Dithiothreitol (DTT) 2 µL 
RNAse OUT 1 µL 
Table 4 SuperScript II reverse transcriptase reagent amounts - 2 
A primer is a single stranded area of DNA which binds to single stranded DNA or 
RNA. In this reaction it binds to a poly(A) tail on the mRNA at the 3’ end and creating a 
3’OH. The mRNA strand can then be turned into a cDNA strand by Reverse Transcriptase 
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separating the mRNA from other RNA and binding to it adding matching nucleotides, 
dNTPs, to the mRNA strand. Not only is cDNA more stable but it is used to amplify the 
genes of interest in quantitative real time PCR (q-RT-PCR). The DEPC water is specially 
treated to ensure no contaminating chemicals are included and that there is no RNA 
included as this could lead to amplification of foreign genes and not sample genes.  
3.2.3.2 Quantitative real-time PCR 
The cDNA that was formed from the first strand synthesis was used to amplify 
the gene of interest. The reactions were carried out within a 96-well fast reaction plate, in 
quadruplicate for each cell line. In these plates the genes of interest were amplified as well 
as a control transcript, which ideally should be ubiquitously expressed within the cells, for 
future experiments should not change expression levels after treatment. This adds not 
only a control but also allows for normalisation in case there is more cDNA in one sample 
than another, as it is not measured after first strand synthesis. A list of the primers used is 
displayed in the table below.  
 
Each reaction contained 1 µL of cDNA, 10 µM of each the forward and reverse 
primers, 10 µL of Platinum SYBR Green qPCR SuperMix-UDG w/ROX (Life Technologies) 
and water q.s.p. a 20 μL reaction. The qPCR reactions were run in the QuantStudio 7 Flex 
Real-Time PCR System (Life Technologies). The settings for temperature cycling 
conditions were as follows: 50oC for 2 minutes, 95oC for 2 minutes, followed by 
temperatures cycling 40 times of 95oC for 15 seconds and 60oC for 1 minute. To finalise 
the reaction temperatures of 95oC for 15 seconds, 60oC for 1 minute and 95oC for 15 
seconds, which allowed melt-curve analysis.  
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Target Forward Sequence Reverse Sequence 
MGMT 5’-CCT GGC TGA ATG CCT 
TCC AC - 3’ 
5’-GCA GCT TCC ATA ACA 
CCT GTC TG- 3’ 
XRCC1 5’- CGG ATG ACA CGG ACA 
GTG A -3’ 
5’- GAA GGC TGT GAC GTA 
TCG GAT G -3’ 
AAG 5’- CCC CGC AAC CGA GGC 
ATG TT -3’ 
5’- AGC AAG ACG CAA GCC 
CCG TC-3’ 
AAG, at another area on 
mRNA strand 
5’ – CCC ACC ACT CCG GGC 
CCA TA -3’ 
5’- GGC TCC AGT GCT CGC 
AGC AA -3’ 
APEX 5’- CTG CTC TTG GAA TGT 
GGA TGG G -3’ 
5’- TCC AGG CAG TCT CTG 
AAG TTC A -3’ 
POL β 5’-TGC AGA GTC CAG TGG 
TGA CAT G -3’ 
5’- ATG AAC CTT TTG TAA 
CTG CTC CAC -3’ 
LIG 3 5’- GCT ACT TCA GCC GCA 
GTC TCA C -3’ 
5’- GCA GTG GTT TGC CTG 
TCT TGT TG -3’  
LIG 1 5’ –TCA CAG AGG CTG AAG 
TGG CAA C-3’ 
5’- TCA GGC TCT GAA ACG 
CTT TCC G -3’ 
PARP 5’- CCA AGC CAG TTC AGG 
ACC TCA T -3’ 
5’- GGA TCT GCC TTT TGC 
TCA GCT TC -3’ 
PARG 5’- AGT GGC TTG GAA CTC 
CCA TTG AG -3’ 
5’- ACT TCT CCT GCT CGC 
AAA AGA TC -3’ 
Beta Actin 5’ – ATT GCC GAC AGG ATG 
CAG AA – 3’ 
5’- GCT GAT CCA CAT CTG 
CTG GAA -3’ 
Table 5 Forward and reverse primers for mRNA detection of repair proteins 
The temperatures for qPCR allow the DNA to be manipulated by the enzymes that 
amplify the DNA. The initial temperature is to heat activate the DNA polymerase and 
enzyme which binds and reads the DNA. The high temperatures also cause the hydrogen 
bonds between the two strands of DNA to become denatured creating single stranded 
DNA. The single stranded DNA can have the primers for the specific proteins bind during 
the lower temperatures of the cycle. The DNA polymerase can extend the DNA at 60oC 
creating an exponential increase in the amount of DNA after each cycle. 
 
SYBR green dye is a detection method for analysing how much DNA has been 
amplified by the q-RT-PCR. SYBR green dye is incorporated in double stranded DNA, 
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between the two strands. As each new strand of DNA is created, more SYBR green dye 
binds to the double stranded DNA. This increase in DNA allows an increase of bound 
fluorescent dye which gives off an increased signal, this is measured after every cycle, 
hence it is measured in real time.  
3.2.4 Microarray data analysis 
Microarray data was taken from the online database under GSE 23806 (Schulte et 
al. 2011). In their samples of conventional cell lines they used 4 of the 5 in this project. Cell 
lines were A172: GSM587161, LN18: GSM587185, T98G: GSM587179, U87: GSM587180. 
GEO 2 R extracted the p-values from the control sample for expression of the genes of 
interest, which were found through the platform; GPL570. All p values were normalised 
against T98G to make comparable to western blots and qPCR results.   
3.3 Irradiation Protocol 
3.3.1 X-ray protocol 
X-ray irradiations were performed on a Gulmay machine at 250 kVp with a dose 
rate of 0.65 Gy/min (Royal Surrey County Hospital, Guildford, UK or Christie Hospital, 
Manchester, UK). Cells were exposed at room temperature to doses between 0.5 to 5 Gy 
using the monitor units in the table below. Cells were grown in 6-well plates and 
incubated for 5 h before irradiation. 
 
Dose (Gray) Monitor units 
0.5 49 
1 99 
2 197 
3 296 
4 394 
5 493 
 Table 6 X-ray dose delivery of Gy and the monitoring units needed to achieve them 
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3.3.2 Vertical proton irradiation  
Irradiations of cells by proton beam using a broad beam were performed on the 
vertical nanobeam (Wolfson Tower, Ion Beam Centre, University of Surrey). This is a 2 MV 
tandem accelerator which can produce ions at a range of energies (Merchant et al. 2012). 
For these experiments the accelerator is set up to produce protons of 3 MeV energy. 
Irradiations were performed at 0.5 to 5 Gy according to a specific procedure (Jeynes et al. 
2013). The dosimetry was verified using a pin diode which counts particles during 
irradiation and the beam homogeneity is measured by a scintillator, it should show a bell 
curve for a good clean beam. This was further verified using Gafchromic film. 15 µL of the 
cell suspension was pipetted onto 4µm thick polypropylene disks that were suspended in 
place by specially designed holders, as shown in Figure 3-1. The cells were diluted before 
irradiation to a concentration of 1*106 cells/ml leaving the 15,000 cells per droplet.  
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Figure 3-1 Schematic of cell set out on the polypropylene disks. The disks are set on 
the XY stage and the beam comes from underneath the cells. 
To ensure correct dose the pin diode was used to measure the number of 
particles per 30 seconds and this was measured before each irradiation. This was divided 
by 30 to calculate the number of particles that travel through in one second, this is known 
as the fluence. This was then used to ensure the correct dose is given to the cells using the 
below formula.  
Equation 1 Dose rate;  
Dose rate (Gy/s) = 1.6 * 10-9 
L

 
The LET is calculated from the energy of the particle at the centre of the cell layer 
with the units KeV/µm. Fluence is the number of particles travelling through the beam and 
is measured in particles/cm2/s.  ρ is the cell density, which is set to 1. For more details see 
(Jeynes et al. 2013). 
3.3.3 Horizontal proton irradiation  
Horizontal irradiations became a necessity within this PhD project and the 
method was developed and tested within results chapter 6. However, the cells were 
irradiated within 96 well plates. Cells were seeded at a density 3 x 104 cells/well and 
incubated for 24 hours before irradiations took place.   
Metal Securing metal dishdisk 
4µm thick 
polypropylene 
Droplet of 
cells 
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3.4 Chemotherapy treatment protocols 
Temozolomide (TMZ) (Sigma Aldrich), was bought in as a powder and made up 
to a stock concentration of 50 mM in dimethyl-sulfoxide (DMSO). All further dilutions 
were made in media from the stock solution.  
 
Inhibitors; methoxyamine (MX) and pamoic acid (PA) (Sigma Aldrich) were 
dissolved in DMSO to a stock concentration of 100 mM. Working dilutions were then done 
in cell culture media.  
3.4.1 Clonogenic assay  
Clonogenic assays were used to detect the toxicity to the cells from either 
treatment with TMZ alone or after a combination of X-rays/protons with TMZ. Cells were 
seeded into 6 well plates and left to adhere for 24 hours. Cells were then exposed to either 
TMZ, inhibitors, irradiation or a combination of treatments. 24 hours after treatment cells 
had the media replenished with fresh, drug free media. Cells were then incubated for 14 
days at 37oC and 5% CO2 atmosphere. After 14 days media was removed and cells were 
fixed with 70% ethanol before being stained with 5% Crystal violet in PBS to allow 
colonies to be counted. Wells containing more than 20 colonies were counted.  
3.4.2 Viability assay  
The toxicity of inhibitors without further treatment was evaluated using viability 
assays in growing cells over time. Live cells were quantified in 96 well plates at different 
time points over a 72 hour period post-treatment. A non-toxic, non-fluorescent compound, 
Resazurin which is a blue dye which can be reduced within the cells to form a highly 
fluorescent red compound resorufin. Cells were plated and are incubated at 37oC and 5% 
CO2 atmosphere for 24 hours. Cells were then incubated with inhibitors until 2 hours 
before they were due to be read where a 1:11 ratio of Alamar blue to media was incubated 
on the plate cells. After 2 hours the plate was read as according to manufacturer’s 
instructions, 560 nm. Fresh media was replaced on cells until 2 hours before the next time 
point.  
3.4.3 Cell growth assay 
To characterize cell growth, proliferation and doubling times in the presence of 
inhibitors and TMZ growth curves were assessed on two cell lines (U251 and U87). Cells 
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were seeded at a density of 2*104 cells/well and incubated for 24 hours in a 24 well plate 
with 1 mL of media or treatment (50 M of PA or MX). Wells were trypsinised and cells 
counted at 24 hours’ time points over 5 days. Each experiment was performed in 
triplicate.  
3.4.4 Flow cytometry  
To determine if the genotoxic treatment affected cell cycle progression flow 
cytometry was used. Cells were seeded at a density of 5*104 cells/well and incubated for 
24 hours. Cells were then treated with the appropriate treatment protocol and harvested 
72 hours later. Cells were fixed in 70% ethanol for 24 hours and then treated with RNAse 
(100g/mL). Cells were stained with propidium iodide (PI) in PBS (50 g/mL). Cells were 
analysed using a BD canto II for DNA content, as described. 
3.4.5 Activity assay 
The following methods were provided by Eleanor Healing and Dr. Ruan Eliot who 
produced the procedure and completed the experiments 
3.4.6 Assay to measure AAG activity 
For all experiments, the initial oligonucleotide (HX02 or URA03; sequence 
information provided in Table 7) was diluted from 10 µM stock solutions into freshly 
prepared 0.1M bicarbonate buffer (pH 9.6) to a final concentration of 0.5 nM and 100μl of 
this solution was incubated in each well of a Nunc® ImmobiliserTM amino 96-well plate 
overnight at 4°C. The plate was then washed with phosphate-buffered saline containing 
0.1% v/v Tween-20 (PBST) and 100µl of a 0.5nM solution of the appropriate 
complementary oligonucleotide (Loop01T for Hx02, Loop01G for URA03; sequence 
information provided in Table 7) was added following dilution in hybridisation buffer (6x 
saline sodium citrate (SSC) buffer, 5 mM EDTA, 0.1% v/v Tween-20). Each plate was then 
sealed and heated to 95°C for ten minutes in a hybridisation oven, followed by gradual 
cooling to 80°C, maintenance at 80°C for ten minutes and then further gradual cooling to 
21°C. 
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Name Sequence (5’ → 3’) Base modification Substrate for: 
HX02 (P)CACGAA(X)CAACTC 
AGCAACTCCtt(NH2)
2,3,4
 
Hypoxanthine (X) AAG 
URA03 (P)CACGAA(U)CAACT 
CAGCAACTCCtt(NH2) 
Uracil (U) UNG 
Loop01T (Flc)ttGGAGTTGCTGAGTTGTT 
TCGTGAGCACCAACCGGTGCT
1
 
X X 
Loop01G (Flc)ttGGAGTTGCTGAGTTGGT 
TCGTGAGCACCAACCGGTGCT 
X X 
Table 7 Sequences of oligonucleotides used in experiments.
 
1Flc indicates fluorescein; 2NH2 indicates amino group modification; 3P indicates 
phosphorylation; 4lower case letters in the nucleotide sequence indicate nucleotides 
linked via phosphorothiate bonds which also serve as a two-nucleotide spacer between 
the plate and the start of the double stranded nucleotide complex. 
 
To measure alkyl adenine DNA glycosylase (AAG) activity, plates containing 
HX02 annealed to Loop01T were treated with 0.05U T4 DNA ligase in 100 µl of T4 DNA 
ligase buffer (30 mM Tris-HCl pH 7.8, 30 mM NaCl, 10 mM MgCl2, 10 mM DTT, 1 mM ATP) 
for one hour at 37°C. The plates were then heated to 65°C for a further 15 minutes and the 
hot liquid immediately decanted from the wells. Fresh DNA ligase buffer (100 μl) was 
added to each well and the plate heated to 65°C for a further 15 minutes, the liquid 
immediately decanted and the wells washed three times with PBST. This process produces 
double-stranded substrate containing a hairpin loop and one site of damage (Figure 2-1).  
 
These substrates were then incubated with increasing concentrations of 
recombinant enzyme (hAAG1, from New England Biolabs) or cell extract (at a 
concentration of 10 μg/well) in an AAG reaction buffer (20 mM Tris-HCl pH 7.5, 100 mM 
KCl, 5 mM EDTA, 1mM EGTA, 5 mM β-mercaptoethanol, 2 μg/ml Herring Sperm DNA) for 
two hours at 37oC. Following the repair incubation, the contents of the wells were 
decanted and the wells washed three times with PBST. A volume of 150 μl of alkaline 
buffer (0.1x SSC, 0.1M NaOH) was added to the wells and the contents of the plate heated 
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to 95°C for 10 minutes. The liquid was then decanted from the wells and the alkaline 
denaturation step repeated once more prior to three PBST washes. 
 
To measure UNG activity, plates containing URA03 annealed to Loop01G were 
ligated and prepared in the same manner as the substrate for the AAG assay, to produce a 
hairpin loop structure containing a single uracil lesion in a U:G base pair within the double 
stranded region. The substrate was then incubated for one hour at 37°C with varying 
concentrations of recombinant UDG or 2.5μg/well of nuclear extract sample, both in DNA 
repair buffer (Tris-HCl pH 7.8, 100 mM NaCl, 0.4 mM EDTA, 3.4% v/v glycerol, 0.4 mM 
DTT, 2 mM MgCl2, 1 μg/ml herring sperm DNA). Following the repair incubation, the wells 
were then subject to alkaline denaturation as in the AAG assay. 
 
After the final denaturation step of each assay, fluorescein retained in the wells of 
the plates was quantified by colorimetric detection. Each well was incubated with anti-
fluorescein antibody conjugated with horseradish peroxidase (HRP) (Abcam ab6656, 
Cambridge, UK) diluted 10,000-fold in PBST/1% w/v bovine serum albumin for one hour 
at 21°C. The liquid was decanted from the wells and the wells washed four times with 
PBST. TMB Microwell Peroxidase Substrate for HRP (KPL, Wembley, UK) was then added 
(100 μl/well) and incubated at 21°C for ten minutes. Reactions were stopped by addition 
100μl 1M phosphoric acid to each well. Absorbance was read at 450nm using an Omega 
fluostar microplate reader (BMG labtech, Aylesbury, UK). 
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Figure 3-2 Structure of oligonucleotide sequences in their expected orientation 
bound to the well of a 96-well plate. Structure shown is substrate for alkyl adenine DNA 
glycosylase. 
3.5 Statistics 
Assays were conducted in at least triplicate and statistics were performed on 
experiments with a minimum of 3 repeats on separate occasions. Error bars represent the 
standard error of the mean, unless stated otherwise. The linear quadratic model or the 
repairable-conditional repair model was used to analyse clonogenic data involving 
radiation. A 2-way ANOVA with Tukey post hoc test will be used to analyse the TMZ alone 
clonogenic data. 1-way ANOVA were used for western blots, qPCR, cell proliferation and 
growth assays.  
3.5.1 Combination indices 
The CI was calculated using the formula: where CA,X and CB,X are the 
concentration of drug A and B used together in combination to achieve cell death in this 
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case to a certain surviving fraction ICX,A and ICX,B are the concentrations of the single 
drugs to achieve the same effect, and surviving fraction. 
Equation 2 combination indices 
𝐶𝐼 =  
𝐶𝐴𝑋
𝐼𝐶𝑋𝐴
+
𝐶𝐵𝑋
𝐼𝐶𝑋𝐵
 
This equation was originally set out by Chou and Talalay to work out the 
interactions of chemicals in overall in biological settings.  A CI of less then, equal to, or 
more than 1 indicates synergic, additive or antagonistic effect, respectively.  
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4 THE CHARACTERISATION OF 
GLIOBLASTOMA CELL LINES 
4.1 Introduction 
All cells constitutively express DNA repair proteins to deal with exogenous 
assaults on their DNA from chemical and physical agents such as pollution or tobacco 
smoke. Specifically, these DNA repair proteins function to repair damaged DNA which 
lowers genomic changes, chromosomal aberrations and prevents mutations. While some 
repair proteins can act alone, most repair proteins act concertedly in defined cellular 
pathways. However, there will be variation in the expression levels of DNA repair proteins 
amongst individuals’ due to genetic differences or epigenetic regulation. These differences 
in expression levels or mutations in DNA repair proteins can lead to cancer susceptibility 
and have further implications to cancer treatment. For example mutations in the BRCA1 or 
BRCA2 genes can lead to an increased likelihood of developing breast and ovarian 
cancer(Gudmundsdottir & Ashworth 2006). As mentioned previously in chapter 2.4 the 
expression levels of the repair protein O6-methylguanine DNA methyltransferase (MGMT) 
in glioblastoma particularly can lead to a resistance to the common chemotherapeutic 
modality temozolomide (TMZ) (Hermisson et al. 2006; Silber et al. 2012; Brandes et al. 
2008). The expression changes in MGMT levels for glioblastoma are now being proposed 
as a biomarker for treatment modalities, so only MGMT negative patients would receive 
TMZ(Wick & Platten 2014). This is due to MGMT being able to remove the most toxic 
lesion caused by TMZ, O6-methylguanine, in a single enzyme pathway which stops 
apoptosis being initialised due to the cells inability to efficiently repair the lesion (Stupp et 
al. 2001), more detail of this is in chapter 2.4.3.  
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DNA repair protein expression levels can differ within the same individual, same 
tissue and for healthy and cancerous cells. In colon cancer, an increase in the base excision 
repair (BER) proteins  8-oxoguanine DNA glycosylase (OGG1) and poly(ADP-ribose)-
polymerase 1 (PARP1) was seen in comparison to the healthy tissue (Dziaman et al. 2014). 
In glioblastoma, Liu and co-workers found an increase in the expression levels of 
alkyladenine DNA glycosylase (AAG) in correlation with severity and the grading of 
tumour that was different from the healthy tissue surrounding it (Liu et al. 2012).  
 
The first part of this results chapter presents the results of measurements of gene 
expression levels of repair proteins using quantitative polymerase chain reaction (qPCR). 
Genes belonging to the base excision repair pathway were measured in particular as well 
as genes involved in the PAR signal cascade, PARylation and double strand break 
signalling. These measurements of basal level repair gene expression were then compared 
to the cell lines’ ability to repair DNA damage induced by temozolomide and radiation, the 
standard for glioblastoma treatment.  
 
The qPCR results were statistically analysed using a one-way ANOVA after 
experiments were repeated at least three times. The effects of TMZ on cell survival were 
also analysed using two-way ANOVA after experiments were done in triplicate. For 
experiments involving radiation a three-way ANOVA was employed after 3 repeats in 
triplicate as well as fitting to either the linear quadratic (LQ) model. 
 
4.2 Aims and Hypothesis 
In this chapter the overall hypothesis was tested; that an imbalance in the BER 
capacity affects glioblastoma cells repair capability after treatment of temozolomide and 
irradiation. To test this hypothesis this chapter aims to reliably measure the expression 
levels of the proteins of the BER pathway basally expressed in these cell lines and robustly 
measure their survival to treatment.   
To test this the following objectives were set: 
 Discover the expression levels of repair proteins within 5 glioblastoma cell lines. 
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 Confirm these expression levels are consistent to the protein level and the activity 
level.  
 Compare the survival of these cells after traditional treatment.  
4.3  Results 
4.3.1 AAG levels vary in different glioblastoma cell lines  
Gene expression levels for different DNA repair proteins were measured in five 
glioblastoma cell lines to compare their background repair gene expression levels and 
evaluate if any deficiency in gene expression could potentially explain differential 
response in repair ability or response to potential treatment regimens.  
 
The first repair pathway of interest evaluated was the BER pathway.  The BER 
pathway can be seen in Figure 4-1 and is described in detail in chapter 2.4.3.1. The BER 
pathway is initiated by a DNA glycosylase which removes the damaged base by cleaving 
the glycosylic bond linking the base to the DNA sugar phosphate backbone, resulting in the 
formation of an abasic site. The glycosylase can either be monofunctional, performing this 
role only, or bi-functional, additionally cleaving the DNA sugar-phosphate backbone at the 
3'OH position, resulting in the generation of a nick in the DNA strand (Wallace et al. 2013). 
When monofunctional glycosylases initiate BER, the cleavage of the sugar phosphate 
backbone post damaged-base removal is done by an AP endonuclease (APE) enzyme 
(Chohan et al. 2015). This cleavage leaves a 5’dRP in the backbone of the DNA and a single 
strand break. Polymerase β (PolB) than removes the 5’dRP and the 5'OH and inserts the 
replacement base. The DNA is then fully ligated by DNA ligase III (Lig III/I) or I creating 
nick free correct DNA (Srivastava et al. 1998). This pathway is of particular interest as it 
affects the cells response to the majority of the lesions caused by TMZ on the DNA. Over 
70% of the lesions in DNA caused by TMZ are repaired by the BER pathway (Zhang et al. 
2012).  
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Figure 4-1 Damage repair pathways initialised by damage from TMZ. The enzyme 
cascade is initialised by AAG and each enzyme is held in close proximity to the damage by 
XRCC1, scaffolding protein. PARP signals a SSB has been created. O
6
MeG adducts are 
repaired by MGMT if the protein is present.  
 
In the treatment of glioblastoma, TMZ treatment is the first line treatment 
(Beauchesne et al. 2010), and a number of repair pathways are important in whether the 
patient’s tumour will respond to the treatment (Happold et al. 2012). Some of these 
important proteins in the repair of damage caused by TMZ treatment are shown in Figure 
4-1 these were measured for their mRNA expression levels in the 5 cell lines used within 
this study. As illustrated by Figure 4-2, the repair proteins involved in BER show a varied 
expression profile and it is clearly visible that the first protein within the BER pathway 
that deals with TMZ lesions, AAG, has highly variable mRNA expression in different cell 
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lines. The expression levels within T98G were used as a reference point in all 
measurements, and all measurements given are in relation to the expression level of 1 
seen in T98G.  
 
Our first finding using qPCR was of very high levels of variation within AAG 
expression were observed in cell lines, Figure 4-2 a. This was specifically found as high 
levels of AAG in LN18, ~12.85 relative quantification (RQ), and U87, ~15.83 RQ, when 
compared to the other cell lines, which displayed similar expression levels to the 
reference, T98G. The expression levels of AAG in these two cell lines, LN18 and U87, were 
statistically higher than the other cell lines (p <0.0001).  
 
From this we further measured the rest of the BER proteins and found that there 
was variation in expression levels, however, it was lower than those seen in AAG levels. 
However, the cell line LN18 did display higher levels for all the BER proteins compared to 
the other cell lines. The expression levels for APE were highest in LN18, ~1.99 RQ, which 
was statistically higher than all other cell lines (p < 0.0001), seen in Figure 4-2 b. U87 and 
U251 both showed lower levels of APE mRNA, 0.5 and 0.526 RQ, respectively. As seen in 
Figure 4-2 c the expression level of U251 and U87 was statistically lower than the 
reference cell lines T98G (p < 0.0001). The expression levels for PolB were similar for all 
cell lines, with T98G and LN18 expressing 1 and ~1.2 RQ respectively, whilst the other cell 
lines were all below 1 for relative quantification. The difference in expression levels is 
largest between LN18 and U251, p > 0.0001, however, the differences seen between LN18 
and U87 were still significantly different p > 0.0002. The expression levels of mRNA for 
Lig3 (Figure 4-2d) shows similar levels of expression between all cell lines except for 
LN18. The expression level of LN18 is ~2.16 RQ and statistically different from the 
expression seen in all the other cell lines with a p value of <0.0001. The variation between 
gene expression levels may seem large, however, the difference is most notable for the 
AAG gene, whilst the expression of the remaining BER genes is fairly comparable between 
cell lines.  
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Figure 4-2 BER repair mRNA expression levels. a) AAG mRNA expression levels. 
b) APE mRNA expression levels. c) PolB mRNA expression levels. d) Lig3 mRNA expression 
levels. All experiments were conducted on 3 separate mRNA extractions in at least triplicate 
on a minimum of n=3. T98G was always used as a reference sample and so remains at 1 
relative expression, statistical significance was established by one way ANOVA. 
 
As large variations were found in BER proteins, specifically in AAG, we went on to 
measure other repair proteins. As shown in figure Figure 4-1 another important protein in 
the repair of DNA after treatment with TMZ is MGMT. MGMT is a repair pathway in its own 
right, MGMT reverses the O6-methylguanine adduct by removing the methyl group from 
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the damaged base. The qPCR results show that LN18 and T98G both express MGMT, which 
was expected, but U251 had low levels of mRNA detected. Low levels of MGMT expression 
was surprising as the regulation of the production of this protein is through methylation of 
the promoter (Costello et al. 1994) and the protein is either expressed or not.  
 
Further proteins which are complementary but not directly involved in the repair 
of the DNA by BER include PARP, poly(ADP-ribose) glycohydrolase (PARG) and X-ray 
repair cross-complementing protein 1 (XRCC1) therefore the expression of these genes 
were also measured. PARP is important for single strand break (SSB) signalling whilst 
PARG catalyses the hydrolysis of the PARylation formed by PARP aiding in DNA damage 
repair. The expression levels of XRCC1, PARP and PARG are all similarly expressed across 
all 5 cell lines, in comparison to the BER proteins, as can be seen in Figure 4-3.  
 
We found that the expression levels for XRCC1, Figure 4-3 b, are highest in LN18 
and U87, ~1.59 RQ and ~2.0 RQ respectively in comparison to T98G. Which is significantly 
different from the other cell lines expression levels, with the most determinedly different 
expression levels between U87 and U251, p <0.0001, LN18 and U251, p = 0.0007, and 
U87 and A172, p = 0.0002. PARP and XRCC1 have tightly related roles due to PARP being 
closely associated to the stability of XRCC1 at the site of damage (El-Khamisy et al. 2003). 
However, XRCC1 recruitment to the site of damage and recruitment of proteins at BER 
specific damage, is independent of PARP1 (Campalans et al. 2013), however, PARP2 
maybe able to take over this role. Whether this linked role of PARP and XRCC1 effects 
expression over healthy cell lines is unknown, but we found that only LN18 expressed high 
levels of PARP, ~1.7 RQ compared to a relative quantification of 1 to 0.5 and below for the 
other cell lines, Figure 4-3 c, however, how much protein is present is unknown. The 
largest difference is expression levels are between LN18 and both U251 and U87 
(p<0.0001). PARG is involved in degrading the PARylation caused by PARP, signalling the 
SSB (Oka et al. 2006) and if this PARylation is not hydrolysed it can lead to a sensitivity in 
cytotoxicity from toxic agents (Koh et al. 2004), such as TMZ. There are very similar levels 
of PARG in all cell lines, but the highest levels of expression are seen in LN18(~1.32 RQ) 
and U87 (1.52 RQ) Figure 4-3 d. Ligase III, which is a BER protein that predominantly 
ligates DNA damage occurring in the mitochondria  (Simsek, Furda, et al. 2011), was found 
to be higher in the cell line LN18 (~1.5RQ) and U87 (~1.33RQ) as seen in Figure 4-3 e, but 
not to the same extent as the AAG protein overexpression in that cell line. 
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Although there are significant differences between cell lines in the expression 
levels for all these genes, the most extreme difference was in the expression levels of the 
AAG gene, where the cell lines LN18 and U87 had high AAG gene expression levels. 
However, the expression levels of the other genes in U87 were similar to the expression 
levels seen for the other cell lines. Due to the closely linked roles of BER with XRCC1, 
PARP, and PARG which, when repair is orchestrated to allow the enzymes to be in close 
proximity, lowering the time that toxic intermediates are left unrepaired less cell death 
should occur, however, such high levels of AAG in U87could make this cell line more 
susceptible to chemotherapeutic agents than the others.  
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Figure 4-3 Repair protein mRNA expression levels. All experiments were conducted 
on 3 separate mRNA extractions in at least triplicate on a minimum of n=3. T98G was always 
used as a reference sample and so remains at 1 relative expression, statistical significance 
was measuered by one way ANOVA. 
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QPCR results rely on the expression levels of mRNA within a cell, however, mRNA 
levels do not always correspond to the protein levels. In 2004 the human genome project 
was finalised and mapped the 2.85 billion base pairs within the DNA (Lander et al. 2001). 
There are ~200 cell types in the human body which, due to different methylation status of 
the histones and DNA, create different proteins to be translated and expressed and allow 
the cells to have different functions. There are approximately 20,500 proteins coded for 
within the human genome (Clamp et al. 2007) and these can be further modulated as a 
result of alternative splice variants and post-translational modifications which affect the 
function of the proteins. These effects can lead to different protein expression levels. 
Furthermore, proteins are also regularly degraded within the cells through other 
mechanisms some of which are related to stress on the cells.  
 
Because of the effects noted above, there have been a number of studies to look 
into the differences between mRNA expression levels and protein expression levels. One 
such study performed by Lundberg et al. in 2010 took 3 cancer cell lines; U251, A431 
(squamous cell carcinoma) and U-2 OS (osteosarcoma) and compared the mRNA levels to 
the protein levels. They employed the use of RNA seq and found 11,575 genes, which were 
commonly expressed in all cell lines. To compare proteins levels a triple-SILAC method, 
stable isotope labelling by amino acids in cell culture, was employed in which mass 
spectrometry is utilised with triple peak detection locating proteins. This study found that 
only 5333 proteins were expressed across all cell lines, with 65% of these having similar 
expression levels to those found in the RNA seq with a difference of 2 fold expression 
change accepted by the authors (Lundberg et al. 2010).  
 
As can be seen in Figure 4-4, 3 protein levels were measured by western blotting; 
namely, AAG, APE and MGMT, with normalisation to beta-actin levels, once normalised to 
beta actin levels the protein levels, were compared against T98G as 1 in a ratio of 
expression to facilitate comparison to the results obtained by qPCR. AAG showed the 
biggest differences in mRNA expression levels with all other expression levels or repair 
proteins being similar to those found in the qPCR for APE. MGMT is classically thought of 
as being either expressed or not, due to the epigenetic regulation of the protein (Costello 
et al. 1994). However, the qPCR results were not entirely consistent with this finding with 
U251 showing a low level of mRNA transcripts as being present for MGMT. The differences 
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in repair protein mRNA expression levels for AAG show that there is a many fold level of 
diversity between the 5 cell lines. However, this large fold change in expression levels of 
AAG when looking at the protein level show that LN18 has the highest expression of AAG, 
with a 4.8 fold increase from T98G levels.  U87 was also found to have higher levels of AAG 
than the remaining 3 cell lines, however, this was not as high as when measured by qPCR 
and looking at the mRNA. LN18 and U87 always exhibited higher expression levels of AAG 
than the other cell lines whilst the APE expression levels showed that U87 had high levels 
of APE, which were significantly larger than the expression levels seen in LN18 and T98G. 
However, these protein results for the cell line U87, which displayed the highest 
expression levels for the APE protein, do not correlate with the expression levels of mRNA 
seen by qPCR. In the cell line U87, high APE levels found by western blot correlate well 
with a study by Naidu et al., 2010 which found that U87 cells had a higher expression than 
U251, which has been replicated here (Naidu et al. 2010).  
 
 
 
Figure 4-4 Western blot analysis of proteins important to TMZ.  Show 
representative western blots of protein expression for a) AAG, b) APE and c) MGMT 
respectively. D, e and f show AAG,APE and MGMTprotein expressions normalised over a 
minimum of 3 experimental replicates.   
 
A study by Liu et al., which investigated AAG expression levels in patients with 
different WHO graded gliomas, found a positive correlation between the AAG expression 
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level and the grading of tumours with higher graded tumours responsible for lower 
patient survival rates. As all of the cell lines in this research are derived from grade IV 
glioblastoma tumours, this study by Liu would suggest that all the cell lines express high 
levels of AAG in comparison to a grade I glioma (Liu et al. 2012). As Liu et al (2012) found 
high AAG levels correlated to a poor response to therapy it is reasonable to expect that the 
cell lines LN18 and U87 would have a lower survival after TMZ treatment than other cell 
lines, in an MGMT dependent fashion (Liu et al. 2012). This resistance to 
chemotherapeutics due to high AAG levels is supported by Agnihotri, who correlated an 
overexpression of AAG with resistance to TMZ (Agnihotri et al. 2012). However, this does 
not take in to consideration the whole pathway and the important balance that the other 
BER proteins play in successfully repairing the DNA base damage. As well as further 
differences between cell lines and whole human patients, which have more factors that 
will affect survival and tumour growth than just a single cell line.  
 
A study (Schulte et al. 2011) was conducted comparing the expression profiles of 
stem-like glioma cells with traditional glioblastoma cell lines to look for differences in 
gene expression and compare expression with those in in vivo tumours. From this 
transcriptomic profile the authors wanted to find novel treatments which were important 
in real tumour situations for commonly expressed genes in both cell lines, stem-like 
glioma cell lines and tumours. To measure and compare the gene expression the authors 
employed microarray techniques to measure gene expression in a large set of glioblastoma 
cell lines, stem-like glioma cell lines and tumour tissue. This microarray data was then 
loaded into the GEO database for future researchers to use: this dataset is identified as GSE 
23806. In the conventional cell line samples, they used 4 of the 5 that have been worked 
with in this study. These lines are A172, LN18, T98G and U87.  
 
From this GSE set the expression data was extracted for the genes of interest. 
Taking the raw expression of the gene amplified on the microarray chip as provided by 
GEO 2 R expression profiles were normalized to T98G to have an expression of 1, Figure 
4-5, so as to make all results comparable to the western blots and qPCR.  
 
 Controversially from this data set AAG levels are shown to have very little 
variation, unlike what was shown in qPCR and Western blot. There is a little variation in 
the rest of the BER proteins, however, it is lower than seen in our qPCR results. As can be 
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seen in Figure 4-5 a-d LN18 in this microarray had the highest level of all BER proteins, as 
seen in our qPCR results, except for the LIG3 results. The greatest difference in expression 
is seen in MGMT levels, Figure 4-5 e, which was expected, as non-expressing MGMT cell 
lines value were between 0.42 – 0.46 (U87 and A172 respectively), in comparison to 
MGMT expressing values of 1.3 – 1 (LN18 and T98G respectively).   
 
Although it was interesting to compare the results found through qPCR and 
Western blot to microarray data available online, there are issues with trusting results 
from data available online. Within our study and this one the cell lines were cultured in the 
same conditions for both this current study and theirs, however, the authors did not 
provide information on where these cells were obtained from or if they were verified. 
Ours were all obtained from ATCC in August 2015. We take the values that we obtained as 
more important than those found in this microarray data, as these cells were specifically 
used for further  
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Figure 4-5 Microarray analysis from GSE23806 using platform GPL570. Cell lines 
were A172: GSM587161, LN18: GSM587185, T98G: GSM587179, U87: GSM587180. All p 
values were normalised against T98G to make comparable to western blots and qPCR results.   
There are other proteins which are important to the survival of cells from 
radiotherapy treatment as well. In actual tumours are heterogenesis, and some studies 
predict to be filled with glioblastoma cancer stem cells. These studies have shown that the 
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predicted glioblastoma stem like cells, marked by CD133 and nestin, are more 
radioresistant than the other cell lines (Ahmed et al., 2015 and Carruthers et al., 2015). 
And that this difference in radioresistance is linked to a lack of G2/M arrest as the cancer 
stem like cells have an increase in phosphorylation of ATM and Chk1 which this pathway 
affects mitosis through Cdc25c and cell cycle overall (Lui et al., 2018). One of these studies 
have found that the inhibition of CHK1, which is upregulated in these cell types, 
radiosensitizes glioblastoma cells, but not to the same extent in glioblastoma stem like 
cells (Ahmed et al., 2015).  Other studies have shown that ATM kinase sensitises cancer 
stem cells to radiotherapy (Carruthers et al.,2015) and others have shown this is through 
a link with interlukin-6, preventing cell proliferation (Lim et al., 2018).  Although the gene 
regulation for radioresistance is multifactorial, but is controlled or linked through the DNA 
repair and cell cycle systems.  
4.3.2 AAG activity assay 
 
We next wanted to understand how the mRNA expression level and the protein 
expression levels effects the activity levels of AAG within the cells. To do this collaborators, 
Eleanor Healing and Dr. Ruan Eliott, have devised an activity assay which works by 
measuring the release of fluorochromes attached to synthesized DNA containing 
hypoxanthine adducts which AAG can remove. As the hypoxanthine is removed the 
fluorescence decreases, showing an increase in activity. As expected from our results in 
qPCR and western blot, we found higher levels of activity within LN18 than in U251, seen 
in Figure 4-6 a. However, Figure 4-6 b shows the activity levels for A172 and T98G were 
measured on a different day, using a different standard curve and so cannot be directly 
compared with the results from LN18 and U251, but we can clearly see that the activity 
levels are very similar in these two cell lines (Figure 4-6).  
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Figure 4-6 AAG activity in cell lines; a) LN18 and U251 and b) A172 and T98G. 
The nuclear fraction of the cell was extracted, purified and quantified. Normalised levels of 
protein were seeded into a 96 well plate containing fluorescent DNA containing AAG specific 
substrates. One biological repeat was used and the error is standard deviation.  
4.3.3 High AAG levels don’t necessarily lead to an imbalance in BER 
The first thing we did to test whether the enzyme expression levels of BER 
actually led to an imbalance was use an alkylating agent which only causes damage 
repairable by BER. To eliminate the effects of MGMT on survival of cells after treatment 
with TMZ and to elucidate the role of AAG on cell survival after treatment with an 
alkylating agent, 3 cell lines were chosen to be treated with methyl methanesulfonate 
(MMS). MMS is an SN2 alkylator and therefore only adds methyl groups to nitrogen, which 
results in only the BER pathway being activated to repair this alkylation damage (Wyatt & 
Pittman 2006). 
 
The three cell lines chosen were LN18, T98G and U87. T98G has the average 
expression of all the BER enzymes compared to the other cell lines as well as being used as 
the reference sample for the qPCR measurements. LN18 has a high expression of AAG and 
a higher expression of the other BER enzymes compared to the other cell lines. U87 has 
high levels of AAG, however, it has an average expression of other repair proteins. As the 
BER pathway is a multistep pathway which relies on each enzyme to be present and 
active, in turn, to repair the damage to the DNA caused by alkylating agents, higher 
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expression levels of singular enzymes in this pathway has been postulated to increase 
sensitivity to alkylating agents (Fu & Samson 2012). This is because each end-point 
product from the enzymes repairing the DNA in the BER pathway is toxic to the cell except 
the final ligation (Wyatt & Pittman 2006; Fu & Samson 2012). The potential for imbalance 
in BER for the cell line U87 due to the high levels of AAG and lower levels of other repair 
proteins, specifically PolB and PARP could lead to sensitization to MMS. When these cell 
lines are measured for BER sensitivity through treatment with MMS (Figure 4-7) it can be 
seen that the potential imbalance in U87 creates a sensitivity to MMS treatment. U87 is 
more sensitive to MMS, which is noticeable at 1.5 mM. However, this sensitivity is not 
statistically significant in comparison to T98G and LN18, even at 2 or 2.5 mM. T98G and 
LN18 have very similar sensitivities to treatment with MMS, and as mentioned are more 
resistant to MMS. This could be due to both cell lines having balanced BER enzyme level 
pathway. Even though LN18 displays high levels of AAG, it also has higher levels of all the 
other enzymes within the pathway too.   
 
Figure 4-7 Survival curves after treatment with a range of mM doses of MMS for 
T98g, U87 and LN18. A minimum of 3 repeats in triplicate were conducted with two-way 
ANOVA statistics applied.  
4.3.4 Survival of glioblastoma cell lines after treatment is dependent 
on the expression of MGMT 
4.3.4.1 Survival after TMZ 
We next wanted to understand how this BER imbalance affected glioblastoma cell 
lines response to standard treatment. As shown in Figure 4-8 the MGMT positive cell lines, 
namely LN18 and T98G, were more resistant to TMZ treatment compared to the MGMT 
negative cell lines, A172, U251 and U87, even at a low dose of temozolomide (100 μM).  
The predominant factor, within these cell lines, causing resistance to TMZ is MGMT. At low 
doses of TMZ the cell lines LN18 and T98G show some differences in sensitivity from each 
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other as LN18 appears mildly more sensitive to TMZ when examined up to a TMZ dose of 
100 μM. However, at higher doses T98G is the most resistant to TMZ treatment of all the 
cell lines tested. As shown in the table below, these differences in dose sensitivities for 
LN18 and T98G lead to EC50, which is the effective concentration which kills 50% of the 
cells, to be 273 μM of TMZ for LN18 and 229.2 μM for T98G (Table 8).  
 
Despite a similar EC50 for these two MGMT positive cell lines, if we examine the 
survival curves we note survival is similar up to a TMZ dose of 500 M. From then on, 
there is a statistically significant difference in survival (p=0.035) and T98G is more 
sensitive to TMZ than LN18, up to a TMZ dose of 1000 M. The high levels of AAG in LN18 
could explain why it is more resistant to TMZ, as would be justifiable by Agnihotri and 
Liu’s findings however, the doses at which the cells become sensitive to TMZ are far higher 
than those used within a clinical setting and high or low AAG expression would not affect 
treatment outcome in MGMT positive patients.  
 
When comparing the results of the MGMT negative cell lines, A172, U251 and 
U87, the cell line A172 was the most sensitive cell line, with only 10% of the originally 
plated cells forming colonies at 100 M of TMZ. When looking at Table 8 it is clear that 
A172 also had the lowest EC50 (24.62 M) however, we notice that the curves are similar 
until 25µM in TMZ sensitivity. Whereas, the EC50 for both U251 and U87 were similar; 
48.19 and 45.18 M of TMZ respectively. However, towards the high doses of the curves, 
100 M of TMZ, U251 is significantly more resistant to TMZ than A172 and U87(p=0.047). 
At 75 M of TMZ U251 is more resistant to TMZ that A172(p=0.0051) and U87 (p=0.042). 
All of these cells would be sensitive to TMZ in a clinical setting. The BER pathway protein 
expression levels seemingly have no effect on the response of these cells to TMZ.   
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Figure 4-8 GBM cell lines treated with a range of TMZ. A shows all five cell lines 
treated to 100 μM, no statistics were performed on this treatment. B shows MGMT negative 
cell lines. C shows MGMT positive cell lines treated up to 1000μM. A minimum of n=3 on 
triplicate data, a two-way ANOVA was used and the curves fitted with the hill model. 
 
Using survival curves shown above the EC50 values were then calculated for all 
cell lines in the presence of TMZ:  
  
a 
b 
c 
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Cell Line EC50 of TMZ (μM) Std. Error 
A172 24.62 +/- 1.53 
LN18 273 +/- 5.07 
T98G 229.2 +/-9.32 
U251 48.19 +/-3.99 
U87 45.18 +/-4.02 
Table 8 The difference in EC50 after treatment with TMZ in glioblastoma cell lines. 
4.3.4.2 Survival after treatment with radiotherapy  
Cells were characterised for their response to escalating radiation doses to 
determine a survival response to radiation. This allowed further characterisation of the 
cell lines in terms of their ability to repair and survive in light of the knowledge of the 
repair status of the cells. The surviving fractions were calculated and the data fitted to a 
model describing the curve. The cell lines survival were fitted using the LQ model 
Equation 3 with the alpha and beta ratios calculated.  
 
Equation 3 Linear Quadratic (LQ): 
SF = e−(α∗D+β∗D
2) 
D=dose 
α= low dose surviving fractions (linear area of graph) 
= higher dose surviving fractions (Quadratic area of graph) 
 
This equation was further modified to take into account the cell death at 0 Gy 
when cells were treated with TMZ. This produced a further constant to analyse, to show 
the combined effect of TMZ and X-rays together, the Y0.  
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Equation 4 Modified LQ: 
SF = γ ∗ (e−(α∗D+β∗D
2) ) 
The LQ model describes the curve fitting as one exp -*D component and a *D2 
component. The *D section of the equation describes the linear portion of cell killing, 
which represents single tracks throughout the cell causing lethal lesions which are 
repaired linearly (Brenner 2008). The *D2 section describes when multiple tracks 
penetrate the nucleus and cause lethal lesions, leading to a quadratic section of the curve 
(Brenner 2008).  
 
We can clearly see that the MGMT-positive cell lines, LN18 and T98G, 
unsurprisingly, the addition of TMZ treatment did not increase cell killing in combination 
with X-rays (Figure 4-9 a and b). This was expected as these cell lines are not sensitive to 
TMZ as shown above. The addition of the TMZ affected the parameter  (survival at 0 Gy) 
of the MGMT-positive cell lines only slightly, 0.92 and 1.1 for LN18 and T98G respectively 
from a survival of 1, and not even to necessarily lower survival as shown in T98G. We next 
examined the alpha/beta ratio, which represents the dose at which the linear and the 
quadratic area of the graph is equal, but furthermore, low alpha/beta ratios are consistent 
with more radioresistant tissue (Brenner 2008). Most tumours show high alpha/beta ratio 
typically over 10 Gy (Williams et al. 1985). The alpha/beta ratios for LN18 were similar 
for both with (23.33 Gy) and without (21.43 Gy) TMZ (shown in Table 9). However, for 
T98G the doses were wildly different and negative, -28.46 and -60 Gy without and with 
TMZ respectively. Minus doses in Gy are nonsensical and therefore the alpha/beta doses 
for T98G are ignored. Neither cell line, T98G or LN18, reach 10% survival at 5 Gy. Neither 
LN18 or T98G appeared to display hypersensitivity at low doses. This was not expected as 
other studies have found that doses between 0.2-0.8 Gy show hypersensitivity in T98G 
(Short et al. 1999).  
 
 
We next examined the MGMT-negative cell lines response to treatment of X-rays 
with and without TMZ, Figure 4-9 c-e.  All MGMT-negative cell lines displayed sensitivity 
when treated with TMZ and X-rays in combination, with Y0 values that were 0.74, 0.67 and 
0.42 of the fraction was reduced when TMZ was added in A172, U251 and U87 
respectively. With the addition of TMZ at 5 Gy the survival fraction for all cell lines was 
below 10%, with ~ 5% survival for U251 and U87, but 8% survival for A172. This is in 
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contrast to treatment with X-rays alone (5 Gy) where survival for all 3 cell lines is 
approximately at 15%. Hypersensitivity at low doses occurred in one of these cell lines, 
U87, this can be seen in the “dip” in the data points compared to the red curve at 0.5 Gy 
with TMZ and X-rays. The radiosensitivity of the cells was affected by the addition of TMZ 
in these cell lines, however, this was not predictable. This was measurable from looking at 
the change in the alpha/beta ratios, shown in Table 9 The output of the constants from 
fitting either the LQ model to the survival data. Y0 is survival at 0 Gy. 
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Figure 4-9 Survival fractions after treatment with X-rays or X-rays and TMZ. 
a)LN18, b)T98G, c)A172, d) U251 and e) U87. Cell lines fitted with the best fit models for 
each cell line when treated with X-rays with and without 25 μM of TMZ. A minimum of 3 
repeats in triplicate were performed and statistics were model fitting of LQ.  
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Cell line  (Gy-1) Std. error β (Gy
-2
) Std, error α/β (Gy)  
 
R
2 
A172 0.42 0.086 0.0094 0.026 44.68 1 0.94 
A172 + TMZ 0.27 0.060 0.035 0.018 7.71 
4 
0.74 0.97 
LN18 0.30 0.062 0.014 0.017 21.43 1 0.92 
LN18 + TMZ 0.28 0.106 0.012 0.028 23.33 0.92 0.82 
T98G 0.37 0.058   -0.013 0.014 -28.46 1 0.95 
T98G + TMZ 0.36 0.048 -0.006 0.012 -60 1.1 0.97 
U251 0.30 0.12 0.019 0.037 15.79 1 0.81 
U251 + TMZ 0.16 0.14 0.047 0.040 3.40 0.67 0.82 
U87 0.23 0.061 0.028 0.017 8.21 1 0.94 
U87 + TMZ 0.25 0.11 0.015 0.030 16.67 0.42 0.84 
 
Table 9 The output of the constants from fitting either the LQ model to the survival 
data. Y0 is survival at 0 Gy. 
 
 
 
4.4 Summary  
Base excision repair is a multistep DNA repair pathway which is important in the 
treatment of glioblastoma as it repairs the most common lesions formed by the treatment 
with TMZ (Bobola et al. 2012). Expression levels have been monitored by other groups for 
individual repair proteins as a common part of elucidating the mechanisms for resistance 
to treatment to many cancers (Agnihotri et al. 2012; Naidu et al. 2010). No other studies 
report a range of glioblastoma cell lines that are assessed for levels of repair proteins 
specific to TMZ damage. These repair proteins were assessed to examine potential 
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differences in BER expression levels and if these differences affect the cell lines response 
to TMZ and/or X-rays.  
 
What was evident in this chapter is that these 5 cell lines had different expression 
levels of proteins important to the repair of TMZ lesions on the DNA. Three cell lines 
expressed mRNA levels of MGMT, as shown in the table below, however this was only 
evident at the protein level in 2 of the cell lines, LN18 and T98G. MGMT levels had the 
biggest effect on whether the cell line was sensitive to TMZ or not. AAG expression did not 
seem to affect sensitivity to TMZ in the MGMT negative cell lines as A172 was the most 
sensitive, with an EC50 of 24.62 μM. However, in combination treatment with X-rays and 
TMZ U87 was the most sensitive cell line, with the EC50 dropping from 2.46 Gy to 0.059 
Gy.  
 
Cell 
line 
MGMT 
expression 
AAG expression EC50 TMZ 
μM 
EC50 X-rays 
Gy 
EC50 combined 
Gy 
A172 0 1.704 24.62 1.766 1.247 
LN18 0.986 12.880  273 2.046 1.952 
T98G 1 1  229.2 2.377 2.604 
U251 0.0342 0.736 48.19 2.423 1.841 
U87 0 15.8262 45.18 2.461 0.0595 
Table 10 A comparison of the expression levels of AAG and MGMT correlated to 
EC50s from different treatment modalities in glioblastoma cell lines. 
 
From the qPCR and western blot results, a potential imbalance in BER proteins 
was noted in U87, with a balanced increased levels of BER protein expression found in the 
cell line LN18. The other cell lines in the study (A172, T98G and U251) showed similar 
expression levels for all other BER proteins. The other repair proteins of interest to TMZ 
treatment were measured and found to be comparable in all cell lines, with the exception 
of MGMT.  
 
The cell lines’ sensitivity to TMZ treatment, measured as in changes in cell 
survival in clonogenic assays, was shown to be dependent on the MGMT status, as 
previously reported (Hermisson et al. 2006). However, the imbalance in BER was notable 
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when treated with MMS alone, an agent not resulting in O6-MeG adduct formation and 
therefore not requiring MGMT for repair and survival. With these MMS treatments, U87 
was more susceptible to cell death than either LN18 or T98G.  
 
All five cell lines had similar EC50 results from treatment with X-rays alone, 
however, when concurrently treated with TMZ it was shown that the EC50 was 
significantly reduced in U87, to a dose of 0.05947 Gy. This sensitivity could be due to the 
high expression levels of the initial enzyme AAG, however, not of the other enzymes, which 
could lead to a build up of AP sites.  In comparison to the other cell lines, which were 
sensitised to TMZ when treated with X-rays as well, which included A172, LN18, and 
U251, this sensitisation lowered the EC50 for the combined treatment results. However, 
the decrease in combined EC50 for LN18 is not significant. However, T98G had an increase 
in the EC50. This increase in EC50 could be due to there being so very little difference 
between the survival curves with the addition of TMZ. But the increase in the EC50 is by 
237 cGy, which is comparatively quite high. From this it can be clearly deduced that the 
MGMT status on the cell lines has the biggest effect on whether combination treatment 
would have any advantage in cell killing and therefore a consideration when treating 
patients.  
 
The imbalances found within the BER pathway for U87 will be further examined 
in the next chapter, along with trying to create an imbalance in the other cell lines by 
inhibiting different enzymes within the BER pathway and measuring if the cell’s sensitivity 
to different treatments change accordingly.  
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5 INVESTIGATING 
PHARMACOLOGICAL 
MODULATION OF BER WITH 
DIFFERENT TYPES OF 
RADIOTHERAPY 
5.1 Introduction 
As shown in chapter 2.4.4, O6-methylguanine DNA methyltransferase (MGMT) 
positive cell lines are resistant to the chemotherapy used in treating glioblastoma. One of 
the most common ways to overcome this resistance is by combining chemotherapy with 
inhibitors for the proteins which regulate DNA damage, repair and structure. Poly (ADP-
ribose) polymerase (PARP) inhibitors have recently shown promise in trials for ovarian 
and other cancers (Mirza et al. 2016). Currently PARP trials are ongoing for the treatment 
of breast cancer in combination with Herceptin, an antibody to human epidermal growth 
factor receptor which is overexpressed on some breast cancers this treatment triggers the 
immune system to attack the cancer cell,  and temozolomide (TMZ) (Lord & Ashworth 
2017) as well as being the subject of numerous publications (Weil & Chen 2012; Lord & 
Ashworth 2017). As the preferred, or first-line, treatment of glioblastoma is TMZ, which 
causes lesions on the DNA that are mostly repaired by the base excision repair (BER) 
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pathway, modulating this pathway may lead to an increase in cell death due to disturbed 
and unfinished BER. Furthermore, as shown in chapter 2.5, there is a high variation in the 
expression level of BER enzymes in cell lines and, as studies have shown, in cancer 
patients (Leguisamo et al. 2017). This variation in expression levels combined with 
inhibiting certain enzymes within BER whilst treating with TMZ may lead to certain repair 
profiles being more susceptible to cell death with certain combinations of different BER 
inhibitors in conjunction with TMZ or radiotherapy and, if the survival differential is 
statistically significant, could be worth exploring further.  
 
The BER pathway, as explained in detail in chapter 2.4.3.1, is a multi-enzyme 
repair pathway which is initiated by DNA glycosylases, shown in Figure 5-1. For some of 
the TMZ-induced base damage, the initiating glycosylase is alkyladenine DNA glycosylase 
(AAG) (Srivastava et al. 2009). In BER, each repair protein in sequence is held in close 
proximity to the DNA being repaired by the repair accessory protein X-ray repair cross-
complementing protein 1 (XRCC1), which works as a scaffolding protein (Vidal et al. 
2001). This highly organized coordination of the repair pathway is particularly important 
as the DNA repair intermediates generated at each repair enzymatic step, such as AP sites 
and 5’dRP, can lead to cell death if not swiftly resolved (Fu, J. a Calvo, et al. 2012). 
 
Many inhibitors of the BER pathway are currently in clinical trials, including 
methoxyamine (MX) which was used in this study. MX inhibits AP endonuclease (APE) by 
binding to the abasic site formed by AAG activity on the methylated base resulting from 
TMZ treatment (Talpaert-Borlè 1987). The benefit of using MX is that it does not inhibit 
any other action of APE such as its role in metabolism (Evans et al. 2000).  The blocking of 
abasic sites accessibility by MX leads to an increase in unrepaired AP sites as shown in 
Figure 5-1.  Since AP sites are mutagenic, cytotoxic and can lead to single strand break 
(SSB) and double-strand break (DSB) formation during replication, MX treatment should 
lead to detrimental consequences. Therefore, treatment with MX in combination with TMZ 
or irradiation could lead to an increase in SSBs and a corresponding increase in cell death. 
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Figure 5-1 The base excision repair pathway and inhibition with methoxyamine. 
The base excision repair pathway is initialised by AAG which removes the methylated base 
leaving an Apurinic site. Methoxyamine binds to this site preventing APE from cutting this 
site and preventing the rest of the pathway from being activated. This will increase the 
number of Apurinic sites leading to a build up of toxic intermediates and increasing the 
toxicity of other treatments such as TMZ and radiation.  
 
The second inhibitor used in this study was pamoic acid (PA), which is a 
polymerase beta (PolB) inhibitor. PolB is also the next enzyme in the BER pathway after 
APE, has two roles in repairing the DNA comprising; 
 a lyase activity of the 5’dRP, created after the incision to the backbone of the DNA 
by APE 
 a gap-filling role (Sobol et al. 1996) which places new nucleotides into the strand 
of DNA filling the gap 
This is discussed in greater detail in chapter 2.6.3.1 There are a few published 
studies on the potential benefits of blocking PolB for the treatment of multiple cancers but 
most publications, whilst providing some evidence of the value of further investigation, 
did not document successes in in vitro situations (Wallace et al. 2013; Jaiswal et al. 2011; 
Asagoshi et al. 2010). One of the limiting factors for such studies is the lack of specificity of 
PolB inhibitors combined with low binding affinities. This has led to a concerted effort in 
recent years into producing better inhibitors for PolB (Gao et al. 2008). However, despite 
these limitations, we felt that researching the role of PolB inhibition in treatment of 
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glioblastoma with TMZ and irradiation would be useful in identifying potential benefits for 
further study in this area and may also help elucidate a role for unbalanced BER repair 
enzymes to be manipulated in personalised treatments.  
 
This chapter focuses on work with inhibitors to measure toxicity of the inhibitor 
alone, at varying doses, when used to treat cells. Following this, the additional cytotoxicity 
in combination treatment was analyzed for the case of inhibitor and TMZ alone and with 
X-rays/protons and TMZ in combination. These combination studies were intended to 
clarify the role of BER and BER imbalance in treatment for glioblastoma. Currently there is 
very little research available on the effects of inhibiting APE1 and even less on PolB under 
the influence of different radiation types. The majority of the research studies available on 
inhibiting APE1 or PolB is on cells over- or under-expressing BER proteins and their 
response to alkylating agents(Yan et al. 2007; Montaldi et al. 2014; Taverna et al. 2001; 
Hazan et al. 2008; Barakat et al. 2012; Yang et al. 2010).  
 
5.1.1 Aims and hypothesis 
This chapter is focussed on the testing of the hypothesis mentioned previously 
that an imbalance in the BER capacity affects glioblastoma cells repair capability after 
treatment. To further test this hypothesis this chapter aims to take the cell lines previously 
measured for their BER capability to be further modulated with inhibitors for BER to see if 
this creates a greater imbalance sensitizing cells to traditional treatment; X-rays and TMZ 
as well as protons.  
To test this, the following objectives were set: 
 Discover if short term treatment with BER inhibitors leads to cellular toxicity  
 Identify if there is an interaction between BER inhibition and TMZ in cell lines with 
different basal levels of BER proteins 
 Evaluate the combined effect of X-rays and TMZ or Protons and TMZ on 
glioblastoma cellular survival, in presence or absence of BER modulation via 
inhibitors.  
 Establish if this BER imbalance produced from inhibitors affects cell growth and 
cell cycle. 
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5.2 Protons cause a greater cell killing effect in glioblastoma 
cell lines than X-rays.  
Before comparing the interaction of different drugs in combination with 
radiation and temozolomide, two different type of radiation were directly compared. From 
this later in the chapter the combination of drugs with these different radiation types will 
be compared to measure if they lead to greater levels of cell death due to the difference in 
DNA damage and therefore, potential syngerism from  DNA repair pathways.  
 
When comparing clonogenic survival 3 cell lines were chosen; LN18, U87 and 
A172, due to the vastly differing repair capabilities measured in chapter 4. LN18 has high 
expression levels of MGMT and AAG. U87 has high expression levels of AAG but does not 
express MGMT at all. And finally A172 does not express MGMT and has average levels of 
AAG. However these proteins should not affect the cell lines response to radiation damage, 
as they are responsible for repairing damage created by temozolomide and other 
alkylating agents. However, radioresistence is brought on from a plethora of different 
reasons. These are often interlinked to the cell cycle, DNA DSB repair pathways and 
signalling proteins (Krause et al., 2017).  
 
What we can see from figure … below that each cell lines was more sensitive to 
proton irradiation than X-rays. In LN18 and U87 there was visible hypersensitivity 
brought on from proton irradiation, which was not produced from X-ray irradiation. These 
comparisons will be drawn on further in figure 5.9.  
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Figure 5-2 Comparison of both X-rays and protons on the survival of glioblastoma 
cell lines. 3 cell lines; LN18 a), U87  b)and A172 c). Cell lines fitted with the RCR model. A 
minimum of 3 repeats in triplicate were performed. 
 
5.3 Short-term treatment of methoxyamine on glioblastoma 
cell lines does not lead to toxicity alone, but can be 
synergistic with TMZ in BER imbalanced cells 
5.3.1 Inhibiting APE1 
We first wanted to check the binding affinity of MX to abasic sites, so an assay 
was developed by the research team, Ms Eleanor Healing and Dr Ruan Eliot, which 
measures the release of fluorochromes attached to synthesized DNA containing abasic 
sites. The fluorochrome is released upon addition of the purified enzyme, APE, as a result 
of cleavage of the sites. As the abasic sites are cut by APE, fluorochrome attached to the 
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DNA may then be washed off which lowers the absorbance reading from the plate. 
Blocking of the abasic sites by MX inhibits the action of APE resulting in increased 
absorbance/fluorescence. 
 
From this we found in Figure 5-3 a) that 0.3 U/100L of purified APE lowers 
absorbance from 0.45 to 0.2 Abs at 450 nm demonstrating that recombinant APE enzyme 
is added to the modified DNA, cleavage at the abasic site occurs lowering fluorescence. 
Using this assay, it can be seen in Figure 5-3 b) when 32 pM/uL of MX was added to 
0.25pM of abasic site-containing DNA, it bound to approximately100% of the abasic sites 
thus fully inhibiting APE1. (0.33U/100uL of APE1 was added within all of the experiments 
with MX.) These assays show that MX does bind to DNA in an in vitro situation. Note, 
however, that this does not, and cannot, answer the question of whether the MX is taken 
up in to the nucleus to bind to the DNA.   
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Figure 5-3 Methoxyamine inhibition of APE1.  a) Using a fluorescent assay with 
designer DNA with a fluorochrome attached, the number of incisions made to the DNA by 
increasing levels of APE enzyme was measured by the decrease in fluorescence as incised 
DNA containing the fluorochrome was washed away. b) the concentration of methoxyamine 
needed to inhibit APE and stop the incision of DNA, which leads to an increase in 
absorbance as less DNA containing the fluorochrome is washed away. A minimum of 3 
biological repeats was performed. 
5.3.2 Methoxyamine toxicity 
To further study the cellular effects of MX but without any other treatment we 
measured the cytotoxicity of MX in the 5 glioblastoma cell lines which were categorised in 
the previous chapter for their basal levels of BER proteins and response to standard 
treatment modalities. The experimental design is described fully in the methods chapter, 
in summary the cells were measured for growth and viability in the presence of a range of 
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doses of MX. As can be seen in Figure 5-4 doses ranging from 50 M to 10 mM had little 
effect on the viability of the cell lines. However, at 50 mM there was a drop in viability in 
the majority of cell lines apart from U87. This drop in viability, however, could have been 
due to the increase in acidity in the media of the cells. The pH of the MX at stock 
concentration and at 10 mM were measured to have a pH of 6. Because of this acidity 
further experiments were limited to a maximum dose of 1 mM. The lack of toxicity from 
MX correlates with a study by Montaldi and co-workers in which fibroblast cells were 
cultured with MX treatment and left for 72 hours to measure viability, with doses ranging 
from 0.75-15 mM (Montaldi et al. 2014).  
  
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
90  Natalie Mayhead - August 2018 
 
 
 
Figure 5-4 Cytotoxicity of methoxyamine. a) LN18, b) T98G, c) A172, d) U251 and 
e) U87. Cells were seeded at a density of 5,000 cells per well. A range of MX concentrations 
were added to the cells and left for 48 hours. The cells ability to perform redox reactions was 
measured using a 1:10 dilution of alamar blue. Each graph represents a different cell line 
with a minimum of 3 repeats.  
As TMZ is the standard of care for glioblastoma, a combination of inhibitor and 
TMZ was assessed for overall toxicity over a 48 hour period. The concentration of TMZ 
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used for this study was 25 M as this is the amount found within the plasma of patients 
during clinical treatments. It was found that the addition of TMZ with MX showed no effect 
in cell growth or induction of cell death to any of the cell lines (data not shown).  
 
As a combination of MX with 25M TMZ had little to no effect in terms of cellular 
survival, higher doses were chosen according to the sensitivity of the cells due to the 
MGMT status. During 14 day clonogenic assays, the EC50 (TMZ) was found to be below 50 
M for MGMT-negative cell lines and lower than 300 M for MGMT-positive cell lines, 
however as these toxicity assays are over a shorter term, higher doses were used of 75M 
and 350 M for MGMT-negative and -positive cell lines respectively. The MGMT-negative 
cell lines all show in Figure 5-5 only a minimal increase in cytotoxicity when treated at 75 
μM of TMZ and 500 μM of MX. U251 and U87 when treated concomitantly with TMZ and 
MX each had a 9% mean decrease in survival rate.  The survival of A172 decreased by 11% 
with the addition of MX. None of these results were found to be statistically significant (2-
way ANOVA). 
 
The MGMT-positive cell lines both showed a statistically significant effect of the 
MX & TMZ combination with a drop in survival by 11.4% for LN18 and T98G by 10% 
(Figure 5-5). As the levels of AAG are different in these cell lines this indicates that the 
effect of inhibiting APE1 and sensitising cells to TMZ is not AAG dependent. Whilst MGMT 
status affected the cell lines sensitivity to TMZ, in all cases MX did further sensitise the 
cells to TMZ.  
 
In this study lower doses of MX were used in comparison to studies by other 
researchers (Montaldi et al. 2014; Agnihotri et al. 2014) to take into account the results 
from a clinical trial into MX in the plasma after treatment of patients. This trial found that 
levels of MX in the M range, rather than mM range, were found in the blood and as such 
any experiments which would be looking for a correlation between drug interactions for 
clinical usage, we felt, should be conducted at clinically relevant doses. Montaldi et al., 
(2013) treated T98G cells with a combination of MX and TMZ.  The dose of MX remained 
fixed at 20 mM, and although not clinically relevant, found that MX did sensitize these cells 
to the TMZ (Montaldi & Sakamoto-Hojo 2013).  
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Figure 5-5 Viability of MGMT negative a) and positive b) cell lines after treatment 
with MX and TMZ. Cells were seeded at a density of 5,000 cells per well. Cells were treated 
with 500μM of MX concentrations and either 75 μM of TMZ  (a) for MGMT-negative cell 
lines, or 350 μM TMZ  (b) for MGMT-positive cell lines and incubated for 48 hours. The cells 
ability to perform redox reactions was measured using a 1:10 dilution of alamar blue. A 
minimum of 3 repeats. Statistical significance was measured with a 2-way ANOVA. 
 
5.3.3 An AAG mediated effect with methoxyamine and temozolomide 
To further understand the interactions between TMZ and MX in the different cell 
lines the combination indexes (CI) were analysed. This is because the combined 
cytotoxicity of TMZ and MX appears to affect glioblastoma cells in an MGMT expression 
dependent fashion. CI values probe the interactions between multiple drugs using a 
mathematical analysis, developed by Ting-Chao Chou (Chou 2010). The analysis leads to 
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the quantitative description of drug-drug interactions as either; synergistic (CI <1), 
additive (CI=1-1.2) or antagonistic (CI>1.2) (Chou 2010).  
 
Interestingly, the cell line which showed synergism over a large range of doses 
was U87, 25 μM (low) and 100 μM (high) of TMZ with 500 μM of MX. The CI values are 
0.88 and 0.83 at low and high doses of TMZ respectively, as can be seen in Table 11. This 
synergism means that the effect of the two drugs in combination shows more than an 
additive effect of cell killing and is therefore synergistic. This cell line expresses high levels 
of AAG which could suggest that the interaction between TMZ and MX is synergistic when 
high levels of AAG are expressed in the cells, however, there may be other unmeasured 
factors at play here.  
 
U251 and LN18 also both show synergism at higher doses of TMZ, 100 μM and 
500 μM respectively. For LN18, the CI number was 0.46 (highly synergistic) which might 
be explained as follows; as the levels of TMZ are increased the protective role of MGMT is 
negated in the LN18 cell line. As this occurs the potential role for high AAG levels, leading 
to an increase in abasic sites, teams with the action of MX blocking these sites and this is, 
in this way, a synergistic interaction between TMZ and MX. 
 
U251 showed synergy with a CI of 0.45 even though it does not display high 
levels of AAG. This is not consistent with the hypothesis that high levels of AAG leads to 
greater cytotoxicity when cells are co-treated with TMZ and MX. However, this synergism 
is only apparent at doses higher than would be available in blood plasma, and the other 
cell lines may also display synergism at higher levels of TMZ than were tested.  
 
In colon cancer cells the interaction between TMZ and MX showed constant 
synergism over a range of doses (Liu et al. 1999). The distinction between the two cell 
lines used in the Liu et al. study were whether they were MMR proficient or deficient and 
therefore TMZ resistant or sensitive. Only the MMR proficient cell line was potentiated to 
the effects of TMZ by MX. This indicates that another mechanism or repair pathway is 
important in sensitising the interaction, BER being the most logical pathway due to 
amount of damage that can be repaired by BER caused from TMZ. However, Tang et al., 
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found that the increase in expression levels in PolB removes the MX potentiation to TMZ in 
certain cell lines over-expressing AAG (Tang et al. 2011).  
 
Cell line AAG MGMT Dose (TMZ) CI Interaction 
A172 Average No 25 uM 2.16098 No 
LN18 High Yes 25 uM 6.72698 No 
T98G Average Yes 25 uM 58715.1 No 
U251 Average No 25 uM 5.24399 No 
U87 High No 25 uM 0.87568 Synergistic 
A172 Average No 100 uM 1.70520 No 
LN18 High Yes 500 uM 0.45957 Synergistic 
T98G Average Yes 500 uM 1204.13 No 
U251 Average No 100 uM 0.44651 Synergistic 
U87 High No 100 uM 0.83420 Synergistic 
Table 11 A comparison of AAG and MGMT status within cell lines and the 
combination indices derived from TMZ and X-rays. 
 
5.4 Short term treatment with inhibitors leads to toxicity 
lowering cell viability at high doses 
5.4.1 Pamoic acid toxicity 
Besides MX, another inhibitor was examined, as the effect of inhibiting other 
enzymes with in the BER pathway was also of interest. Pamoic acid (PA) is an inhibitor 
which binds to the 8 kDa domain of PolB, as can be seen in Figure 5-6. It is soluble in an 
aqueous buffer allowing for additional analysis with nuclear magnetic resonance 
spectroscopy (NMR) (H.-Y. Hu et al. 2004). 
 
The study conducted by Hazan and his team used AutoDock 3.0.5 to investigate 
the binding structure of PA to the 8 kDa domain of polymerase beta. Different structures 
have been ranked by AutoDock according to their binding affinity with the protein and 
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around of the 100 lowest energy structures were noted for further investigations. When 
AutoDock force fields have been used, the best ligands were selected, with binding 
energies from -9.58 kcal/mol to -8.96 kcal/mol. These numbers, representing free energy 
binding and final intermolecular energy respectively, illustrate the suitable attachment 
between ligand and active site (Hazan et al. 2008). This study indicates the area in which 
PA bound to PolB inhibiting its action.  
 
Figure 5-6 Structure of polymerase beta and how pamoic acid binds to it. A) shows 
the whole protein with PA bound to the active site. B) shows just the amino acids within the 
active site where PA binds. Taken from (Hazan et al. 2008) 
The cytotoxicity of PA was measured in the 5 cell lines used throughout this 
work. The experimental design is described in the methods chapter, however; briefly the 
cells were measured for growth and viability in the presence of a range of doses of PA. As 
can be seen in Figure 5-7 a-e. with doses ranging from 100 M to 1 mM, all of the cell lines 
were sensitive to PA in short term toxicity testing with alamar blue. This could be due to a 
multitude of reasons, including the specificity of the PA to PolB rather than other 
polymerases and the importance of PolB to general cell cycle and DNA repair.  
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Figure 5-7 Cytotoxicity assay of glioblastoma cell lines treated with pamoic acid 
(PA). a) LN18, b) T98G, c) A172, d) U251 and e) U87. Cells were seeded at a density of 5,000 
cells per well. A variation of PA concentrations were added to the cells and left for 48 hours. 
The cells ability to perform redox reactions was measured using a 1:10 dilution of alamar 
blue. Each graph represents a different cell line with a minimum of 3 repeats.  
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5.4.2 48 hour measurement of temozolomide toxicity 
As TMZ is the standard of therapy for glioblastoma, in this study we chose a 
treatment combination of PA with TMZ which was examined for overall toxicity after 
treatment over a 48 hour period. As this was examined for MX and TMZ studies above, 
similar doses were used, as this allows for a direct comparison between the effects of 
either MX or PA with TMZ. Examining both PA and MX interactions with TMZ can help 
elucidate if inhibition of one enzyme over the other could lead to a better cell killing effect, 
in general or in different genetic profiles.  
 
In this study a direct comparison of cell lines being treated with 100 M of TMZ 
with and without 100 μM of PA was examined (Figure 5-8). Although all of the cell lines 
were more sensitive to TMZ in the presence of PA this was not found to be statistically 
significant. The mean changes in the MGMT-negative cell lines (a) were; 11.6%, 28.7% and 
11.7% for A172, U87 and U251 respectively however, the large error bars due to repeats 
make these changes not statistically significant. The large effect seen in U87 with 
combination treatment may be due to the high AAG expression however more repeats 
would be needed to confirm this.  
 
MGMT-positive cell lines were also treated with 350 μM of TMZ in the presence 
of PA (Figure 5-8 b). These cell lines also experienced a decrease in viability however this 
was not significant. LN18 had a reduction in viability of 7.9% and T98G was reduced by 
9%.  
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 Figure 5-8 Viability of MGMT negative a) and positive b) cells after treatment 
with PA and TMZ. Cells were seeded at a density of 5,000 cells per well. Cells were treated 
with 100μM of PA concentrations and either 100 μM of TMZ (a) for MGMT-negative cell 
lines, or 100 μM TMZ  (b) for MGMT-positive cell lines,  and left for 48 hours. The cells 
ability to perform redox reactions was measured using a 1:10 dilution of alamar blue. A 
minimum of 3 repeats. Statistical significance was measured with a 2-way ANOVA. 
 
 
5.4.3 When stimulating the BER pathway only for repair inhibitors had 
a small effect potentiating effect in imbalanced cell lines 
We then wanted to test how the inhibitors affected the different cell lines when 
the BER pathway was challenged by treatment with a BER-specific alkylator. To do this, 
methyl methanosulphonate (MMS) was used. MMS is an SN2 alkylator which adds methyl 
groups to nitrogen resulting in only the BER pathway being activated to repair the 
alkylation damage (Wyatt & Pittman 2006). It creates lesions on the DNA distributed as 
11% 3-methyladenine (N3-MeA) and 0.3% O6-methylguanine (O6-MeG). This change in 
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damage distribution, in comparison to TMZ, means that the O6-MeG lesion is not of 
concern and therefore the MGMT status and MMR pathways will not affect cell death. Since 
O6-MeG lesions are not formed at any significant level, this means that the BER pathway is 
examined only.  
 
We found that in all cell lines the addition of an inhibitor increased sensitivity of 
the cells to MMS-induced toxicity (Figure 5-.5-9). In MGMT-positive cell lines, LN18 a) and 
T98G b), and MGMT-negative A172 c) and U251 d), MX increased cell death induced by 
MMS treatment. However, the error bars overlap hence the mean difference between MMS 
alone or MMS with PA or MX is not statistically significant. Studies conducted on PA and 
MMS have previously used higher doses of PA, which we found to be cytotoxic, which lead 
to a greater sensitization to MMS (H.-Y. Hu et al. 2004). 
 
The MGMT-negative cell line U87 e), which displayed high levels of AAG was 
more acutely sensitised to MMS by both inhibitors in comparison to the other cell lines. In 
this cell line PA sensitised U87 to MMS more than MX, specifically at doses 1 mM (p = 
0.0096) and 2 mM (p= 0.0077) of MMS. The increase in MMS sensitivity from both 
inhibitors could be explained by the high AAG levels, leading to an increase in BER 
intermediates which are further prohibited from repair activity by either inhibitor.  
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Figure 5-.5-9 Viability after MMS and inhibitor treatment on glioblastoma cell 
lines. a) LN18, b) T98G, c) A172, d) U251 and e) U87. Cells were treated with serum free 
media for and drugs for 1 hour, and then fresh media was added back in. Viability was 
measured with alamar blue 48 hours later. Experiments were plated in triplicate and with a 
minimum of an n=3. 2-way ANOVA measured statistical significance. 
5.5 MGMT-negative cell lines are potentiated to X-rays and 
Protons by imbalancing BER through inhibitors. 
5.5.1 Clonogenic Assay for combined treatment of X-rays with and 
without temozolomide and inhibitors  
We next wanted to compare the effects of the inhibitors with or without TMZ in 
the presence of either X-rays or protons. To do this three cell lines were selected; LN18, 
U87 and A172 chosen because these three cell lines had the widest variation in genetic 
background for BER and MGMT expression.  
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All experiments included radiation with and without TMZ and no treatment at all 
as the base/control and to allow comparison between the different treatments. X-rays 
versus protons are compared directly.  
 
Survival data for the next section was fitted with either the linear quadratic (LQ) 
model (Equation 4) or the repair capability repair (RCR) model (Equation 5). Both with a 
modified constant  at the start to describe where the line cuts the Y axis, how the other 
treatment affects the 0 Gy dose. These values are further analysed later.  
Equation 5 Modified RCR equation: 
 
S(D) =  ∗ (exp −(α ∗ D) +  β ∗ D ∗ exp (−C ∗ D)) 
 
Where  is a modification constant to adjust the curves to cross the y axis where 
the data starts rather than at 1. This is important for treatment to cells at the 0 Gy with 
temozolomide (TMZ). With the parameters being equivalent to no damage, repair and 
misrepair.  No damage to cells (e-D) and the cells which were able to repair themselves 
(De-cD) are parameters which are described within the equation as a whole(Brahme & 
Lind 2010).  However the last section of the equation, which specifies repair is 
characteried by a misrepair section also (e-cD). This means that at higher doses the amount 
misrepaired and ultimately leading to cell death increases. We used this equation to fit the 
data as we first noted a difference in the curves produced from vertical protons to 
horizontal protons which would not allow the commonly used linear quadratic equation 
(LQ) to fit all the data.  
 
The RCR model is a new model used to fit survival curves which is appropriate to 
accommodate hypersensitivity at low doses of irradiation (Brahme & Lind 2010). The 
model chosen to fit the data depended on the rr value for each model and the general 
appearance of the line produced, this is further explained in chapter 6.2.3.1. The RCR 
model was of particular importance in this chapter as we see low-dose hypersensitivity, 
which the RCR model can fit better (Nilsson 2004).  
 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
102  Natalie Mayhead - August 2018 
5.5.2 Pamoic acid: 
 
The first experiments involved X-rays treatment with or without TMZ and PA; it 
can be seen that in all of the cell lines, survival increased when treated with PA and X-rays 
in combination compared to X-rays alone or other combinations, Figure 5-10 Comparison 
of both X-rays and protons with TMZ and PA on the survival of glioblastoma cell lines. 3 
cell lines; U87 a) X-rays b) protons, LN18 c) X-rays d) protons and A172 e) X-rays f) 
protons, were treated with 50 μM of PA, 25μM of TMZ, combination of both and either X-
rays, left hand side, or protons, right hand side. Cell lines fitted with the RCR model. A 
minimum of 3 repeats in triplicate were performed. However, this observation does not 
hold true when treated with protons and inhibitors, as A172 had higher levels of survival 
when treated with protons alone.  
 
In the MGMT-positive cell line, LN18 Figure 5-10 c and d, it can be seen that 
concomitant treatment of TMZ with radiation and PA leads to more cells surviving then 
with radiation and/or TMZ alone. This is seen in both X-ray treated and proton treated 
cells. Although protons lead to an increase in cell death in comparison to X-rays, the 
addition of either chemotherapeutic provided no benefit to the radiation treatment 
regime. X-rays, have a lower cell killing effectiveness than protons but with both radiation 
modalities the addition of chemotherapy showed no increase in cell death. The 
combination of treatments led to an increase in survival fraction of X-rays at 2 Gy; 47.6%, 
50.8%, 81% and 72.4% for X-rays alone, with TMZ, with PA, and with TMZ and PA 
respectively. These results show that the addition of PA greatly increases the number of 
surviving colonies. The surviving fractions at 2 Gy for protons were very similar; 24.7%, 
26.7%, 27.6% and 27.9% for protons alone, with TMZ, with PA, and with TMZ and PA 
respectively. This shows that, although protons are more toxic to the LN18 cell line, the 
combination of treatments cause higher numbers of surviving cefractions.   
 
When examining the proton irradiation protocol for the LN18 cell line, Figure 
5-10 d, it is observed that LN18 displayed hypersensitivity to all treatment combinations. 
This is low dose hypersensitivity resulting in a much steeper reduction in cell survival at 
0.5 Gy when treated with protons than would be expected when compared to higher 
doses. This hypersensitivity in LN18 is most prominent in treatment with protons alone, 
with a survival fraction of 28%, however treatment with protons, TMZ and PA combined, 
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although displaying hypersensitivity, had a surviving fraction of 44%. This 
hypersensitivity is not seen when cells are treated with X-rays and is therefore a proton 
irradiation-specific effect. These results also illustrate that the addition of TMZ to the 
MGMT-positive cell line LN18 increases the fractions of cells surviving to treatment.  
 
In the MGMT-negative cell lines, U87 a and b and A172 e and f, the addition of PA, 
as mentioned above, did lead to a higher colony-forming percentage of cells than the 
control. However, the combination of PA, TMZ and irradiation led to an increased level of 
cell death in both cell lines after X-rays treatment, but only in U87 after proton irradiation. 
The greatest difference in survival is seen at 0.5 Gy for both cell lines between X-rays alone 
and X-rays with PA; 75.4% and 137% for U87, and 82.7% and 145% for A172. As both of 
these cell lines are MGMT-negative they are sensitive to treatment with TMZ. Both U87 
and A172 are further susceptible to the combined treatment of X-rays, TMZ and PA 
together. The greatest range in survival fractions is at 2 Gy where for A172 the percentage 
survived with X-rays alone was 71.7%, X-rays and TMZ combined was 44.9% whereas 
when treated with X-rays, TMZ and PA the mean survival was 25.4% and the surviving 
fractions at 2 Gy for U87 were 54.1% for X-rays alone, 29.1% for X-rays and TMZ 
combined and 21.9% for X-rays, TMZ and PA. In these treatment regimes, the addition of 
TMZ reduced the survival of each cell line by 26.8% for A172, and 25% for U87. But when 
PA was added in combination the reduction of survival dropped further by 19.4% for 
A172 and 7% for U87. This difference with the addition of PA was not expected as U87 
already has an imbalance in the BER enzyme expression levels, and as such we expected it 
to be more susceptible to inhibiting PolB than A172.  
 
All cell lines treated with protons exhibited low dose hypersensitivity. In addition 
it was clear that the hypersensitivity to proton irradiation shifted and continued into 
higher doses, than the normal under 1 Gy, in particular treatment combinations. This shift 
in hypersensitivity could be due to the methylation status and expression of MGMT which 
could lead to further sensitisation by PA and protons combined. The hypersensitivity 
observed in A172 shifted from the peak of the trough being at 0.5Gy when treated with 
TMZ and protons to 1.1 Gy when treated with TMZ, PA and protons. At 0.5 Gy the 
differences between protons alone, with TMZ or with TMZ and PA are 54.3%, 12.2% and 
11.6% respectively for A172. 
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For U87 the surviving fractions are 32.2% for protons alone, 15% for with TMZ 
and 17% for TMZ and PA together at 0.5Gy. These surviving fractions show that A172 was 
more sensitive to combination therapy than U87. Unlike A172, U87 when treated with 
0.5Gy of protons, TMZ and PA combined, was no further sensitised than when treated with 
protons and TMZ alone. 
 
At 2 Gy, the differences between surviving fractions for treatment with TMZ and 
TMZ with PA are 8.3% and 0.7% for U87 and A172 respectively. Clearly, for A172, the 
increased radiation dosage shows a diminishing effect and, for both cell lines, virtually 
disappear by 3Gy. 
 
The results demonstrate that proton irradiation lowers cell survival far more 
effectively than X-rays and both of the MGMT-negative cell lines would experience greater 
cell death from the combination of protons with TMZ and PA at lower radiation levels. The 
specific nuances of the response of each cell line in the presence of the different radiation 
types could be due to the AAG expression level differences and the type of damage the 
radiation types predominantly cause but, as only BER has been measured and no other 
repair proteins, this is speculative and has not been rigorously tested.  
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Figure 5-10 Comparison of both X-rays and protons with TMZ and PA on the 
survival of glioblastoma cell lines. 3 cell lines; U87 a) X-rays b) protons, LN18 c) X-rays d) 
protons and A172 e) X-rays f) protons, were treated with 50 μM of PA, 25μM of TMZ, 
combination of both and either X-rays, left hand side, or protons, right hand side. Cell lines 
fitted with the RCR model. A minimum of 3 repeats in triplicate were performed. 
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5.5.3 Methoxyamine 
We next wanted to compare the cellular effects of APE1 inhibition with MX, when 
combined with radiation and TMZ. The survival curves for the cell lines treated with 
combinations of radiation, TMZ and MX are presented below in Figure 5-11. 
 
The graphs show that the MGMT-negative cell line, LN18 Figure 5-11 c and d, 
showed increased cell survival when treated with radiation and MX in comparison to 
radiation alone with surviving fraction differences of 26% (X-rays) and 21% (protons). 
 
For A172 and U87, the combination of MX, TMZ and radiation together lead to a 
decrease in cell survival in comparison to other treatment combinations. At 2 Gy of X-rays 
the percentage increase in cell death from TMZ treated to TMZ and MX treated is 7% 
(U87) and 11.5% (A172). When treated with protons the difference in survival between 
TMZ and TMZ with MX is much larger in U87 than A172; 6% compared to 1.3% at 3 Gy. 
Therefore, it is clear that the addition of MX to a combination of TMZ and radiation 
increases cell death rates except in LN18.  
 
LN18, which is MGMT-positive, is not sensitive to the addition of TMZ or MX or a 
combination of the two. However, treatment with protons affect the cells survival at lower 
doses than expected, with the LN18 cell line exhibiting low-dose hypersensitivity at 0.5 Gy, 
which is not the case for X-rays. Therefore, in this MGMT-positive cell line, combination 
therapy which exploits the BER pathway does not increase cell death, and in patients 
could just lead to further toxicity of healthy cells. However, protons lead to a greater cell 
killing ability, as at 2 Gy the cell death fraction was 24% compared to 47% for X-rays.  
 
The radiosensitivity shown in U87 and A172 is seen in other cell lines when MX is 
added to irradiation treatment (Oleinick et al. 2016). In small-cell lung cancer cell lines the 
addition of 20 mM of MX treatment to two cell lines mildly increased radiosensitisation 
when treated concurrently with gamma-rays up to a dose of 6 Gy. However, LN18, the 
MGMT positive cell line, regardless of the combinations of treatments used, showed little 
difference from the treatments in terms of cell survival. This seems to suggest that the 
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MGMT status and not the status of the BER enzymes, are of more importance when 
examining radiosensitivity caused by BER inhibitors in the treatment of glioblastoma.  
 
As seen in all cell lines and treatments, protons lower cell survival far more 
effectively than X-rays. With this in mind, U87 and A172 show a greater relative biological 
effect upon the addition of MX, TMZ and X-rays together, as the potential increase in single 
strand breaks and strain on single strand break repair mechanisms leads to an increase in 
cell death higher than other treatment regimes when treated with X-rays. However, when 
cells are treated with protons the additional benefit to treatment with TMZ and MX is very 
low.  As mentioned above, no treatment combination provides a clear advantage for 
MGMT-positive LN18, other than protons over X-rays.  
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Figure 5-11 Comparison of both X-rays and protons with TMZ and MX on the 
survival of glioblastoma cell lines. 3 cell lines; U87, LN18 and A172 were treated with 50 μM 
of MX, 25μM of TMZ, combination of both and either X-rays, left hand side, or protons, right 
hand side. Cell lines fitted with the best fit models for each cell line and radiation type; RCR 
model for everything except A172 X-rays and MX. A minimum of 3 repeats in triplicate were 
performed.  
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5.5.3.1 Mathematical analysis of the effects modulation of BER during irradiation 
We next wanted to understand the effect of the different radiation types on the 
overall survival of the cells. The relative biological effectiveness (RBE) is a ratio defining 
how two different sources of radiation compare by dose for equivalent cell killing. This 
measure shows how effective the type of radiation is at damaging DNA and leading to cell 
death. The higher the ratio the more damage the radiation causes. Any end point can be 
taken to derive the RBE; survival at 50%, number of H2AX foci, etc.  
 
Protons are considered to be 10% more effective than photons traditionally 
however different models are used to measure the reliability of this and many papers find 
variations in this ratio (Paganetti et al. 2002; Ding et al. 2015). The endpoint chosen for 
the RBE and the cell line, determined how high the ratio was for the effect of protons in 
comparison to photons. Meta-analysis studies (Carabe et al. 2013) have shown that as / 
ratios increase RBE decreases as Table 12 and Table 13 below show, this theory holds true 
for RBE20. However, RBE50 gives very high ratios and is thought to be due to the 
hypersensitivity seen at low doses.  
 
The RBE20  ratio increases in each cell line as the / ratio decreases though not 
in an obvious relationship. What the RBE20 shows is that the response of LN18 to a higher 
LET radiation type, protons, is less strong than the sensitivity to protons from U87 and 
A172. This could be due to a number of reasons, either the size of the nucleus or the repair 
proteins present within the cells.  
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 X-rays/Protons 
 RBE 50 RBE 20 
LN18 5.326 1.026 
U87 6.635 1.985 
A172 1.900 1.989 
Table 12 A comparison of relative biological effectiveness. 
 
To further elucidate how PA and MX can affect the cell lines response to radiation 
damage with or without the addition of TMZ the survival fraction at 3 Gy were compared. 
However, without the addition of TMZ in some of the cell lines, an inhibitor and radiation 
could lead to higher surviving fractions and therefore not be beneficial to patient 
prognosis. Comparing the differences between the radiation type and inhibitor type, Table 
13 shows the surviving fractions for 3 Gy. MX is the better sensitizer in combination with 
TMZ and radiation in all cell lines and likewise, in all cell lines, protons produce a greater 
cell killing effect.   
 
Surviving fraction at 3 Gy 
 X-rays, TMZ and 
PA 
X-rays, TMZ and 
MX 
Protons, TMZ and 
PA 
Protons, TMZ and 
MX 
A172 0.166 +/- 
0.0596 
 
0.126 +/- 
0.00538 
 
0.122 +/- 
0.0233 
 
 
0.0777 +/- 
0.0242 
 
 
LN18 0.565 +/- 0.136 
 
0.291 +/- 0.0545 0.154 +/- 0.0856 
 
0.212 +/- 0.0611 
U87 0.177 +/- 0.0228 
 
0.131 +/- 0.0231 
 
0.115 +/- 0.0278 
 
0.0556 +/- 0.0137 
 
Table 13  A comparison of the surviving fractions at 3 Gy after trimodal treatment. - 
significant figures test 
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We furthered our understanding of these interactions by looking at the 
sensitizing enhancement ratio (SER) of TMZ with MX, PA and alone, Table 14. The addition 
of TMZ is most effective in the MGMT-negative cell lines at sensitizing the cells to the 
radiation with treatment of either X-rays or protons (U87 4.835 and 3.019, A172 4.293 
and 208.507 for X-rays and protons respectively). The addition of TMZ and inhibitors 
sensitized A172 to both radiation types (MX; 15.171 and 13.154 and PA: 10.480 and 
13.723 for X-rays and protons respectively). However, the sensitization of U87, to either 
TMZ or radiation, by the inhibitors was so strong that the 0 Gy was below 50% survival. 
This enhanced sensitisation could be due to the already imbalanced BER pathway within 
this cell line. 
 
 with TMZ With MX With PA with MX and 
TMX 
with PA and 
TMZ 
 SER50 
X-rays 
SER50 
Protons 
SER50 
X-rays 
SER50 
Protons 
SER50 
X-rays 
SER50 
Protons 
SER50 
X-rays 
SER50 
Protons 
SER50 
X-rays 
SER50 
Protons 
L 1.0378 0.676 0.948 0.631 0.658 0.639 1.0605 0.573 0.682 0.578 
U - - 1.095 1.656 0.845 2.321 - - - - 
A 4.293 208.50
7 
1.0749 2.262 1.002 2.278 15.171 13.154 10.480 13.723 
 Table 14 A comparison of the sensitizing enhancement ratio after a series of 
combinations of treatments. L= LN18, U = U87, A = A172. 
 
Vermeulen and co-workers found that knocking out PolB and inhibiting APE1 
with MX increased radiosensitivity greatly when blocking each enzyme individually 
(Vermeulen et al. 2007). Unfortunately blocking both APE and PolB was not performed 
within these studies and could be a point for future work to try and elucidate the role of 
BER in glioblastoma resistance to common treatment modalities.  
 
One of the striking features of these graphs was the increase in proliferation 
when the cells were exposed to the inhibitors alone with no other treatment. This 
observation led us to further investigate to see if there were any negative effects from 
treatment with inhibitors alone. 
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5.6 Treatment with BER inhibitors promotes increased cell 
growth.  
During the previous experiments, results obtained after treatment with 
inhibitors led to some questions being raised about cell growth under the influence of 
these inhibitors such as: Does inhibiting AP site repair of PolB action lead to an increase in 
cell growth? Do the number of colonies forming increase? And does combined treatment 
with TMZ and BER inhibitors lower colony formation? To answer this the growth and 
proliferation of the cell lines was measured when treated with the inhibitors alone and 
with TMZ (Figure 5-12). Treatment with MX did not significantly increase or decrease the 
number of colonies formed on any of the cell lines. The proliferation of A172, LN18 and 
U251 was decreased by MX by 19, 2 and 15% respectively, except for U87, where there is a 
clear increase in colonies formed by 23%. However, when treated with PA, all cell lines 
except for U251 showed a large increase in colony numbers. The mean increase in number 
of colonies formed is 90, 40 and 47% for A172, LN18 and U87 respectively whilst the 
colony formation decreased for U251 by 10%. 
 
The next question to answer was this; when 50 M of MX was added to 25M of 
TMZ, was the growth of the cells increased from treatment with TMZ alone? If so, then this 
is clearly not a good treatment pathway to pursue under clinically relevant treatment 
conditions. We found in Figure 5-12 b, for U251 and LN18 the growth under treatment 
with MX and TMZ showed increases over treatment with TMZ alone of 20 and 9% 
respectively. Both of these cell lines have a balanced expression of BER proteins, however 
LN18 expresses MGMT protein, removing the main toxic effects of TMZ, and U251 
expresses MGMT mRNA although this does not affect the toxic lesion formation from TMZ. 
U87 shows a non-significant decrease (5%) whilst A172 also shows a decrease (4%). U87 
does display an imbalance in the BER pathway due to high levels of AAG whereas A172 has 
a balanced BER pathway. Neither cell lines express any MGMT protein or mRNA.  
 
When growth under the influence of PA and TMZ was analysed (Figure 5-12 d) it 
was found that U87 had a decrease in cell growth and proliferation under the influence of 
PA and TMZ combined (11%) in comparison to TMZ alone. This could be due to the 
imbalance in expression of BER proteins. A172 and LN18 showed increases in cell growth 
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and proliferation under the influence of TMZ and PA in combination in comparison to 
treatment with TMZ alone of 9 and 22% respectively. U251 displayed a similar growth 
profile with TMZ and PA however there was a mild increase in colony formation of 3% in 
comparison to TMZ alone.  
 
In PA experiments, A172 treated with TMZ alone and TMZ and PA both showed 
significant changes when compared to PA alone (p=0.0001 for both) with a decrease in 
cell colonies formed.  U87 treated with PA was significantly different to treatment with 
TMZ alone (p=0.0009) and TMZ with PA (p = 0.0001). For A172 and U87 there is an 
increase in colony formation when treated with PA alone than when treated with TMZ or a 
combination (Figure 5-12). This means that if PA, or another POLB inhibitor, was brought 
into clinical trials, dosing times and regimens would have to be examined carefully to 
ensure that they did not lead to an increase in tumour mass. For MX, which is in clinical 
trials (Gordon et al. 2013) only U87 showed an increase in colony formation. The reason 
for this increase in colony formation should be examined further as MX is in clinical trials 
and treatment regimes should be examined very carefully, whilst investigating the protein 
profile which could cause this, to ensure harm is not occurring to the patients. However, in 
treatments with MX and TMZ on A172 and U87 it was shown that both cell lines decreased 
in proliferation significantly when compared to TMZ alone or MX alone, p values are 
0.0052/0.0043 and <0.0001 respectively.    
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Figure 5-12 Number of colonies formed after treatment with PA. 4 cell lines; A172, 
LN18, U87 and U251 were treated with 50 μM of MX, a and b, or PA a and d, 25μM of TMZ 
and a combination of both, b and d. Cells were left to form colonies over 14 days until stained 
with crystal violet to count colonies. Results were compared to controls, left hand side. A 
minimum of 3 repeats were performed and 2-way ANOVA statistics were performed to look 
for significant changes in colony numbers.   
 
As the growth profiles of these cells showed an increase when treated with 
inhibitors alone and the colony staining and size also showed an increase in intensity, the 
next question was whether or not this was due to an increase in the size of the cells, the 
number of cells present or, alternatively, to an increase in DNA within the cells as the cells 
are proliferating faster hence there is more DNA for the crystal violet to bind to 
5.6.1 Growth curve after treatment with 50 M of each inhibitor 
We next went on to analyse two cell lines for their growth rate, U87 and U251. 
These were chosen due to their vastly different colony forming responses to the addition 
of PA and MX during clonogenic analysis. Whilst their responses were different, the 
expression level of BER proteins were also different, with U87 expressing high levels of 
AAG and average levels of the other proteins, whilst U251 expressed average levels of all 
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BER proteins. Neither cell line expressed MGMT however this is not expected to affect 
their response to inhibitors as the inhibitors do not affect the O6-MeG repair.  
 
In Figure 5-13 below we can see that the two cell lines were treated with either 
PA or MX at 50 μM and incubated on the cells until they were harvested to be counted for 
proliferation. What is immediately clear is that U87 and U251 have very different growth 
profiles with U87’s growth plateauing at day 3 after it has doubled whilst U251 continues 
doubling.  
 
U251 grew at similar rates regardless of whether it was treated with an inhibitor 
or not. This similarity in growth was in agreement with the results found in the clonogenic 
assays and by day 5 there were approximately 20 *104 cells per mL in each treatment 
group. Whether treated with MX or left alone, U87 had produced approximately 9*104 cells 
per mL but when treated with PA the number of cells by day 5, per mL, was 20 *104 cells. 
The number of cells in the U87 cohort treated with PA was significantly greater than the 
cell numbers in the MX or no treatment group, p value of 0.0021. This increase in cell 
number is greater than what was found in the clonogenic assay experiments, however the 
clonogenic assay was looking at the ability of cells to form colonies and not how they were 
proliferating within these colonies.   
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Figure 5-13 Growth curves with and without treatment of inhibitors. a) shows 
proliferation of U87 over 5 days, 1*10
4
 cells were seeded per well, and counted each day after 
treatment with either 50μM of PA or MX. B) shows proliferation of U251 over 5 days, 1*104 
cells were seeded per well, and counted each day after treatment with either 50μM of PA or 
MX. A minimum of 2 repeats were conducted. Statistical significance was measured by 1-way 
ANOVA. 
 
5.6.2 Cell cycle 
The observed increases in proliferation and increased clonogenic ability when 
cells are treated with inhibitors was further examined by identifying which stage of the 
cell cycle the cells were in 72 hours after treatment, Figure 5-14. This was then compared 
to the cell cycle profile of cells following treatment with TMZ and inhibitors, Figure 5-14.  
 
In normal cell cycle analysis of untreated control cells, the majority of cells are in 
growth with one DNA copy (G1/G0) (60%, 46% and 53% for LN18, U87 and U251 
respectively), with less cells passing through synthesis (S) phase or Growth with two 
copies of DNA in to mitosis (G2/M) which we can see in Figure 5-14. The cells in these 
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phases is expected as the cells are not synchronized and are cycling through growth 
phases where they spend the majority of time in G1. Upon treatment with TMZ there was a 
change in the predominant phase of the cell they were in, as cells were arresting in S (9% 
increase for U251) and G2/M phase (37.6% and 18.9% increase for LN18 and U87).  
 
When the cells were treated with inhibitors, the cell cycle distribution of the cell 
lines shifted from the large G1/G0 of the control to an increase in the number of cells in S 
phase. This S phase arrest was seen in all cell lines with both inhibitors. In clonogenic 
assays, LN18 forms a similar number of colonies after MX treatment and an increase after 
PA, whereas when U87 is treated with either inhibitor more colonies are formed and U251 
experiences a small decrease in colonies after treatment with either inhibitor. These 
trends were also evident in the growth curves. An increase in the percentage of cells in S 
phase could indicate either an increase in DNA replication and an increased rate of 
proliferation or, alternatively, an arrest in DNA replication, leaving the cells arrested and 
unable to progress into mitosis. LN18 and U251 had the largest increase in cells in the S 
phase; 39.5% and 33.5% in LN18 when treated with PA and MX respectively and 30.7% 
and 26% in U251 when treated with PA and MX respectively.  
 
When TMZ and inhibitors were combined the cell lines reacted differently and 
the response to each inhibitor also varied; LN18 when treated with a combination of TMZ 
and PA showed a similar cell cycle distribution to the treatment with PA alone. When 
treated with TMZ and MX the cell cycle distribution mimics that of treatment with TMZ 
alone however the proportion of cells in G2/M phase is increased in the TMZ + MX 
treatment by 52.3% over the control.  
 
The cell cycle phase distribution in the cell line U87 shifted after treatment with 
TMZ and MX concurrently and displays an increase in G2/M (32.2% over control). This 
treatment appears to create a much greater G2/M phase shift than when treated with 
either TMZ, which looks like MX is potentiating the effect of  TMZ on the cells to increase 
this G2/M phase. This combination of TMZ and MX together leads to a much greater 
response than either drug does on the cell cycle alone. When U87 is treated with TMZ and 
PA concurrently the cell cycle profile is very similar to the treatment of PA alone. This is 
because TMZ and PA as well as PA alone leads to an arrest in the S/early G2 (40.5% and 
43% for PA and TMZ PA together, respectively). 
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Cell cycle changes after U251 is treated with inhibitors produce a similar 
response to the shift seen in U87, however the arrest in S phase is greater. However, 
treatment with TMZ and PA led to an increase in cells in G2/M phase (45% increase).  
Whereas the G2/M phase arrest when treated with PA alone was 19%. This G2/M phase 
was larger when U251 was treated with TMZ (26.5%), these results show that PA 
enhances the effect on the cell cycle produced by TMZ to the G2/M phase.  
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 Figure 5-14 Cell cycle analysis of cells treated with either 25 μM of TMZ, 50 μM of 
PA, 50 μM of MX or combinations of in 3 cell lines; LN18, U87 and U251. There were 2 
repeats on each day, with 2 days per cell line. Results were plotted as the mean of all results 
as percentage of cells in each phase.  
 
5.7 Summary 
The results presented in this chapter showed the effects of inhibiting different 
BER repair proteins in five glioblastoma cell lines (A172, LN18, T98G, U251 and U87). 
Cells were evaluated for their ability to repai        r and grow under the influence of these 
inhibitors of APE1 and PolB. Neither inhibitor was found to be toxic at low doses, which 
were later selected for the further studies.  
 
MGMT negative cell lines, A172 and U251, were not sensitive to the combination 
of temozolomide with the BER inhibitors. However, U87 at most doses was shown to have 
a synergistic relationship with MX and TMZ (CI value). This could indicate an imbalance in 
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BER due to the high AAG levels and the imbalance being further exacerbated by the 
inhibitor, leading to an increase in the formation of single strand breaks through inhibiting 
repair of damage, this could explain lower levels of cell survival. This theory is further 
supported by the analysis of the treatment of all five cell lines with MMS, indicating that 
the MGMT status no longer matters as repair of the alkylation damage induced, is carried 
out by the BER process. For the U87 cell line, BER inhibition led to a significant reduction 
in cell survival to MMS treatment. We propose U87 has a BER imbalance due to high levels 
of AAG but not of the other downstream BER proteins. In contrast, LN18 should not 
display BER imbalance since it expresses high levels of all the BER proteins.  
 
In this study the efficacy of protons was confirmed to create a greater level of cell 
death in comparison to X-rays. Three cell lines (A172, LN18 and U87) were chosen to 
compare the effects of concurrent treatments of an inhibitor with TMZ and an irradiation 
type, selected due to their very differing genetic profiles for BER proteins. With both 
inhibitors it was found that the major protein influencing cell radiation sensitisation was 
the MGMT status and not the perceived imbalance in BER and therefore inhibiting either 
APE1 or PolB in MGMT negative cells, could lead to an increase in cell death with 
irradiation and TMZ.  
 
Although in treatments of TMZ with inhibitors the biggest effects in increasing 
cell death was seen in the MGMT positive cell lines, LN18 and T98G, the EC50 was not 
reduced sufficiently for this to be clinically relevant and therefore, when concurrent 
treatment regimes with radiation were conducted, no increase in cell death was seen as 
only clinically relevant doses were studied.  
 
Treatment with low doses of the inhibitors led to an increase in cell proliferation 
in the cell line U87, suggesting BER inhibition was mitogenic in this cell line. However, 
when also treated with TMZ, significant toxicity was seen and BER inhibition sensitised 
the cell lines to TMZ-induced cytotoxicity. In contrast, the LN18 cell line had a small 
increase in colonies formed when treated with PA alone, and a slight decrease when 
treated with MX, however, a combination of treatments had little to no effect on survival 
even when combined with radiotherapy; this shows that MGMT status still has the 
greatest effect on survival even when the BER pathway is inhibited. At clinically relevant 
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doses only the cell line with an imbalanced BER (U87) was sensitised to combination 
treatment.  
 
These findings, in conjunction with the proliferation studies showing U87 
proliferating faster when treated with PA and forming more colonies when treated with 
MX, raises some concerns for the current clinical trials in MX. However in vitro studies are 
not directly comparable to full systems and therefore clinical trials, but the treatment 
regime, timings and overall effect on cancer cell growth could lead to a poorer prognosis 
than if the patients were treated with TMZ and radiotherapy alone.  
 
The results showing the interaction between PA, TMZ and radiation were 
unexpected; knocking out PolB, which is more efficient at blocking its role than inhibiting 
it, showed an increase in radiosensitivity in a study performed on MEF cells (Vermeulen et 
al. 2007). However, this increased radiosensitivity did depend on the confluence of the 
cells being irradiated. Confluent cells were found to be more radiosensitive when PolB was 
knocked out. This was not tested in our study as cells were already plated at the correct 
numbers for the colony-forming assay before irradiation. This difference in confluence 
could explain the difference in results as well as the difference in cell lines used as higher 
doses of irradiation need higher numbers of cells to be plated.  
 
 The experiments into cell cycle were enlightening to show arrest, or maybe 
potential changes in the growth phase due to inhibitors, however, we note that this 
experiment could have been strengthened by staining with yo-pro for apoptosis, PI for a 
live/dead indicator and Hoescht or Draq5, that can be taken up by live cells, to measure 
DNA content. This would have strengthened the experiment such that not only the cell 
cycle stage could be measured, but also whether this had led to cell death and further the 
percentage of cell death per cell line and treatment. This is important as the cells may have 
arrested in a particular stage of the cell cycle, but would be able to amend the damage and 
continue replication. There may also be a shift in cell cycle due to an increase in 
proliferation.  
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6 DOSIMETRY ON AN EXTERNAL 
BEAM LINE FOR CELLULAR 
RADIATION EXPERIMENTS 
6.1 Introduction 
Cellular radiation with protons at the University of Surrey has traditionally been 
conducted using the Ion Beam Centre’s Vertical microbeam line (Jeynes et al. 2013). There 
are many positives to irradiating cells using this method, most notably the following; Due 
to the positioning of the beam the cells are covered in media and are thus maintained in a 
homeostatic environment during irradiation lowering cellular stress. There are also a 
number of limitations including; 
 cells are not in growth phase as they cannot attach to the polypropylene sheet 
they are irradiated on.  
 it is a low throughput system which means that, for multiple experiments and 
different treatments, it can need quite a lot of beam time to cover all the 
irradiation conditions.  
To overcome the above drawbacks we decided to explore a new methodology for 
high throughput studies at the ion beam centre, named HOBBIT.  
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 Figure 6-1 Diagram of the two accelerator set ups at the ion beam centre. The top 
half of this figure shows the vertical beam line configuration. With a 90
o
bend in the beam 
line to allow the cells to be irradiated from underneath. This means that it is unknown how 
many cell layers are produced, and the cell thickness is increased. In the bottom half of the 
diagram a linear beamline without a bend leading to a horizontal irradiation system is used. 
The cells are irradiated without media whilst attached to the plastic wells and much thinner 
than the rounded vertical cells.  
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As can be seen in figure …the new methodology the same accelerator was used, 
however the beamline, which is more commonly used for external beam MeV SIMS, was 
adapted for use as a broadbeam cellular irradiation station (Merchant et al. 2009). To do 
this the stage was reprogrammed for correct dosage delivery by changing the movement 
protocol and blocks were put in place to hold cell dishes. The experimental design was 
modelled in simulations to work out LET and correct dosing. Gaf Chromic RTQA paper was 
used to measure beam homogeneity to ensure correct, expected dosage was delivered. 
 
6.1.1 Aims and hypothesis 
In a change from the overall hypothesis this chapter details methodology 
development for a new radiation method. The methodology devised and described in this 
chapter contributes to the overall results for the hypothesis. However, the aim for this 
chapter was to devise a new cellular irradiation mechanism, using a different beamline off 
of the same accelerator. To do this a number of objectives were set: 
 Calculate the LET that the cells will receive using this beam line. 
 Simulate scatter of particles from the proton beam into the cellular radiation dish  
 Measure the beam homogeneity using RTQA Gafchromic .  
 Evaluate and compare the surviving fractions of cells between vertical beam 
irradiations and horizontal.  
6.1.2 Dosimetry 
The absorbed dose is measured in Grays (Gy), where one Gy is one Joule of 
radiation energy absorbed by 1Kg of matter (units J/Kg).  A Joule is a unit of energy and 
can be defined in multiple ways but is the work required to produce one watt of power for 
one second. To work out the dose given in Gy from an accelerator, be it a medical device or 
research, the equation used is Equation 1 Dose rate;  
Dose rate (Gy/s) = 1.6 * 10-9 
L

 
Where L is the LET (keV m-1),  is the particle flux (particles per second) and  
is the density of the medium (g cm-3). To use this calculation in determining the dose, we 
first have to work out the LET through the cells. 
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6.1.3 Beam stability and homogeneity 
To ensure a stable dose distribution to the cells, the beam homogeneity needs 
first to be measured and then adjusted. This is so that while the beam scans the plate, the 
dose the cells receive remains consistent. Noting the fluctuation of current through the 
accelerator during the start and end of the irradiation period, allows for that error to be 
taken into account. In addition, the step movement of the cell dish holder also had to be set 
to ensure that the beam was covering the whole cell area and didn’t leave gaps or overlap. 
To measure these things RTQA was employed for its fast colour change and accessibility.  
6.2 Results 
6.2.1 LET 
The LET was calculated using the stopping and range of ions in matter (SRIM) 
program. SRIM is designed specifically for working out stopping distances and can be used 
for LET calculations through different materials and is a program which allows you to set 
up the dimensions and materials of your target area, however it does not allow you to 
define the geometry of the detector/target area. With SRIM you can simulate the LET 
changes through the materials and how far the beam will travel through them. With SRIM, 
the thickness of the material layers is described in angstroms and then the beam energy, 
ion type and direction can be simulated allowing the LET to be calculated. SRIM is user 
friendly and hence a collection of different set ups were simulated to measure the change 
in LET through the target.  
 
 
The first setup parameter to determine was how far the accelerator window 
would be from the lid on the plates that contained the cells. In figure Figure 6-2 a) it shows 
that the air gap used has an effect on the change in LET initially, with a linear trend 
depending on the gap increase.  
 
In figure Figure 6-2 b) the air gap effect on the LET within the cellular target 
show that the change in initial LET due to the air gap has a minimal effect on the LET 
within the cells and the trend in energy loss is comparable. Due to configurational 
implications within the actual set up, a distance of 2 mm from exit window to the lid was 
utilised. The LET starts at 11.3 keV/µm and ends at approximately 11.45 keV/µm. We 
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therefore chose an LET to calculate the dose in Gy given as 11.32 keV/µM. The LET 
changes are documented precisely in Table 15 below. 
 
Figure 6-2 SRIM calculations for LET. Figure a) shows the change in LET through 
the distance of the cell for different stretches of air gap. Figue b) shows the mean LET 
dependent on the airgap from silicon window to polypropylene lid.  
 
To calculate the mean LET throughout the cell using SRIM, the LET was taken at 
different entrance, exit and midpoint and then used to integrate the LET throughout the 
whole cell. This integrated LET can then be used to calculate the dose given over a set 
time. These values are displayed in Table 15 below for different distances from the 
window of the accelerator to the lid of the plate. 
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Table 15 SRIM calculations of the changing LET values as the air gap increases 
from accelerator window to cell dish. 
6.2.2 Beam homogeneity and stability 
When designing an irradiation system capable of delivering reliable dosimetry, 
one of the important factors is to ensure the beam does not overlap or misses sections of 
the area being irradiated. To measure dose delivery GafChromic was used, which is a 
radiochromic material which has water equivalent dosimetry. GafChromic is comprised of 
an outer layer of lithium 10,12-pentacosydiayonate micro-crystalline monomers between 
clear polyester sheets. During irradiation photo-induced polymerisation occurs forming 
rod shapes as the absorbed dose increases, as does the polymerisation and colour 
formation. The polymerisation reaction which occurs when the material is exposed to 
radiation is independent of the energy and can be used over a range of MV beams. There 
are many different types of GafChromic some of which have high resolution, however, the 
film used in this case, RTQA, has a lower resolution but is accurate at low doses, important 
for this experiment.  
 
The control of the radiation delivery was through a “rooks move” control of the 
end-station, which brought the plate and each well, in front of the beam window at a 
constant rate, to ensure consistent delivery to all cells. The stepwise movement to ensure 
broadbeam irradiation by the pencil beam was tested at a number of different steps: 1.5, 
1.6, 1.7 M, a representation is shown in Figure 6-3. As can be seen, the steps of the “rooks 
move” movement on the end-station were initially too big, resulting in the GafChromic 
forming striations over the area irradiated, as some parts of the film were not irradiated. 
As the colour change was instantaneous the stepping action was able to be monitored and 
corrected at the time of irradiation before cellular radiations had taken place. This was 
measured at the start of each day of experiments. The gap and colour was not analysed in 
these films.  
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 Figure 6-3 GAF Chromic radiated at 0.5 Gy through a 96 well plate, with the well 
bottoms removed. And a polypropylene lid applied. Beam homogeneity was checked through 
immediate colour change.  
 
Beam homogeneity, correct scanning for dose delivery and beam stability over 
different days was measured using Gaf Chromic. The methodology used to analyse the 
RTQA was adapted from a paper by Thomas and Warrington. This paper found that the 
error is largest in the smaller doses, however, the differences within sensitivity are 
greatest at lower doses, below 8 Gy (Thomas & Warrington 2006). This is why RTQA was 
selected for these studies.  
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Therefore, for the analysis of the colour change due to polymerisation the red 
channel only was analysed on imageJ, adapted from methodology due to Thomas and 
Warrington in their investigative research into the use of GafChromic in X-ray 
measurements (Thomas & Warrington 2006). What needs to be taken into account when 
measuring the variation in dose over different days, is that there is not a linear 
relationship between colour formation and Gy. As we can see in Figure 6-4 the change in 
colour increases over dose, as expected, however, not linearly. The highest level of 
variation over radiations was at 2 Gy with a standard deviation of 1.09. The standard 
deviation was much lower for the other doses for colour saturation. These high numbers 
of replicates with low levels of variation within the repeats makes us feel certain that the 
stability of the beam, its homogeneity in one run and dose replication is accurate.  
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Figure 6-4 Analysis of RTQA Gaff Chromic colour change after irradiation with a 
3.5 MeV proton beam. Experiments were repeated on each day of irradiations, with each 
“well” being measured for colour change N=6.  
6.2.3 Comparison of vertical beam irradiations with HOBBIT 
irradiations 
The vertical beam line that was used at Surrey has been previously well 
documented for cellular radiation set up (Jeynes et al. 2013) and used to research 
radiation in cellular models (Barazzuol et al. 2013). The main use of the vertical beam line 
was for broadbeam irradiation (Wéra et al. 2014; Jeynes et al. 2013). As detailed in the 
paper by Jeynes and co-workers, once the current was measured, the timings were 
changed to give different doses to different droplets on one dish, which meant the current 
and therefore particle flux remained constant. However, during development of the 
HOBBIT system it was felt that as the current was readily changed and beam stability was 
reliable, due to a shorter beamline than the vertical beamline, the time would be held 
constant. The importance of this extends to ensuring the cells were out of media for the 
same amount of time. During horizontal beam irradiations the current was changed 
between doses and the time of irradiation remained the same, increasing the number of 
particles that the cells are exposed to as the dose increases. Therefore, the only change 
between radiation styles is time, media coverage and cell angle.  
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The survival curves produced from vertical and horizontal radiations were fitted 
with a modified RCR equation Equation 5.  
 
 Equation 5 Modified RCR equation:  
S(D) =  ∗ (exp −(α ∗ D) +  β ∗ D ∗ exp (−C ∗ D)) 
Where  is a modification constant to adjust the curves to cross the y axis where 
the data starts rather than at 1. This is important for treatment to cells at the 0 Gy with 
temozolomide (TMZ). With the parameters being equivalent to no damage, repair and 
misrepair.  No damage to cells (e-D) and the cells which were able to repair themselves 
(De-cD) are parameters which are described within the equation as a whole(Brahme & 
Lind 2010).  However the last section of the equation, which specifies repair is 
characteried by a misrepair section also (e-cD). This means that at higher doses the amount 
misrepaired and ultimately leading to cell death increases. We used this equation to fit the 
data as we first noted a difference in the curves produced from vertical protons to 
horizontal protons which would not allow the commonly used linear quadratic equation 
(LQ) to fit all the data.  
 
Horizontal protons produce a very obvious low-dose hypersensitivity in the cell 
lines LN18 and U87 and, after treatment with TMZ, in A172 (Figure 6-5). This 
hypersensitivity is not evident in cells treated by vertical proton beam irradiations. At 0.5 
Gy, without TMZ, in LN18 the survival is 0.90 for vertical and 0.29 for horizontal beam. 
However, at 1 Gy, the survival fraction is very similar as it has plateaued for horizontal 
beam irradiation, but has reduced greatly for vertical beam irradiation to 0.243. This 
difference in sensitivity at low-doses was unusual and the potential reasons for it are 
explored below in the discussion. As mentioned above, the only differences in how the 
cells were irradiated were whether they were covered in media or not, the time of 
irradiation and confluence/attachment of the cells.  
 
After the low-dose of 0.5 Gy, both the vertical and horizontal irradiations 
produced very similar survival fractions in LN18 and A172, as shown in Table 16. U87 
only had a similar survival after 3 Gy and it would be recommended to irradiate up to 
higher doses to check for survival fraction differences there. At 2 Gy, LN18 had between 
20-25% survival and A172 survival was approximately 30%. At 3 Gy the survival fraction 
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reduces by a further 0.1 for each cell line, this incremental decrease in cellular survival 
then appears to mimic a linear quadratic survival. 
 
Figure 6-5 RCR Model fitting for clonogenic assay data for protons on 3 cell lines 
in either vertical irradiation or horizontal irradiation systems.   
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Dose LN18 V LN18 H A172 V A172 H U87 V U87 H 
1 0.243 +/-  
0.
023 
 
0.243 +/-  
0.
093 
 
0.437 +/-  
0.
083 
 
0.398 +/-  
0.
164 
 
0.778 +/-  
0.
042 
 
0.388 +/-  
0.
109  
2 0.201 +/-  
0.
050 
 
0.247 +/-  
0.
062 
 
0.294 +/-  
0.
121 
 
0.322 +/-  
0.
101 
 
0.541 +/-  
0.
054 
 
0.301 +/-  
0.
087 
 
3 0.165 +/-  
0.
073 
 
0.136 +/-  
0.
046 
0.238 +/-  
0.
095 
 
0.192 +/-  
0.
050 
 
0.320 +/-  
0.
061 
 
0.243 +/-  
0.
051 
Table 16 Mean surviving fractions from 1 - 3 Gy for either vertical (V) or horizontal 
(H) radiation methods. With +/- standard deviation.  
6.2.3.1 RCR parameter comparison of vertical versus horizontal irradiation 
To directly compare the effects of the different angles of radiation and the 
general setup, the constants from the RCR fitting were analysed. Studies have shown that 
the equation could relate to cells that were not damaged from radiation (e-D) and the cells 
which were able to repair themselves (De-cD) (Brahme & Lind 2010). Experiments with 
glioma cell lines MO59K (DNA protein kinase subunit c (DNA PKC) efficient) and MO59J 
(DNA PKC deficient) found that, at low doses, Non-homologous end joining (NHEJ) is the 
main repair pathway and at higher doses it is homologous recombination (HR). Misrepair 
(e-cD), due to the error-prone NHEJ repair mechanism, causes lowers survival at low doses 
leading to low-dose hypersensitivity, whereas at higher doses both repair pathways work 
together to repair the DNA damage, however the damage is greater so an increase in cell 
death still results(Brahme & Lind 2010).  
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To avoid the low-dose hypersensitivity issue for horizontal irradiation, we used 
the RCR model parameters displayed in Table 18 and calculated, at a dose of 2 Gy the 
damaged, undamaged and misrepaired components for vertical and horizontal irradiation 
of the various cell lines, shown in Table 17.  What we can see straight away from the table 
is that vertical irradiations lead to a higher fraction of cells being left undamaged in all cell 
lines.  This is most evident in the U87 cell line, where the undamaged fraction goes from 1 
for vertical beams to 0.29 for horizontal irradiation. Also strongly evident is a decrease in 
fraction of cells able to repair from the damage caused from horizontal irradiations. 
Furthermore, there is also a decrease in the fraction of cells misrepaired when 
horizontally irradiated. In LN18 the fraction of misrepaired cells goes from 0.69 to 0.01. 
This decrease in misrepair could explain how the surviving fractions remain similar 
between the two irradiation protocols. This analysis highlights a big difference in damage 
occurring to cell lines, which would be interesting to further investigate, but also suggests 
that the cells have different repair capacity for DSBs between the radiation types.  
 
Although there are studies which justify the parameters of the RCR falling into 
either undamaged, repaired and misrepaired, for specific cell lines, this may not be the 
case here. It seems nonsensical to have a negative proportion of cells repaired, however, 
the negative parameter fits and describes the curve accurately. The negative “repaired” 
parameter describes the recovery after low dose hypersensitivity, before the continued 
cell death, represented by the exponential “misrepaired” section.  
2Gy undamaged repaired misrepaired 
Cell lines e-D De-cD e-cD 
A172 V 0.999 -0.699 0.552 
A172 H 0.346 -0.0452 0.0167 
LN18 V 0.999 -0.658 0.686 
LN18 H 0.292 -0.0596 0.0105 
U87 V 1 -0.498 0.769 
U87 H 0.294 -0.0376 0.00487 
Table 17 Parameters of the RCR equation fit to 2 Gy for vertical and horizontal 
irradiation systems. 
Some constraints were put on the constants produced from the curve fitting for 
the proton irradiations. As there were multiple parameters and a low number of data 
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points it leads to a high degree of freedom for the fitting which allows the equation to fit 
easily without logical constants being produced. We therefore constrained the alpha 
parameter to only produce positive constants. This is because irradiation of cells will 
cause a decrease in cellular survival. This could have been corrected for by creating more 
data points to higher Gy; as the dose increases the c section of the graph would lead to 
lower and lower repair, we therefore constrained the parameters for c to also produce 
positive constants. What we can tell from looking at the constants is that the alpha for 
vertical irradiations is much lower than those for horizontal irradiations. The larger the 
alpha value the lower the step in the equation leading to a more gradual change in 
gradient on the curve. As beta increases, this effects the curve linearly with an increase in 
survival, which constrains c to be positive to lead to an overall decrease in the curve. As 
the beta values are negative, this forces the curve to decrease and a smaller c value is 
needed to describe the overall decrease in survival. 
 
Cell line α β c r2 
A172 V 0.000004579 -0.6328 0.297 0.77 
A172 H 0.5303 -1.356 2.047 0.99 
LN18 V 0.0002327 -0.4793 0.1882 0.57 
LN18 H 0.6158 -2.836 2.278 0.93 
U87 V 1.22E-16 -0.3238 0.1314 0.93 
U87 H 0.6124 -3.859 2.662 0.99 
Table 18 Constants and goodness of fit for the RCR model vertical versus horizontal 
irradiation 
6.3 Discussion 
In this chapter we aimed to set up a new methodology for radiation of cells in a 
high-throughput manner. After discovering the LET using SRIM and checking the beam 
homogeneity and stability using RTQA, the physical data was collected and analysed. From 
the analysis of the RTQA we can see that beam stability was good over individual 
irradiations as well as over different days. This led us to have faith in our system and use it 
to irradiate cells. A comparison of the two different radiation methods was undertaken. 
This mostly looked at the difference in shape produced after irradiation, as well as a 
comparison of the means at 1-3 Gy. This showed that although horizontal irradiation 
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produced low dose hypersensitivity, the overall survival means were similar and within 
reasonable error margin of each other. Due to the overall similarity in results, it was 
concluded that a reliable and accurate dose delivery method had been produced. This 
method of high-throughput horizontal irradiations was used in the proton results seen in 
chapter 5. 
 
Cells covered in media replicate in vivo conditions as tumours would have a 
constant stream of nutrients whilst being irradiated within the body. Cells that are entirely 
dry could implode due to osmosis, leading to an increase in cell death if the cells are left 
fully dry for too long. Even in the preparation of cells for dry conditions where the cells are 
fixed, they need to be slowly dried with increasing alcohol concentrations (Ring et al. 
2011). Studies have shown that cellular levels of ROS are higher in cell culture in 
comparison to in vivo situations due to the culture methodology, including the media 
(Halliwell 2003). Radiation causes the formation of ROS through radiolysis of water 
(Azzam et al. 2012) and therefore the irradiation of cells within media could lead to an 
increase in ROS formation which could damage the DNA further. This assault on the cells, 
from media radiolysis as well as background induction of ROS, could lead to an increase in 
cell death in cell culture. However, this potential source of cell death is not realised or does 
not contribute to the overall cell enough as irradiation of the cells without media has 
higher levels of cell death especially at low doses.  
 
The time of irradiation between doses remained the same for the horizontal 
irradiation but varied for the vertical beam irradiation of cells, the current and therefore 
particle flux, was not always the same for the vertical irradiations over different days. The 
current for each dose, although changed between doses, was kept constant for the 
horizontal method over different days. This constant change should lower the difference 
and variability which is clearly seen at low doses on the horizontal irradiation system, 
however it could cause an effect as the amount of particles entering the cell area is double 
in the same space of time as the dose before.  
 
The final variable in these different irradiation systems was the confluence of 
cells and their attachment. Cells on the vertical beam are irradiated within a droplet, 
detached from the surface of the radiation dish (polypropylene surface), whereas cells 
irradiated in the HOBBIT system are attached to the plastic well and are approximately 
70% confluent. However, in the dosimetry for the vertical beamline described by Jeynes 
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(2013), although the cells are balled up and should be 10µM rather than the calculation 
they chose for flattened cells of 6µM. This fault in their dosimetry however would not 
explain the low dose hypersensitivity seen in the HOBBIT system. One of the potential 
mechanisms of bystander effect is the creation of reactive oxygen species (ROS)(Shao et al. 
2005),  which the cellular gap junction is important for the communication of this damage 
and to the transmission of the ROS (Shao et al. 2003).  However, in treatment with drugs, 
confluence is shown to lead to resistance in breast carcinoma cells from doxorubicin (Fang 
et al. 2007). 
 
Without further testing, we cannot be sure why low-dose hypersensitivity occurs 
in cells irradiated on the horizontal system and not on the vertical system. However, 
confluence may be the biggest factor, due to the spread of ROS and other cell signalling 
chemicals.  
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7 DISCUSSION  
The current survival rate for glioblastoma is only 14.6 months when treated with 
both temozolomide (TMZ) and X-rays (Stupp et al. 2005a). In Iran only 7.7% of diagnosed 
cases survive two years post-diagnosis between the periods of 1990-2008 (Ahmadloo et 
al. 2013). As such, resistance to current treatment modalities needs to be assessed (Lee 
2016) and therapeutic improvements need to be made. In this study, we aimed to 
understand further mechanisms in resistance with a view to find potential areas to exploit 
in the current treatment.   
 
To do this we measured repair enzymes for base excision repair (BER), O6-
methylguanine DNA methyl transferase (MGMT) and accessory proteins needed for the 
repair of TMZ-induced damage. From this it was tested whether or not these expression 
levels correlated to the cellular repair proficiency after treatment with TMZ and 
irradiation.  
7.1.1 Naturally occurring BER protein expression levels can lead to an 
imbalance  
Studies have shown that faulty proteins, due to mutations leading to misfolding 
and functional inadequacy are correlated with different cancer incidence (Koukourakis et 
al. 2001; Gudmundsdottir & Ashworth 2006; Lavin 2008). Of these mutations, many of the 
short patch (sp)-BER proteins have been linked to different cancers; colon (Nemec et al. 
2012), breast (Duell et al. 2001) and non-small cell lung cancer (Zienolddiny et al. 2006). 
However, it has also been shown that in some cancers there is a correlation between 
prognosis of cancer and expression of BER proteins (Liu et al. 2012; Leguisamo et al. 2017; 
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Dziaman et al. 2014). Some studies in cancer patients go on to link expression to 
resistance or sensitisation to treatment. For example APE expression in head and neck 
cancers to chemoresistance (Koukourakis et al. 2001), and variant expression of XRCC1 
leading to radiosensitivity (Patrono 2014). This link to prognosis many researchers have 
postulated by many researchers that an imbalance in BER pathway proteins would lead to 
sensitization to chemotherapeutics such as temozolomide (Fu, J. a Calvo, et al. 2012; 
Engelward et al. 1996; Pegg 2011).  
 
An imbalance in BER has previously been created by knocking-out alkyladenine-
DNA-glycosylase (AAG) in mouse models which has lead to a decrease in sensitivity to 
methylmethanesulfonate (MMS) (Engelward et al. 1997; Calvo et al. 2013a). This 
imbalance in BER lowers the initiation of removal of methylated base damage, and 
therefore, lowers the amount of toxic intermediates being formed such as AP sites and 
further down/along the pathway, SSBs. Furthermore, it has been found that over-
expressing AAG in breast cancer cells sensitizes them to TMZ (Rinne et al. 2004), as well as 
in colo-rectal cancer cells (Leguisamo et al. 2017), and ovarian cancer (Fishel et al. 2007). 
Notably suppressing APE1, a protein further down in the repair pathway, leads to 
sensitizing cells to the alkylating agents: MMS, TMZ and carmustine (BCNU) (Silber et al. 
2012; Ono et al. 1994).  
 
 In this research, the aim was to determine if cell lines had a naturally 
occurring imbalance in BER, and whether this could be correlated to the cell lines 
response to treatment, which has not been previously done. Here in, we showed that BER 
was naturally imbalanced in one cell line, U87, and another cell line showed potential to be 
imbalanced, LN18. A potential imbalance was determined as the AAG expression levels in 
LN18 were high, but the expression of the other repair proteins for BER was also higher 
than measured in the other cell lines. The other cell lines however had a coordinated 
expression of the BER proteins.  
 
The determination of whether a cell line had an imbalanced or coordinated BER 
pathway was confirmed through quantitative polymerase chain reaction (qPCR), western 
blots, activity assays and response to MMS. Through qPCR and western blot experiments it 
was found that AAG levels varied among cell lines, with highest levels shown in LN18 and 
U87. LN18 also was shown to have an increase in AAG activity in comparison to U251.  It 
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was felt that if this variation is not accompanied by compensatory changes in levels of 
enzymes downstream in the pathway, BER imbalance could occur. High levels of AAG in 
LN18 were previously found and correlated with TMZ resistance (Shao et al. 2015). Two 
cell lines out of the glioblastoma panel express MGMT; LN18 and T98G, which has also 
previously been shown in other research (Barazzuol et al. 2012). The differences in 
expression of MGMT and AAG/BER proteins allowed a good comparison for the role of 
MGMT and AAG in the treatment of GBM with TMZ and inhibitors.  
7.1.2 BER imbalance only sensitizes cells when treated with a SN2 
alkylating agent 
SN2 alkylating agents such as MMS do not form O6-MeG adducts, and therefore 
negate the role of MGMT within the cells and the mismatch repair (MMR) efficiency when 
cells are treated with this agent. Therefore, to elucidate the role of BER alone, and 
establish if these cell lines exhibit a BER imbalance, three cell lines were chosen for 
studying the effect of MMS on survival. Specifically, these cells were LN18, T98G and U87. 
LN18 showed slightly higher levels of all BER proteins and therefore there is a potential 
for the BER pathway to be imbalanced. There were high levels of AAG in U87, but not other 
BER proteins leading to an imbalance of the repair, and potentially an increase in the 
formation of abasic sites. It was shown in this experiment that U87 was more sensitive to 
MMS than LN18 or T98G. When AAG only is overexpressed and cells are treated with MMS 
they develop an increased sensitivity to the cytotoxic effects (Calleja et al. 1999; Rinne et 
al. 2004; Calvo et al. 2013b). Other studies have modulated the AAG expression, leaving 
the expression of other BER proteins normal, an imbalance in BER is created, and from 
this we draw the assumption that LN18 may not have an imbalanced BER.  
 
After these measurements were collated we further confirmed that MGMT had 
the greatest effect on the cell killing proficiency of TMZ, this was demonstrated in the 
clonogenic assays. MGMT expression protects cells from TMZ induced O6-MeG related 
apoptosis (Gaspar et al. 2010; Kaina et al. 2007). In this study it was shown that MGMT 
expression increased the EC50 for LN18 and T98G cells  in comparison to other cell lines 
by approximately 10 fold.  
 
These results showing that the sensitivity to TMZ is solely or predominantly due 
to MGMT status agrees with other studies; in the study by Hermisson et al., they showed 
that MGMT expressing cell lines only become sensitive to TMZ effects at doses over 500µM 
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(Hermisson et al. 2006). However, the fold change between the cell lines used in this 
study, and others have been collated in meta analysis to show that T98G and U87 differ 
from 5 to 100 fold difference, due to MGMT status (Lee 2016). Although Lee showed the 
EC50 varied considerably for all cell lines, and each one in this study was mentioned in the 
meta analysis, what was constant was that MGMT expression was the major determining 
factor in a higher or lower EC50 for glioblastoma cell lines treated with TMZ (Lee 2016). 
 
The amount of TMZ in blood plasma after treatment in patients has been shown 
to be around 25-65 M. In this study we showed therefore that clinically relevant doses of 
TMZ would not affect MGMT positive glioblastoma cell lines as the EC50 for LN18 and 
T98G is over 100 µM. This shows that clinically relevant doses of TMZ would not affect 
GBM patients who express MGMT and therefore they should not be treated with TMZ. 
Unless significant sensitization can be made with combination treatment for these patients 
without increasing toxicity in healthy cells, TMZ should not be used.  
 
The MGMT negative cell lines were compared for their TMZ sensitivity, and for 
BER protein balance. A172 has been shown to be extremely sensitive to TMZ, even in 
comparison to U251 and U87, the other MGMT negative cell lines. This finding has been 
shown in other studies, however, it was then correlated with a lack of AAG expression 
(Agnihotri et al. 2012). Agnihotri measured AAG expression through western blot and 
immunohistochemistry whereas in this study AAG expression was measured through 
qPCR, western blot, and activity assays; further testing was done through analysis of 
microarray data found online to add justification to the results found experimentally. Note 
that, the cell line, A172, may have been from different sources actually providing different 
base lines leading to these differences. Whatever the cause for the difference in expression 
data, both studies found A172 to be the most sensitive cell line. Agnihotri reasoned that 
within different cell lines that the effects of MGMT and AAG contribute equally to TMZ 
resistance. To do this he overexpressed AAG in A172, which he found increased resistance 
to TMZ. Studies using other types of cancer cells showed that in breast cancer cells, AAG 
sensitised cells to TMZ (Rinne et al. 2004) and in resistant ovarian cell lines over 
expression of  AAG led to a massive increase in sensitivity to TMZ (Fishel et al. 2007). 
However, in glioma cells, overexpression of AAG leads to only a mild sensitization to TMZ 
(Tang et al. 2011). The difference in the studies cited above and this one is that the 
sensitization to TMZ through AAG levels are all manipulated through over expression 
levels which are higher than would be found naturally; and as such the sensitization is 
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much greater than would be seen in clinical samples or unmodified cell lines. This may 
help to explain why U87 is not more sensitive than A172, as although the expression levels 
are greater in U87, they are not over expressed. Furthermore, there are other repair 
pathways involved in TMZ sensitization, such as MMR, which were not measured.  
 
Other studies have also shown A172 to have high levels of AAG with some studies 
suggesting that a high AAG expression has been linked as a hallmark of GBM (Liu et al. 
2012; Tang et al. 2011).This shows that although a BER imbalance sensitizes cells to MMS, 
the interaction of MMR on the O6-MeG adduct formed by TMZ could create or exhibit a 
greater influence to cell death and therefore the sensitization of cells to TMZ after MGMT 
expression.  
 
In this study we find that MGMT status affects glioblastoma cell lines 
sensitization to treatment more than BER status. The most sensitive cell line to TMZ was 
A172 which does not have an imbalance in BER that we could detect or high AAG levels. 
Therefore, we accept our null hypothesis that a natural imbalance in BER without 
modulation does not sensitize glioblastoma cells to TMZ treatment. U87, which not only 
has a high AAG level but, due to the median expression of other proteins, would then have 
an imbalance in BER which, if our theory was right, would have led to a greater sensitivity 
to TMZ treatment (Fu, J. a. Calvo, et al. 2012). This was not seen and we therefore conclude 
that the treatment with TMZ is not sensitized by BER imbalance or high AAG levels.  
7.1.3 X-rays and temozolomide are additive 
For MGMT positive cell lines there is no combined effect of treatment with TMZ 
and X-rays (Barazzuol et al. 2012). As no effect is seen, the recommendations made by 
other researchers (Chen et al. 2013; Wick et al. 2012; Stupp et al. 2009) for using MGMT as 
a biomarker for whether to treat a patient with TMZ or a different chemotherapeutic is 
also recommended from the outcome of this work. In MGMT negative cell lines the 
addition of TMZ increased cell killing greatly. In patients who do not express MGMT within 
the tumours this treatment modality is currently the best course of treatment.  
7.1.4 MGMT status important in sensitizing cells to TMZ with MX and 
PA 
We next modulated BER through the use of inhibitors at clinically relevant doses 
for methoxyamine (MX) and similarly low doses for pamoic acid (PA). These studies 
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aimed to try to create an imbalance in cell lines, except in U87 where we aimed to further 
deregulate the coordination of BER to increase sensitivity to TMZ, as well as to ascertain if 
the deregulation of BER leads to sensitization of glioblastoma to current treatment which 
could be used clinically. MX is currently in clinical trials (Yang et al. 2012) as it binds to 
AP-sites, blocking their repair (Talpaert-Borlè 1987). However, due to the poor specificity 
PA (Hazan et al. 2008) or other PolB inhibitors are not (H.-Y. Hu et al. 2004).  
 
At clinically doses close to the EC50 of TMZ and MX, MGMT-positive cell lines 
were sensitized to TMZ (T98G and LN18). These findings for T98G agree with others 
studies (Montaldi & Sakamoto-Hojo 2013), however, the sensitization is not great. This 
low level sensitisation is seen in other studies, however they find that over expression of 
AAG and treatment of MX leads to even further sensitization (Tang et al. 2011). We do not 
see an increase in sensitization of LN18 to TMZ due to its high AAG expression levels, 
however this could be due to a number of reasons; The AAG levels in LN18 are not 
modulated, unlike the studies above, and much lower levels of MX are used in this study, to 
keep it clinically relevant. However, we did find that the interaction of TMZ and MX in the 
cell line LN18 was synergistic.  
 
The effect of MX on sensitizing the MGMT-negative cell lines to TMZ was not 
significant. Although there was a decrease in viability after treatment with MX and TMZ. 
This is similar to results found from knocking out APE and treating with TMZ in U87, 
however, Montaldi found knocking down APE and treating with TMZ led to an increase in 
SSBs (Montaldi et al. 2015). However, we did find that the AAG highly expressing cell line, 
U87 had TMZ and MX interact synergistically to cause cell death. In the cell line U251 
higher doses of TMZ and MX lead to a synergisitic interaction, and this was not due to AAG 
status. These findings have not been found before, and the further sensitization of MGMT-
negative cells could still be of importance to help increase survival rates in MGMT-negatve 
patients too.  
 
The combined treatment of PA and TMZ lead to a non-significant increase in 
sensitivity in all cell lines. In TMZ resistant colon cancer cells, PA sensitises cells to the 
effects of TMZ (Jaiswal et al. 2009). Studies have shown that inhibiting PolB sensitises cells 
to TMZ, however, an increase in AAG expression did not further enhance the cells 
sensitization to TMZ from PolB inhibition (Gregory C. Stachelek, Shibani Dalal, Katherine 
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A. Donigan & Joann B. Sweasy 2010). The greater sensitization seen in the study by 
Gregory may be due to the difference in PolB inhibitor used. One study shows that the 
greatest sensitization to alkylating agents would be to inhibit, through knockout and 
inhibition, both APE1 and PolB (Horton & Wilson 2007) and as such this could be explored 
further in an attempt to understand the effect of BER on TMZ resistance.  
 
The MGMT status of the cells affects whether or not they will be sensitised by the 
inhibitor to TMZ. This could be due to the fact that the levels of unrepaired BER 
intermediates is still too low in comparison to the more toxic O6-methylguanine adducts, 
which lead to apoptosis in MGMT negative cells but are removed in MGMT-positive cells. 
Another repair pathway which needs to be taken into account whilst correlating repair of 
these cell lines is MMR as the MGMT-negative cell lines repair the O6-methylguanine 
adducts through this pathway, and could lead to further differences in sensitivity.  
7.1.5 Protons are more cytotoxic than X-rays 
Within the investigation into dysregulation of BER through the use of inhibitors, 
different types of radiation and the effects they have on cell death fractions were also 
studied. It is well known that protons cause more damage than X-rays (Goodhead 2006). 
Due to the difference in damage from different radiation sources relative biological 
effectiveness (RBE) is taken into account in treatment planning for protons (Paganetti et 
al. 2002; Carabe et al. 2013; Burigo et al. 2014).  
 
We found hypersensitivity to protons was found at low doses in all cell lines, 
which were potentiated by the addition of TMZ and inhibitors together. This furthers the 
case for use of protons in the treatment of hard to treat cancers, as well as adding validity 
and importance to the building of the 2 proton therapy centres in the UK. The potential 
reasons for this are discussed further on in this chapter.  
7.1.6 Inhibiting BER in combination with radiotherapy and TMZ offers 
benefit only in MGMT negative cells 
MGMT does not have a role in the toxicity of damage caused by radiation as 
radiation does not cause O6-MeG lesions. Studies have previously found that 
overexpressing APE in U251 and U87 leads to an increase in radioresistance (Naidu et al. 
2010). AP-sites are formed from radiation damage making MX a good drug for not just co-
treatment with TMZ, but also with radiation.  
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In this study low doses of radiation were used and it was found that MX produced 
a better cell killing response at 3 Gy. Osteosarcoma cells are sensitized to -radiation by 
MX treatment at doses from 2-6 Gy (Montaldi et al. 2014). We found that MX led to 
sensitization in the MGMT-negative cell lines to X-rays.  Furthermore, it has been shown 
that non-small cell lung cancer cells are sensitised to -irradiation through 3mM MX 
treatment (Oleinick et al. 2016). The results for U87 being sensitized to X-rays from MX 
are comparable to results showing an increase in DNA damage and slow repair after MX 
treatment and X-rays (Neshasteh-Riz et al. 2008). In this study it was further found that 
the combination of TMZ, MX and X-rays in MGMT-positive cell lines led to an increase in 
sensitisation, that was so great for U87, it could not be calculated from the data points 
collected. The enhanced sensitization to treatment to MX, TMZ and X-rays in U87 could be 
linked to the high AAG expression and lack of MGMT.  
 
When the radiation source was protons, the cellular response to MX was 
different, with U87 not being sensitized at all, whilst A172 was. However, treatment with 
MX and TMZ with protons do not produce sensitization or an increase in cell death.  
 
The response of LN18 with radiation, TMZ and inhibitors was not significantly 
different to any other combination. Therefore we conclude that at clinically relevant levels 
MGMT expression affects the cell lines sensitization to trimodal therapy. But furthermore, 
the effect of cell killing is not enhanced by radiation and MX. However, this is not the case 
when the radiation source was protons in the treatment of LN18, as protons alone 
lowered survival more than combination therapies.  
 
The role of PolB in radiation damage repair is important as radiation can cause 
single strand breaks which are then repaired by PolB through BER. However, damage by 
radiation causes predominantly double strand breaks, more so when treating with 
protons, and as such these double strand breaks are repaired predominantly by NHEJ or 
HR (Gerelchuluun et al. 2015; Hunt et al. 2013).  
 
In experiments with PA it was found it can lead to a decrease in cell viability 
therefore low doses were used within the rest of the studies conducted. PA binds to the 
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8kDa domain on PolB which binds to single stranded DNA and has a d’RP lyase activity 
(Beard & Wilson 2006). PA is not a very specific PolB inhibitor, hence there is a push to 
develop improved versions (Barakat et al. 2012; Gao et al. 2008). A study by another lab 
showed that inhibiting PolB with PA led to a decrease in DNA synthesis (H. Y. Hu et al. 
2004), perhaps through unspecific binding to polymerases involved in DNA synthesis, 
which could explain the short term toxicity of the cell lines in increasing presence of PA. 
Because of this, low doses of PA were used in these studies.  
 
In this study it was shown that PA and X-rays lead to an increase in cell survival. 
There was little difference between proton and PA survival fractions. This was unexpected 
as PolB knock-outs increased radiosensitivity (Vermeulen et al. 2007). Of course, due to 
the low specificity of PA to PolB, these studies are not easy to compare. However, the 
combination of PA, TMZ and radiation increased cell death in MGMT-negative cell lines but 
not MGMT positive LN18.  
 
During this study we found that the interaction between radiation and inhibitors 
in MGMT-negative cell lines is worth further investigation. Both inhibitors increased the 
sensitivity of the cell line to the radiation but, in conjunction with TMZ the enhancement 
was so great in U87 that a ratio could not be calculated. The cause of this difference in 
reaction would be important for the current clinical trials in MX, and could be tested in 
individuals with the best genetic chance to experience benefit from this treatment 
combination. The increase in sensitivity in combination with TMZ and radiation could be 
associated with the high AAG levels and imbalanced BER. We therefore conclude that in 
glioblastoma cells with a propensity to have an imbalanced BER, if further deregulated 
with BER inhibitors, specifically MX, the combination of TMZ and radiation enhances cell 
death rates in MGMT negative cells.  
 
We further elucidated the role of these inhibitors in potentiating cell growth in 
certain cell lines when cells were treated with inhibitors alone and is critical for these 
patients in current clinical trials. Conversely, other studies have shown that MX reduces 
cell growth and viability, in osteosarcoma cell lines (Montaldi et al. 2014), which, in this 
work, is seen in every cell line but U87. This difference in response to viability could be 
due to BER expression, however, this would need to be further tested to draw conclusions. 
These questions should be answered before further clinical trials. Regardless of how these 
inhibitors affect cell lines alone, when trimodal treatment is utilized in both MGMT 
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negative cell lines, there was an increase in cell death, and further investigation could 
discover what type of cell death the cells undergo.  
 
The different radiation methodologies showed a difference in response at low 
doses. With low doses of horizontal protons displaying low dose hypersensitivity, whilst 
vertical irradiation did not show this. As discussed in chapter 6.2.3.1 low dose 
hypersensitivity has been linked to repair capacity (Chalmers et al. 2004; Daşu & 
Denekamp 2000). As well as cell cycle arrest and apoptosis (Marples 2004; Enns et al. 
2004). However, in these experiments a difference in repair capacity leading to changes in 
cell cycle distribution response to apoptosis is unlikely, and other mechanisms should be 
explored.  
7.2 Future work 
This work characterised how MGMT-positive cell lines cannot be sensitized to 
treatment at clinically relevant doses, despite potential natural, non-modified BER 
imbalances. In our work with protons we showed that the interaction between a 
combination of drugs and protons in certain cell lines lead to much lower relative 
biological effect then when treated with X-rays. It was shown that MX has an overall better 
inhibitory effect leading to an increase in sensitization to TMZ and radiation in MGMT 
negative cell lines. However, neither inhibitor or treatment combination lead to an 
increase in cell death for MGMT-positive cell lines. Furthermore, AAG levels or BER 
imbalance may have had an influence in sensitivity in trimodal treatment in an MGMT 
dependent manner. From this further questions were raised which could be addressed.  
 
Within this work we started correlating survival after treatment with TMZ to the 
expression level of BER proteins. This, however, is not the only repair pathway of interest 
when treating with TMZ. As mentioned in the introduction and through-out this work, the 
BER pathway repairs the majority of the adducts formed by TMZ treatment, however, the 
suicide enzyme, MGMT, repairs the lesion on the O6-guanine and mismatch repair 
incorrectly processes this damage. This lesion if attempted to be repaired through the 
MMR pathway, leads to apoptosis due to a futile repair cycle leading to double strand 
breaks and cellular exhaustion leading to apoptosis. In chapter 4.3.1, MMR proteins were 
evaluated from microarray data from other studies only, and as such cannot be reliably 
traced to the same cell lines used in this study. As such, for future works we would 
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measure the expression levels of MMR proteins, and try to correlate this with the MGMT-
negative cell lines sensitivity to TMZ alone.  
 
One of the interesting results of the inhibitor studies was that when cells were 
treated alone there was an increase in colonies formed, cell growth and cell cycle. As this 
was further investigated it was found that inhibitors alone created a shift in the cell cycle, 
leading to an arrest in S/G2/M.  This should be further examined, as MX is currently in 
clinical studies a few questions should be answered; is this a problem with the timing of 
the delivery of the inhibitor and as such would these effects be seen if MX, TMZ and 
radiation are given in too long a time frame. To measure this staggered time points could 
be taken on differing treatment regimens to measure the following end points; Survival via 
clonogenic assay and proliferation via Bromine deoxyribonucleotide Uracil (BrdU).  
 
Furthermore, from this line of study the cell cycle measurements were very 
interesting and needs to be further tested. The work with inhibitors and protons needs to 
be further explored by looking into the changes in cell cycle in combination treatment. 
Furthermore to this measuring for cell cycle check point kinases and their regulation to 
confirm where in the cell cycle the cells are arresting.  
 
 
7.2.1 Conclusions  
 
Despite BER imbalances naturally occurring in glioblastoma cell lines, these 
imbalances had little effect on the response of the cells to treatment. The modulation of 
the BER pathway during treatment with TMZ and radiation only caused an increase in cell 
death in MGMT-negative cell lines, but no improvement was shown in MGMT-positive cell 
lines. To increase the efficacy of treatment regimes in glioblastoma for MGMT-positive cell 
lines a different style of treatment should be used, especially as clinical trials found that 
inhibiting MGMT with O6-benzylguanine lead to an increase in toxic side effects.  
  
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
150  Natalie Mayhead - August 2018 
8 REFERENCES 
Agnihotri, S. et al., 2012. Alkylpurine – DNA – N-glycosylase confers resistance to 
temozolomide in xenograft models of glioblastoma multiforme and is associated with 
poor survival in patients. The Journal of Clinical Investigations, 122(1), pp.253–266. 
Agnihotri, S. et al., 2014. ATM regulates 3-Methylpurine-DNA glycosylase and promotes 
therapeutic resistance to alkylating agents. Cancer discovery. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25100205. 
Ahmadloo, N. et al., 2013. Treatment outcome and prognostic factors of adult glioblastoma 
multiforme. Journal of the Egyptian National Cancer Institute, 25(1), pp.21–30. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S1110036212000726 
[Accessed April 23, 2013]. 
Allen, C., Halbrook, J. & Nickoloff, J.A., 2003. Interactive Competition Between Homologous 
Recombination and Non-Homologous End Joining 1 1 NIH grant CA77693 to J . A . N . 
Interactive Competition Between Homologous Recombination and Non-Homologous 
End Joining. , pp.913–920. 
Amaldi, U. et al., 2010. Accelerators for hadrontherapy: From Lawrence cyclotrons to 
linacs. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, 
Spectrometers, Detectors and Associated Equipment, 620(2–3), pp.563–577. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S0168900210007357 
[Accessed February 20, 2013]. 
Amaldi, U., 2012. Edoardo Amaldi , Scientist Edoardo Amaldi , Scientist. In AIP conference. 
Anderung, L., 2012. Universitat Klinikum Heidelberg; proton and heavy ion centres in the 
Chapter 8: References 
Natalie Mayhead - August 2018   151 
world. Available at: http://www.klinikum.uni-heidelberg.de/Therapy-centers-in-the-
world.113000.0.html?&L=1. 
Arvold, N.D. & Reardon, D. a, 2014. Treatment options and outcomes for glioblastoma in 
the elderly patient. Clinical interventions in aging, 9, pp.357–67. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3937103&tool=pmcen
trez&rendertype=abstract. 
Asaeda,  a et al., 2000. Substrate specificity of human methylpurine DNA N-glycosylase. 
Biochemistry, 39(8), pp.1959–65. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10684645. 
Asagoshi, K. et al., 2010. DNA polymerase beta-dependent long patch base excision repair 
in living cells. DNA repair, 9(2), pp.109–19. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2819632&tool=pmcen
trez&rendertype=abstract [Accessed October 14, 2013]. 
Audebert, M., Salles, B. & Calsou, P., 2004. Involvement of poly(ADP-ribose) polymerase-1 
and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks 
rejoining. The Journal of biological chemistry, 279(53), pp.55117–26. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15498778 [Accessed August 6, 2014]. 
Aymard, F. et al., 2014. Transcriptionally active chromatin recruits homologous 
recombination at DNA double-strand breaks. Nature structural & molecular biology, 
21(4), pp.366–74. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4300393&tool=pmcen
trez&rendertype=abstract. 
Azzam, E.I., Jay-gerin, J. & Pain, D., 2012. Ionizing radiation-induced metabolic oxidative 
stress and prolonged cell injury. Cancer Letters, 327(1–2), pp.48–60. Available at: 
http://dx.doi.org/10.1016/j.canlet.2011.12.012. 
Balducci, M. et al., 2014. Low-dose fractionated radiotherapy and concomitant 
chemotherapy for recurrent or progressive glioblastoma : Final report of a pilot 
study. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... 
[et al], 190(4), pp.370–376. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24429479 [Accessed April 10, 2014]. 
Ballarini, F. et al., 2008. Heavy-ion effects: from track structure to DNA and chromosome 
damage. New Journal of Physics, 10, p.17. 
Barakat, K.H., Gajewski, M.M. & Tuszynski, J.A., 2012. DNA polymerase beta (pol ??) 
inhibitors: A comprehensive overview. Drug Discovery Today, 17(15–16), pp.913–
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
152  Natalie Mayhead - August 2018 
920. Available at: http://dx.doi.org/10.1016/j.drudis.2012.04.008. 
Barazzuol, L. et al., 2013. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 
combined with radiotherapy and temozolomide in glioblastoma. Radiation oncology 
(London, England), 8(1), p.65. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3622565&tool=pmcen
trez&rendertype=abstract [Accessed August 21, 2014]. 
Barazzuol, L. et al., 2012. In Vitro Evaluation of Combined Temozolomide and 
Radiotherapy Using X Rays and High-Linear Energy Transfer Radiation for 
Glioblastoma. Radiation Research, 177, pp.651–662. 
Barton, M.B. et al., 2014. Estimating the demand for radiotherapy from the evidence: A 
review of changes from 2003 to 2012. Radiotherapy and Oncology, 112(1), pp.140–
144. Available at: http://dx.doi.org/10.1016/j.radonc.2014.03.024. 
Barzilay, G. et al., 1995. Identification of critical active-site residues in the multifunctional 
human DNA repair enzyme HAP1. Nature structural biology, 2(7), pp.561–568. 
Barzilay, G. & Hickson, I.D., 1995. Structure and function of apurinic/apyrimidinic 
endonucleases. BioEssays, 17(8), pp.713–719. 
Baylin, S.B. et al., 2001. Aberrant patterns of DNA methylation, chromatin formation and 
gene expression in cancer. Human molecular genetics, 10(7), pp.687–92. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11257100. 
Beard, W.A. & Wilson, S.H., 2006. Structure and Mechanism of DNA Polymerase. 
Beauchesne, P. et al., 2010. Prolonged survival for patients with newly diagnosed, 
inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. 
Neuro-oncology, 12(6), pp.595–602. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2940649&tool=pmcen
trez&rendertype=abstract. 
Bennett, R. a et al., 1997. Interaction of human apurinic endonuclease and DNA 
polymerase beta in the base excision repair pathway. Proceedings of the National 
Academy of Sciences of the United States of America, 94(14), pp.7166–7169. 
Bobola, M.S. et al., 2005. Apurinic/apyrimidinic endonuclease activity is associated with 
response to radiation and chemotherapy in medulloblastoma and primitive 
neuroectodermal tumors. Clinical Cancer Research, 11(20), pp.7405–7414. 
Bobola, M.S. et al., 2001. Apurinic / Apyrimidinic Endonuclease Activity Is Elevated in 
Human Adult Gliomas Apurinic / Apyrimidinic Endonuclease Activity Is Elevated in 
Chapter 8: References 
Natalie Mayhead - August 2018   153 
Human. , pp.3510–3518. 
Bobola, M.S. et al., 2004. Apurinic endonuclease activity in adult gliomas and time to tumor 
progression after alkylating agent-based chemotherapy and after radiotherapy. 
Clinical Cancer Research, 10(23), pp.7875–7883. 
Bobola, M.S. et al., 2012. Repair of 3-methyladenine and abasic sites by base excision 
repair mediates glioblastoma resistance to temozolomide. Frontiers in oncology, 2, 
p.176. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3515961&tool=pmcen
trez&rendertype=abstract [Accessed August 10, 2014]. 
Boerrigter, M.E.T.I., 1991. SPECIAL ARTICLE DNA Strand Break Metabolism in Human 
Lymphocytes : A Reevaluation. Experimental Cell Research, 196(5), pp.1–5. 
Bonner, W.M., 2004. Phenomena leading to cell survival values which deviate from linear-
quadratic models. Mutation research, 568(1), pp.33–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15530537 [Accessed August 1, 2014]. 
BOOT, H.A.H., 1961. Long Anode Magnetrons. In Crossed-field Microwave Device. Elsevier, 
pp. 261–274. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/B9780123955548500231 [Accessed 
November 15, 2017]. 
Brahme, A. & Lind, B.K., 2010. A systems biology approach to radiation therapy 
optimization. Radiation and environmental biophysics, 49(2), pp.111–24. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/20191284 [Accessed July 14, 2014]. 
Brandes, A.A. et al., 2008. MGMT promoter methylation status can predict the incidence 
and outcome of pseudoprogression after concomitant radiochemotherapy in newly 
diagnosed glioblastoma patients. Journal of Clinical Oncology, 26(13), pp.2192–2197. 
Brenner, D., 2008. Point: The linear-quadratic model is an appropriate methodology for 
determining iso-effective doses at large doses per fraction. Radiation Oncology, 
18(4), pp.234–239. 
Burigo, L. et al., 2014. Nuclear Instruments and Methods in Physics Research B 
Microdosimetry spectra and RBE of 1 H , 4 He , 7 Li and studied with Geant4 C nuclei 
in water. Nuclear Inst. and Methods in Physics Research, B, 320, pp.89–99. Available 
at: http://dx.doi.org/10.1016/j.nimb.2013.10.018. 
Burma, S. et al., 2001. ATM phosphorylates histone H2AX in response to DNA double-
strand breaks. The Journal of biological chemistry, 276(45), pp.42462–7. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/11571274 [Accessed December 13, 2013]. 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
154  Natalie Mayhead - August 2018 
Caldecott, K.W., 2003. XRCC1 and DNA strand break repair. DNA Repair, 2(9), pp.955–969. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S1568786403001186 
[Accessed May 27, 2014]. 
Caldecott, K.W. et al., 1996. XRCC1 polypeptide interacts with DNA polymerase beta and 
possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular “nick-
sensor” in vitro. Nucleic acids research, 24(22), pp.4387–94. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=146288&tool=pmcent
rez&rendertype=abstract. 
Calleja, F. et al., 1999. Modulation of the toxic and mutagenic effects induced by methyl 
methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-
alkylpurine-DNA glycosylase. Mutation Research, 425, pp.185–194. 
Calvo, J. a et al., 2013a. Aag DNA glycosylase promotes alkylation-induced tissue damage 
mediated by Parp1. PLoS genetics, 9(4), p.e1003413. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3617098&tool=pmcen
trez&rendertype=abstract. 
Calvo, J. a et al., 2013b. Aag DNA glycosylase promotes alkylation-induced tissue damage 
mediated by Parp1. PLoS genetics, 9(4), p.e1003413. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3617098&tool=pmcen
trez&rendertype=abstract [Accessed February 20, 2014]. 
Campalans, A. et al., 2013. Distinct spatiotemporal patterns and PARP dependence of 
XRCC1 recruitment to single-strand break and base excision repair. Nucleic Acids 
Research, 41(5), pp.3115–3129. 
Campalans, A. et al., 2005. XRCC1 interactions with multiple DNA glycosylases: a model for 
its recruitment to base excision repair. DNA repair, 4(7), pp.826–35. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15927541 [Accessed May 29, 2014]. 
Carabe, A. et al., 2013. Clinical consequences of relative biological effectiveness variations 
in proton radiotherapy of the prostate, brain and liver. Physics in Medicine and 
Biology, 58(7), pp.2103–2117. Available at: http://stacks.iop.org/0031-
9155/58/i=7/a=2103?key=crossref.7d7cb0de94ab1e9b90c0c4e46ca554b1. 
Chakravarti, D. et al., 1991. Cloning and Expression in Escherichia coli of a Human cDNA 
Encoding the DNA Repair Protein N-Methylpurine-DNA Glycosylase ”. The Journal of 
Biological Chemistry, 266(24), pp.15710–15715. 
Chalmers, A. et al., 2004. PARP-1, PARP-2, and the cellular response to low doses of 
Chapter 8: References 
Natalie Mayhead - August 2018   155 
ionizing radiation. International Journal of Radiation Oncology Biology Physics, 
58(2), pp.410–419. 
Chen, D.S., Herman, T. & Demple, B., 1991. Two distinct human DNA diesterases that 
hydrolyze 3???-blocking deoxyribose fragments from oxidized DNA. Nucleic Acids 
Research, 19(21), pp.5907–5914. 
Chen, Y. et al., 2013. MGMT promoter methylation and glioblastoma prognosis: a 
systematic review and meta-analysis. Archives of medical research, 44(4), pp.281–
90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23608672 [Accessed March 
17, 2014]. 
Chohan, M. et al., 2015. Human Apurinic/Apyrimidinic Endonuclease 1 (APE1) Has 3′ RNA 
Phosphatase and 3′ Exoribonuclease Activities. Journal of Molecular Biology, 427(2), 
pp.298–311. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0022283614006172. 
Chou, T.C., 2010. Drug combination studies and their synergy quantification using the 
chou-talalay method. Cancer Research, 70(2), pp.440–446. 
Chu, E.C. & Tarnawski, A.S., 2004. PTEN regulatory functions in tumor suppression and cell 
biology. Medical science monitor : international medical journal of experimental and 
clinical research, 10(10), pp.RA235-A241. 
Clamp, M. et al., 2007. Distinguishing protein-coding and noncoding genes in the human 
genome. Proceedings of the National Academy of Sciences of the United States of 
America, 104(49), pp.19428–33. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18040051. 
Cleary, J., Gelband, H. & Wagner, J., 2015. Cancer: Disease Control Priorities. Disease 
Control Priorities 3rd Edition, pp.1–363. Available at: 
http://www.ncbi.nlm.nih.gov/books/NBK343628/pdf/Bookshelf_NBK343628.pdf. 
Cohen, A., Holman, S. & Colman, H., 2013. IDH1 and IDH2 Mutations in Gliomas. Current 
neurology and neuroscience reports, 13(5). 
Coogan, T.P., Motz, J. & Christie, N.T., 1992. Repair of X-ray induced DNA strand damage by 
isolated rat splenic lymphocytes. Mutation research, 293(1), pp.39–46. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1383809. 
Coomberl, B.L. et al., 1987. Quantitative morphology of human glioblastoma multiforme 
microvessels: structural basis of blood-brain barrier defect. Journal of Neuro-
Oncology, 5(4), pp.299–307. 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
156  Natalie Mayhead - August 2018 
Costello, J.F. et al., 1994. Graded methylation in the promoter and body of the O6-
methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT 
expression in human glioma cells. Journal of Biological Chemistry, 269(25), 
pp.17228–17237. 
Dalal, S. et al., 2005. Prostate-Cancer-Associated I260M Variant of DNA Polymerase β Is a 
Sequence-Specific Mutator. Biochemistry, 44(48), pp.15664–15673. Available at: 
http://dx.doi.org/10.1021/bi051179z. 
Daşu,  a & Denekamp, J., 2000. Inducible repair and intrinsic radiosensitivity: a complex 
but predictable relationship? Radiation research, 153(3), pp.279–88. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10669549. 
Delaney, G.P. & Barton, M.B., 2015. Evidence-based Estimates of the Demand for 
Radiotherapy. Clinical Oncology, 27(2), pp.70–76. Available at: 
http://dx.doi.org/10.1016/j.clon.2014.10.005. 
Denker, A. et al., 2007. Ion accelerator applications in medicine and cultural heritage. 
Nuclear Instruments and Methods in Physics Research, 580, pp.457–461. 
Denny, B.J. et al., 1994. NMR and molecular modeling investigation of the mechanism of 
activation of the antitumor drug temozolomide and its interaction with DNA. 
Biochemistry, 33, pp.9045–9051. 
Dianova, I.I. et al., 2004. XRCC1-DNA polymerase beta interaction is required for efficient 
base excision repair. Nucleic acids research, 32(8), pp.2550–5. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=419455&tool=pmcent
rez&rendertype=abstract [Accessed April 26, 2014]. 
Ding, X. et al., 2015. A Fast Method to Calculate RBE Weighted Dose Distribution. 
International Journal of Radiation Oncology*Biology*Physics, 93(3), p.E566. 
Available at: http://dx.doi.org/10.1016/j.ijrobp.2015.07.1996. 
Drummond, J.T. et al., 1995. Isolation of an hMSH2-p160 heterodimer that restores DNA 
mismatch repair to tumor cells. Science (New York, N.Y.), 268(5219), pp.1909–12. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/7604264. 
Dudás, A. & Chovanec, M., 2004. DNA double-strand break repair by homologous 
recombination. Mutation research, 566(2), pp.131–67. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15164978 [Accessed September 27, 2013]. 
Duell, E.J. et al., 2001. Polymorphisms in the DNA Repair Gene XRCC1 and Breast Cancer. 
Cancer Epidemology, Biomarkers & Prevention, 10, pp.217–222. 
Chapter 8: References 
Natalie Mayhead - August 2018   157 
Dziaman, T. et al., 2014. PARP-1 expression is increased in colon adenoma and carcinoma 
and correlates with OGG1. PLoS ONE, 9(12). 
El-Khamisy, S.F., 2003. A requirement for PARP-1 for the assembly or stability of XRCC1 
nuclear foci at sites of oxidative DNA damage. Nucleic Acids Research, 31(19), 
pp.5526–5533. Available at: 
http://nar.oxfordjournals.org/lookup/doi/10.1093/nar/gkg761 [Accessed June 17, 
2014]. 
El-Khamisy, S.F. et al., 2003. A requirement for PARP-1 for the assembly or stability of 
XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Research, 31(19), 
pp.5526–5533. 
Engelward, B.P. et al., 1997. Base excision repair deficient mice lacking the Aag 
alkyladenine DNA glycosylase. Proceedings of the National Academy of Sciences of 
the United States of America, 94(24), pp.13087–92. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24267&tool=pmcentr
ez&rendertype=abstract. 
Engelward, B.P. et al., 1996. Repair-deficient 3-methyladenine DNA glycosylase 
homozygous mutant mouse cells have increased sensitivity to alkylation-induced 
chromosome damage and cell killing. The EMBO journal, 15(4), pp.945–52. Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=450292&tool=pmcent
rez&rendertype=abstract. 
Enns, L. et al., 2004. Low-dose radiation hypersensitivity is associated with p53-dependent 
apoptosis. Molecular cancer research : MCR, 2(10), pp.557–66. Available at: 
https://e-reports-
ext.llnl.gov/pdf/306755.pdf%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/15498930
%5Cnhttp://mcr.aacrjournals.org/content/2/10/557.short. 
Evans,  a R., Limp-Foster, M. & Kelley, M.R., 2000. Going APE over ref-1. Mutation research, 
461(2), pp.83–108. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11018583. 
Fang, Y., Sullivan, R. & Graham, C.H., 2007. Confluence-dependent resistance to 
doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-
inducible factor-1 activity. Experimental Cell Research, 313(5), pp.867–877. 
Fernandez-Capetillo, O. et al., 2004. H2AX: the histone guardian of the genome. DNA 
repair, 3(8–9), pp.959–67. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15279782 [Accessed September 29, 2013]. 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
158  Natalie Mayhead - August 2018 
Fishel, M.L. et al., 2007. Manipulation of base excision repair to sensitize ovarian cancer 
cells to alkylating agent temozolomide. Clinical Cancer Research, 13(1), pp.260–267. 
Fleckenstein, J. et al., 2011. The impact of individual in vivo repair of DNA double-strand 
breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. 
International journal of radiation oncology, biology, physics, 81(5), pp.1465–72. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/20947264 [Accessed July 18, 
2013]. 
Frankenberg, D., 1994. Repair of DNA double-strand breaks and its effect on RBE. 
Advances in space research : the official journal of the Committee on Space Research 
(COSPAR), 14(10), pp.235–48. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11539957. 
Freeman, R. & Morris, G.A., 2015. The Varian story. Journal of Magnetic Resonance, 250, 
pp.80–84. Available at: http://dx.doi.org/10.1016/j.jmr.2014.12.001. 
Fu, D., Calvo, J. a. & Samson, L.D., 2012. Balancing repair and tolerance of DNA damage 
caused by alkylating agents. Nature Reviews Cancer, 12(February). 
Fu, D., Calvo, J. a & Samson, L.D., 2012. Balancing repair and tolerance of DNA damage 
caused by alkylating agents. Nature reviews. Cancer, 12(2), pp.104–20. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3586545&tool=pmcen
trez&rendertype=abstract [Accessed October 23, 2013]. 
Fu, D. & Samson, L., 2012. Direct Repair of 3,N4-Ethenocytosine by the Human ALKBH2 
Dioxygenase is blocked by the AAG/MPG Glycosylase. DNA repair, 11(1), pp.46–52. 
Gállego Pérez-Larraya, J. et al., 2011. Temozolomide in elderly patients with newly 
diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 29(22), pp.3050–5. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21709196 [Accessed March 20, 2014]. 
Gao, Z. et al., 2008. Inhibitors of DNA polymerase beta: activity and mechanism. Bioorganic 
& medicinal chemistry, 16(8), pp.4331–40. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18343122. 
Gaspar, N. et al., 2010. MGMT-independent temozolomide resistance in pediatric 
glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene 
signature. Cancer research, 70(22), pp.9243–52. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3935452&tool=pmcen
Chapter 8: References 
Natalie Mayhead - August 2018   159 
trez&rendertype=abstract [Accessed August 19, 2014]. 
Gerelchuluun, A. et al., 2015. The Major DNA Repair Pathway after Both Proton and 
Carbon-Ion Radiation is NHEJ, but the HR Pathway is More Relevant in Carbon Ions. 
Radiation Research, 356, p.150304074808001. Available at: 
http://www.rrjournal.org/doi/10.1667/RR13904.1. 
Golding, S.E. et al., 2012. Dynamic inhibition of ATM kinase provides a strategy for 
glioblastoma multiforme radiosensitization and growth control. Cell Cycle, 11, 
pp.1167–1173. 
Goode, E.L., Ulrich, C.M. & Potter, J.D., 2002. Polymorphisms in DNA Repair Genes and 
Associations with Cancer Risk Polymorphisms in DNA Repair Genes and Associations 
with Cancer Risk 1. , pp.1513–1530. 
Goodhead, D.T., 2006. Energy deposition stochastics and track structure: what about the 
target? Radiation protection dosimetry, 122(1–4), pp.3–15. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17276998 [Accessed August 1, 2014]. 
Gordon, M.S. et al., 2013. A phase 1 study of TRC102, an inhibitor of base excision repair, 
and pemetrexed in patients with advanced solid tumors. Investigational New Drugs, 
31(3), pp.714–723. 
Gregory C. Stachelek, Shibani Dalal, Katherine A. Donigan, D.C.H. & Joann B. Sweasy,  and 
P.M.G., 2010. Potentiation of Temozolomide Cytotoxicity by Polymerase β Inhibition 
Is Increased in the Absence of BRCA2. October, 28(30), pp.4439–4448. 
Grubbé, E.H., 1933. Priority in the Therapeutic Use of X-rays. Radiology, 21(2), pp.156–
162. Available at: http://pubs.rsna.org/doi/10.1148/21.2.156. 
Gudmundsdottir, K. & Ashworth, A., 2006. The roles of BRCA1 and BRCA2 and associated 
proteins in the maintenance of genomic stability. Oncogene, 25(43), pp.5864–5874. 
Available at: http://www.nature.com/doifinder/10.1038/sj.onc.1209874. 
Haince, J.-F. et al., 2007. Ataxia telangiectasia mutated (ATM) signaling network is 
modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to 
DNA-damaging agents. The Journal of biological chemistry, 282(22), pp.16441–53. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/17428792 [Accessed August 6, 
2014]. 
Hall, E.J., 1985. Radiation biology. Cancer, 55(9 Suppl), pp.2051–2057. 
Halliwell, B., 2003. Oxidative stress in cell culture: An under-appreciated problem? FEBS 
Letters, 540(1–3), pp.3–6. 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
160  Natalie Mayhead - August 2018 
Hanahan, D. & Weinberg, R. a, 2011. Hallmarks of cancer: the next generation. Cell, 144(5), 
pp.646–74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21376230 
[Accessed July 9, 2014]. 
Hanahan, D., Weinberg, R. a & Francisco, S., 2000. The Hallmarks of Cancer Review 
University of California at San Francisco. , 100, pp.57–70. 
Hanahan, D., Weinberg, R.A. & Francisco, S., 2000. The Hallmarks of Cancer Review 
University of California at San Francisco. , 100, pp.57–70. 
Happold, C. et al., 2012. Distinct molecular mechanisms of acquired resistance to 
temozolomide in glioblastoma cells. Journal of Neurochemistry, 122(2), pp.444–455. 
Hassler, M. et al., 2006. Diversity of cytogenetic and pathohistologic profiles in 
glioblastoma. Cancer genetics and cytogenetics, 166(1), pp.46–55. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16616111 [Accessed March 17, 2014]. 
Hazan, C. et al., 2008. Structural insights on the pamoic acid and the 8 kDa domain of DNA 
polymerase beta complex: towards the design of higher-affinity inhibitors. BMC 
structural biology, 8, p.22. 
Hedglin, M. & O’Brien,  and P.J., 2010. Hopping Enables a DNA Repair Glycosylase to Search 
Both Strands and Bypass a Bound Protein. ACS Chemical Biology, 5(4), pp.427–436. 
Helfferich, J. et al., 2016. Neurofibromatosis type 1 associated low grade gliomas: A 
comparison with sporadic low grade gliomas. Critical Reviews in 
Oncology/Hematology, 104, pp.30–41. Available at: 
http://dx.doi.org/10.1016/j.critrevonc.2016.05.008. 
Hermisson, M. et al., 2006. O6-methylguanine DNA methyltransferase and p53 status 
predict temozolomide sensitivity in human malignant glioma cells. Journal of 
neurochemistry, 96(3), pp.766–76. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16405512 [Accessed February 19, 2013]. 
Herring, C.J. et al., 1998. Levels of the DNA repair enzyme human apurinic/apyrimidinic 
endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity 
of cervical cancers. British journal of cancer, 78(9), pp.1128–1133. 
Hickman, M.J. & Samson, L.D., 1999. Role of DNA mismatch repair and p53 in signaling 
induction of apoptosis by alkylating agents. Proceedings of the National Academy of 
Sciences of the United States of America, 96(19), pp.10764–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=17957&tool=pmcentr
ez&rendertype=abstract. 
Chapter 8: References 
Natalie Mayhead - August 2018   161 
Hill, M. a., 1999. Radiation damage to DNA: The importance of track structure. Radiation 
Measurements, 31(1–6), pp.15–23. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S1350448799000906. 
Horton, J.K. & Wilson, S.H., 2007. Hypersensitivity phenotypes associated with genetic and 
synthetic inhibitor-induced base excision repair deficiency. DNA Repair, 6(4), 
pp.530–543. 
Hu, H.-Y. et al., 2004. Identification of small molecule synthetic inhibitors of DNA 
polymerase beta by NMR chemical shift mapping. The Journal of biological chemistry, 
279(38), pp.39736–39744. 
Hu, H.Y. et al., 2004. Identification of small molecule synthetic inhibitors of DNA 
polymerase β by NMR chemical shift mapping. Journal of Biological Chemistry, 
279(38), pp.39736–39744. 
Hunt, C.R. et al., 2013. Histone modifications and DNA double-strand break repair after 
exposure to ionizing radiations. Radiation research, 179(4), pp.383–92. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23373901 [Accessed September 16, 2013]. 
Iyama, T. & Wilson, D.M., 2013. DNA repair mechanisms in dividing and non-dividing cells. 
DNA repair, 12(8), pp.620–36. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23684800 [Accessed September 23, 2013]. 
Jaiswal, A.S. et al., 2009. A novel inhibitor of DNA polymerase beta enhances the ability of 
temozolomide to impair the growth of colon cancer cells. Molecular cancer research : 
MCR, 7(12), pp.1973–83. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19996303%5Cnhttp://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=PMC2796282. 
Jaiswal, A.S. et al., 2011. DNA polymerase B as a novel target for chemotherapeutic 
intervention of colorectal cancer. PLoS ONE, 6(2). 
Jäkel, O., 2008. The relative biological effectiveness of proton and ion beams. Zeitschrift für 
Medizinische Physik, 18(4), pp.276–285. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0939388908000822 [Accessed 
October 11, 2013]. 
Jellinger, K., 1978. Glioblastoma multiforme: Morphology and biology. Acta 
Neurochirurgica, 42(1–2), pp.5–32. 
Jeynes, J.C.G. et al., 2013. “Broadbeam” irradiation of mammalian cells using a vertical 
microbeam facility. Radiation and environmental biophysics, 52(4), pp.513–21. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/23963461 [Accessed February 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
162  Natalie Mayhead - August 2018 
20, 2014]. 
Jiricny, J., 2006. The multifaceted mismatch-repair system. , 7(May), pp.335–346. 
Kaina, B. et al., 2007. MGMT : Key node in the battle against genotoxicity , carcinogenicity 
and apoptosis induced by alkylating agents. DNA repair, 6, pp.1079–1099. 
Karpenshif, Y. & Bernstein, K. a, 2012. From yeast to mammals: recent advances in genetic 
control of homologous recombination. DNA repair, 11(10), pp.781–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22889934 [Accessed October 2, 2013]. 
Kavanagh, J.N. et al., 2013. DNA double strand break repair: a radiation perspective. 
Antioxidants & redox signaling, 18(18), pp.2458–72. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23311752 [Accessed February 20, 2014]. 
Kelley, M.R. et al., 2001. Elevated and Altered Expression of the Multifunctional DNA Base 
Excision Repair and Redox Enzyme Ape1 / ref-1 in Prostate Cancer Elevated and 
Altered Expression of the Multifunctional DNA Base Excision Repair and Redox 
Enzyme Ape1 / ref-1 in Prostate Canc. , 7(April), pp.824–830. 
Kemp, M., 1998. Röntgen ’ s rays. Nature, p.35. 
Kim, Y.-J. & Wilson, D.M., 2012. Overview of base excision repair biochemistry. Current 
molecular pharmacology, 5(1), pp.3–13. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3459583&tool=pmcen
trez&rendertype=abstract. 
Kirkby, K.J. et al., 2007. A scanning focussed vertical ion nanobeam: A new UK facility for 
cell irradiation and analysis. Nuclear Instruments and Methods in Physics Research, 
Section B: Beam Interactions with Materials and Atoms, 260(1), pp.97–100. 
Koh, D.W. et al., 2004. Failure to degrade poly(ADP-ribose) causes increased sensitivity to 
cytotoxicity and early embryonic lethality. Proceedings of the National Academy of 
Sciences of the United States of America, 101(51), pp.17699–17704. Available at: 
http://www.pnas.org/cgi/doi/10.1073/pnas.0406182101%5Cnpapers3://publicati
on/doi/10.1073/pnas.0406182101. 
Kondo, N. et al., 2010. DNA Damage Induced by Alkylating Agents and Repair Pathways. 
Journal of Nucleic Acids, 2010, pp.1–7. Available at: 
http://www.hindawi.com/journals/jna/2010/543531/. 
Koukourakis, M. et al., 2001. Nuclear Expression of Human Apurinic / Apyrimidinic 
Endonuclease ( Hap1 / Ref-1 ) in Head-and-Neck Cancer Is Associated With 
Resistance To Chemoradiotherapy and Poor Outcome. Int J Radiation Oncology Biol 
Chapter 8: References 
Natalie Mayhead - August 2018   163 
Phys, 50(1), pp.27–36. 
Kulshrestha, P. et al., 2008. Treatment of Glioblastoma Multiforme by Stereotactic Radio 
Therapy/Intensity Modulated Radiation Therapy. Apollo Medicine, 5(3), pp.223–227. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S0976001611604912 
[Accessed July 18, 2013]. 
Lamers, M.H. et al., 2000. The crystal structure of DNA mismatch repair protein MutS 
binding to a G·T mismatch. Nature, 407(6805), pp.711–717. 
Lander, E.S. et al., 2001. Initial sequencing and analysis of the human genome. Nature, 
409(6822), pp.860–921. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11237011%5Cnhttp://www.nature.com/nat
ure/journal/v409/n6822/pdf/409860a0.pdf. 
Lang, T. et al., 2007. The E295K DNA polymerase beta gastric cancer-associated variant 
interferes with base excision repair and induces cellular transformation. Molecular 
and cellular biology, 27(15), pp.5587–96. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1952088&tool=pmcen
trez&rendertype=abstract. 
Larsen, E. et al., 2007. Organ and cell specificity of base excision repair mutants in mice. 
Mutation research, 614(1–2), pp.56–68. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16765995 [Accessed March 17, 2014]. 
Lau,  a Y. et al., 2000. Molecular basis for discriminating between normal and damaged 
bases by the human alkyladenine glycosylase, AAG. Proceedings of the National 
Academy of Sciences of the United States of America, 97(25), pp.13573–8. Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=17617&tool=pmcentr
ez&rendertype=abstract. 
Lau, P.J. & Kolodner, R.D., 2003. Transfer of the MSH2·MSH6 complex from proliferating 
cell nuclear antigen to mispaired bases in DNA. Journal of Biological Chemistry, 
278(1), pp.14–17. 
Lavin, M.F., 2008. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell 
signalling and cancer. Nature reviews. Molecular cell biology, 9(10), pp.759–69. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18813293 [Accessed January 
29, 2013]. 
Lavin, M.F., 2007. ATM and the Mre11 complex combine to recognize and signal DNA 
double-strand breaks. Oncogene, 26(56), pp.7749–58. Available at: 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
164  Natalie Mayhead - August 2018 
http://www.ncbi.nlm.nih.gov/pubmed/18066087 [Accessed December 13, 2013]. 
Lee, S.Y., 2016. Temozolomide resistance in glioblastoma multiforme. Genes and Diseases, 
3(3), pp.198–210. Available at: http://dx.doi.org/10.1016/j.gendis.2016.04.007. 
Leguisamo, N.M. et al., 2017. Base excision repair imbalance in colorectal cancer has 
prognostic value and modulates response to chemotherapy. , 8(33), pp.54199–
54214. Available at: www.impactjournals.com/oncotarget. 
Liauw, S., Connell, P. & Weichselbaum, R., 2013. New paradigms and future challenges in 
Radiation Oncology: An Update of Biological Targets and Technology. Scientific 
translational medicine, 70(4), pp.646–656. 
Lin, C.. et al., 2003. The conditional probabilities of survival in patients with anaplastic 
astrocytoma or glioblastoma multiforme. Surgical Neurology, 60(5), pp.402–406. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S0090301903003227 
[Accessed April 22, 2013]. 
Liu, C. et al., 2012. Aberrant expression of N-methylpurine-DNA glycosylase influences 
patient survival in malignant gliomas. Journal of biomedicine & biotechnology, 2012, 
p.760679. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3303893&tool=pmcen
trez&rendertype=abstract [Accessed April 26, 2014]. 
Liu, L. et al., 1999. Pharmacologic disruption of base excision repair sensitizes mismatch 
repair-deficient and -proficient colon cancer cells to methylating agents. Clinical 
Cancer Research, 5(10), pp.2908–2917. 
Lord, C. & Ashworth, A., 2017. PARP inhibitors: Synthetic lethalityin the Clinic. Science, 
355(March), pp.1152–1158. 
Louis, D.N. et al., 2007. The 2007 WHO classification of tumours of the central nervous 
system. Acta neuropathologica, 114(2), pp.97–109. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1929165&tool=pmcen
trez&rendertype=abstract [Accessed March 20, 2014]. 
Lu, Q.R. et al., 2001. Oligodendrocyte lineage genes (OLIG) as molecular markers for 
human glial brain tumors. Proceedings of the National Academy of Sciences of the 
United States of America, 98(19), pp.10851–6. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=58563&tool=pmcentr
ez&rendertype=abstract. 
Lundberg, E. et al., 2010. Defining the transcriptome and proteome in three functionally 
Chapter 8: References 
Natalie Mayhead - August 2018   165 
different human cell lines. Molecular Systems Biology, 6(450), pp.1–10. Available at: 
http://msb.embopress.org/cgi/doi/10.1038/msb.2010.106. 
Mandina, T. et al., 2011. Dose-response relationship of γ-H2AX foci induction in human 
lymphocytes after X-rays exposure. Radiation Measurements, 46(9), pp.997–999. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S1350448711001818 
[Accessed July 9, 2013]. 
Marples, B., 2004. Is low-dose hyper-radiosensitivity a measure of G2-phase cell 
radiosensitivity? Cancer and Metastasis Reviews, 23(3–4), pp.197–207. 
Martins, M.N. & Silva, T.F., 2012. Electron accelerators: History, applications and 
perspectives. Radiation Physics and Chemistry. 
Masuda, Y., Bennett, R.A.O. & Demple, B., 1998. Dynamics of the interaction of human 
apurinic endonuclease (Ape1) with its substrate and product. Journal of Biological 
Chemistry, 273(46), pp.30352–30359. 
Matsumoto, Y. & Kim, K., 1995. Excision of deoxyribose phosphate residues by DNA 
polymerase beta during DNA repair. Science (New York, N.Y.), 269(5224), pp.699–
702. Available at: 
http://www.sciencemag.org/cgi/doi/10.1126/science.7624801%5Cnhttp://www.n
cbi.nlm.nih.gov/pubmed/7624801. 
McDonald, M.W. & Fitzek, M.M., 2010. Proton therapy. Current problems in cancer, 34(4), 
pp.257–96. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20647112 
[Accessed June 16, 2013]. 
McNamara, M.G., Sahebjam, S. & Mason, W.P., 2013. Emerging biomarkers in glioblastoma. 
Cancers, 5(3), pp.1103–19. Available at: http://www.mdpi.com/2072-
6694/5/3/1103/htm. 
Merchant, M.J. et al., 2012. A focused scanning vertical beam for charged particle 
irradiation of living cells with single counted particles. Radiation research, 178(3), 
pp.182–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22823572. 
Merchant, M.J. et al., 2005. Characterisation of the University of Surrey Ion Beam Centre in-
air scanning microbeam. Nuclear Instruments and Methods in Physics Research 
Section B: Beam Interactions with Materials and Atoms, 231(1–4), pp.26–31. 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S0168583X05000492 
[Accessed July 25, 2014]. 
Merchant, M.J., Palitsin, V. & Grime, G.W., 2009. The use of the Wien filter to eliminate 
object slit scattering in MeV ion nanobeam systems. Nuclear Instruments and 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
166  Natalie Mayhead - August 2018 
Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms, 
267(12–13), pp.2021–2023. Available at: 
http://dx.doi.org/10.1016/j.nimb.2009.03.075. 
Metzger, M.J., Stoddard, B.L. & Monnat, R.J., 2013. PARP-mediated repair, homologous 
recombination, and back-up non-homologous end joining-like repair of single-strand 
nicks. DNA repair, 12(7), pp.529–34. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23684799 [Accessed September 30, 2013]. 
Miao, F., Bouziane, M. & O’Connor, T.R., 1998. Interaction of the recombinant human 
methylpurine-DNA glycosylase (MPG protein) with oligodeoxyribonucleotides 
containing either hypoxanthine or abasic sites. Nucleic acids research, 26(17), 
pp.4034–41. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=147787&tool=pmcent
rez&rendertype=abstract. 
Mirza, M.R. et al., 2016. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent 
Ovarian Cancer. New England Journal of Medicine, 375(22), pp.2154–2164. Available 
at: http://www.nejm.org/doi/10.1056/NEJMoa1611310. 
Miwa, K. et al., 2014. Hypofractionated high-dose irradiation with positron emission 
tomography data for the treatment of glioblastoma multiforme. BioMed research 
international, 2014, p.407026. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4055095&tool=pmcen
trez&rendertype=abstract [Accessed July 16, 2014]. 
Mladenov, E. & Iliakis, G., 2011. Induction and repair of DNA double strand breaks: The 
increasing spectrum of non-homologous end joining pathways. Mutation Research - 
Fundamental and Molecular Mechanisms of Mutagenesis, 711(1–2), pp.61–72. 
Available at: 
http://www.sciencedirect.com/science/article/pii/S0027510711000285?via%3Dih
ub [Accessed November 25, 2017]. 
Mol, C.D. et al., 2000. DNA-bound structures and mutants reveal abasic DNA binding by 
APE1 and DNA repair coordination [corrected]. Nature, 403(6768), pp.451–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10667800. 
Montaldi, A.P. et al., 2014. Base Excision Repair Inhibition by Methoxyamine Impairs 
Growth and Sensitizes Osteosarcoma Cells to Conventional Treatments. , (April), 
pp.307–314. 
Chapter 8: References 
Natalie Mayhead - August 2018   167 
Montaldi, A.P., Godoy, P.R.D. V & Sakamoto-Hojo, E.T., 2015. APE1/REF-1 down-regulation 
enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. 
Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 793, pp.19–
29. Available at: http://dx.doi.org/10.1016/j.mrgentox.2015.06.001. 
Montaldi, A.P. & Sakamoto-Hojo, E.T., 2013. Methoxyamine sensitizes the resistant 
glioblastoma T98G cell line to the alkylating agent temozolomide. Clinical and 
Experimental Medicine, 13(4), pp.279–288. 
Musgrave, D.R., Sandman, K.M. & Reeve, J.N., 1991. DNA binding by the archaeal histone 
HMf results in positive supercoiling. Proceedings of the National Academy of Sciences 
of the United States of America, 88(23), pp.10397–401. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=52935&tool=pmcentr
ez&rendertype=abstract. 
Mutamba, J.T. et al., 2011. XRCC1 and base excision repair balance in response to nitric 
oxide. DNA repair, 10(12), pp.1282–93. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3593656&tool=pmcen
trez&rendertype=abstract [Accessed April 13, 2013]. 
Naidu, M.D. et al., 2010. Radiation Resistance in Glioma Cells Determined by DNA Damage 
Repair Activity of Ape1/Ref-1. Journal of Radiation Research, 51(4), pp.393–404. 
Available at: http://joi.jlc.jst.go.jp/JST.JSTAGE/jrr/09077?from=CrossRef [Accessed 
August 19, 2014]. 
Nemec, A.A. et al., 2012. Colon cancer-associated DNA polymerase β variant induces 
genomic instability and cellular transformation. Journal of Biological Chemistry, 
287(28), pp.23840–23849. 
Neshasteh-Riz, A., Saki, M. & Khoei, S., 2008. Cytogenetic damages from lododeoxyuridine -
induced radiosensitivity with and without methoxyamine in human glioblastoma 
spheroids. Yakhteh, 10(1). 
Newlands et al., 1997. Temozolomide: a review of its discovery, chemical properties, pre-
clinical development and clinical trials. Cancer Treatment Reviews, 23, pp.35–61. 
Newlands, E.S. et al., 1992. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 
362856). British Journal of Cancer, 65(2), pp.287–291. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1739631%5Cnhttp://www.ncbi.nlm.nih.gov
/pmc/articles/PMC1977719/pdf/brjcancer00066-0149.pdf. 
Nilsson, J., 2004. Accurate description of heterogeneous tumors for biologically optimized 
radiation therapy Johan Nilsson, 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
168  Natalie Mayhead - August 2018 
Oka, S., Kato, J. & Moss, J., 2006. Identification and characterization of a mammalian 39-kDa 
poly(ADP-ribose) glycohydrolase. Journal of Biological Chemistry, 281(2), pp.705–
713. 
Oleinick, N.L. et al., 2016. Radiosensitization of non-small-cell lung cancer cells and 
xenografts by the interactive effects of pemetrexed and methoxyamine. Radiotherapy 
and Oncology, 121(2), pp.335–341. Available at: 
http://dx.doi.org/10.1016/j.radonc.2016.10.007. 
Olive, P.L. & Banáth, J.P., 1993. Induction and rejoining of radiation-induced DNA single-
strand breaks: “tail moment” as a function of position in the cell cycle. Mutation 
research, 294(3), pp.275–83. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/7692267. 
Oliveri, D.R., Harris, P. V & Boyd, J.B., 1990. X-Ray sensitivity and single-strand DNA break 
repair in mutagen-sensitive mutants of Drosophila melanogaster. Mutation research, 
235, pp.25–31. 
Ono, Y. et al., 1994. Stable expression in rat glioma cells of sense and antisense nucleic 
acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat Res, 
315(1), pp.55–63. 
Ostermann, S. et al., 2004. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of 
Temozolomide in Malignant Glioma Patients Plasma and Cerebrospinal Fluid 
Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. , 
pp.3728–3736. 
Paganetti, H. et al., 2002. Relative biological effectiveness (RBE) values for proton beam 
therapy. International journal of radiation oncology, biology, physics, 53(2), pp.407–
21. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12023146. 
Pal, S. et al., 2014. Isoform-level gene signature improves prognostic stratification and 
accurately classifies glioblastoma subtypes. Nucleic acids research, pp.1–11. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/24503249 [Accessed April 7, 
2014]. 
Pathania, M. et al., 2017. H3.3 K27M Cooperates with Trp53 Loss and PDGFRA Gain in 
Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. 
Cancer Cell. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S153561081730418X [Accessed 
November 9, 2017]. 
Chapter 8: References 
Natalie Mayhead - August 2018   169 
Patrono, C., 2014. Polymorphisms in base excision repair genes: Breast cancer risk and 
individual radiosensitivity. World Journal of Clinical Oncology, 5(5), p.874. Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4259949&tool=pmcen
trez&rendertype=abstract. 
Paull, T.T. et al., 2000. A critical role for histone H2AX in recruitment of repair factors to 
nuclear foci after DNA damage. Current biology : CB, 10(15), pp.886–95. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10959836. 
Pegg, A.E., 2011. Multifaceted Roles of Alkyltransferase and Related Proteins in DNA 
Repair , DNA Damage , Resistance to Chemotherapy , and Research Tools. Chemical 
Research in Toxicology, 24, pp.618–639. 
Petersen, S. et al., 2001. AID is required to initiate Nbs1/γ-H2AX focus formation and 
mutations at sites of class switching. Nature, 414(6864), pp.660–665. Available at: 
http://www.nature.com/doifinder/10.1038/414660a. 
Prakrajanga, K. et al., 2013. MeV single-ion beam irradiation of mammalian cells using the 
Surrey vertical nanobeam, compared with broad proton beam and X-ray irradiations. 
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions 
with Materials and Atoms, 307, pp.586–591. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168583X13003303 [Accessed 
November 27, 2017]. 
Prasad, R. et al., 2010. Substrate channeling in mammalian base excision repair pathways: 
Passing the baton. Journal of Biological Chemistry, 285(52), pp.40479–40488. 
Prise, K.M. et al., 2010. Europe PMC Funders Group Microbeam Studies of the Bystander 
Response. , 50, pp.1–8. 
Redon, C. et al., 2002. Histone H2A variants H2AX and H2AZ. Current opinion in genetics & 
development, 12(2), pp.162–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11893489. 
Redon, C.E. et al., 2012. γ-H2AX and other histone post-translational modifications in the 
clinic. Biochimica et biophysica acta, 1819(7), pp.743–56. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22430255 [Accessed May 21, 2013]. 
Riballo, E. et al., 2004. A pathway of double-strand break rejoining dependent upon ATM, 
Artemis, and proteins locating to gamma-H2AX foci. Molecular cell, 16(5), pp.715–24. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/15574327. 
Ring, E. et al., 2011. Silicon nitride windows for electron microscopy of whole cells : 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
170  Natalie Mayhead - August 2018 
SILICON NITRIDE WINDOWS FOR ELECTRON MICROSCOPY OF WHOLE CELLS. 
Journal of Microscopy, 243(3), p.no. Available at: http://dx.doi.org/10.1111/j.1365-
2818.2011.03501.x. 
Rinne, M., Caldwell, D. & Kelley, M.R., 2004. Transient adenoviral N -methylpurine DNA 
glycosylase overexpression imparts chemotherapeutic sensitivity to human breast 
cancer cells Transient adenoviral N -methylpurine DNA glycosylase overexpression 
imparts chemotherapeutic sensitivity to human breast . , pp.955–967. 
Rogakou, E.P., 1998. DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation 
on Serine 139. Journal of Biological Chemistry, 273(10), pp.5858–5868. Available at: 
http://www.jbc.org/cgi/doi/10.1074/jbc.273.10.5858 [Accessed December 20, 
2013]. 
Romano, F.J. et al., 2016. Role of DNA repair machinery and p53 in the testicular germ cell 
cancer : a review. , 7(51), pp.85641–85649. 
Roots, R. & Okada, S., 1975. Estimation of Life Times and Diffusion Distances of Radicals 
DNA Strand Breaks Involved in X-Ray-Induced or Killing of Mammalian Cells ’. , 320, 
pp.306–320. 
Rubinson, E.H. et al., 2016. A New Protein Architecture for Processing Alkylation Damaged 
DNA : The Crystal Structure of DNA Glycosylase AlkD A New Protein Architecture for 
Processing Alkylation Damaged DNA : The Crystal Structure of DNA Glycosylase AlkD. 
, (September 2008). 
Sartori, A.A. et al., 2008. Europe PMC Funders Group Human CtIP promotes DNA end 
resection. Nature, 450(7169), pp.509–514. 
Saunders, W.M., 1985. RADIATION ONCOLOGY : THE USE OF BEAMS OF PHOTONS OR 
PARTICLES FOR THE TREATMENT OF TUMORS ec t Increasing tumor dose Optimal 
Tumor Treatment Dose. Radiation Physics and Chemistry, 24(3), pp.357–364. 
Schulte, A. et al., 2011. A distinct subset of glioma cell lines with stem cell-like properties 
reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as 
therapeutic target. Glia, 59(4), pp.590–602. 
Schultz, L.B. et al., 2000. p53 binding protein 1 (53BP1) is an early participant in the 
cellular response to DNA double-strand breaks. The Journal of cell biology, 151(7), 
pp.1381–1390. 
Scott, J.G. et al., 2012. Recursive partitioning analysis of prognostic factors for glioblastoma 
patients aged 70 years or older. Cancer, 118(22), pp.5595–600. Available at: 
Chapter 8: References 
Natalie Mayhead - August 2018   171 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3402652&tool=pmcen
trez&rendertype=abstract [Accessed April 8, 2014]. 
Shao, C. et al., 2005. Bystander signaling between glioma cells and fibroblasts targeted 
with counted particles. International Journal of Cancer, 116(1), pp.45–51. 
Shao, C. et al., 2003. Role of Gap Junctional Intercellular Communication in Radiation-
Induced Bystander Effects in Human Fibroblasts. Radiation research, 160, pp.318–
323. 
Shao, H. et al., 2015. Chip-based analysis of exosomal mRNA mediating drug resistance in 
glioblastoma. Nature Communications, 6(May), p.6999. Available at: 
http://www.nature.com/doifinder/10.1038/ncomms7999. 
Short, S. et al., 1999. Low dose hypersensitivity in the T98G human glioblastoma cell line. 
International journal of radiation biology, 75(7), pp.847–855. 
Silber, J.R. et al., 2012. O 6 -Methylguanine-DNA methyltransferase in glioma therapy : 
Promise and problems. Biochemical and Biophysical Research Communications- 
Reviews on Cancer, 1826(1), pp.71–82. Available at: 
http://dx.doi.org/10.1016/j.bbcan.2011.12.004. 
Silber, J.R. et al., 2002. The Apurinic/Apyrimidinic Endonuclease Activity of Ape1 / Ref-1 
Contributes to Human Glioma Cell Resistance to Alkylating Agents and Is Elevated by 
Oxidative Stress. , 8(September), pp.3008–3018. 
Silberstein, E.B., 2012. Radioiodine: The classic theranostic agent. Seminars in Nuclear 
Medicine, 42(3), pp.164–170. Available at: 
http://dx.doi.org/10.1053/j.semnuclmed.2011.12.002. 
Simon, A. et al., 2004. The new Surrey ion beam analysis facility. Nuclear Instruments and 
Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms, 
219–220(1–4), pp.405–409. 
Simsek, D., Furda, A., et al., 2011. Crucial roles for DNA ligase III in mitochondria but not in 
XRCC1-dependent repair. Nature, 471(7337), pp.245–248. 
Simsek, D., Brunet, E., et al., 2011. DNA ligase III promotes alternative nonhomologous 
end-joining during chromosomal translocation formation. PLoS genetics, 7(6), 
p.e1002080. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3107202&tool=pmcen
trez&rendertype=abstract [Accessed July 10, 2014]. 
Smith, S. a & Engelward, B.P., 2000. In vivo repair of methylation damage in Aag 3-
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
172  Natalie Mayhead - August 2018 
methyladenine DNA glycosylase null mouse cells. Nucleic acids research, 28(17), 
pp.3294–300. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=110696&tool=pmcent
rez&rendertype=abstract. 
Sobol, R.W. et al., 1996. Requirement of mammalian DNA polymerase-beta in base-excision 
repair. Nature, 379(6561), pp.183–186. 
Srivastava, D.K. et al., 1998. Mammalian Abasic Site Base Excision Repair. J. Biol. Chem., 
273(33), pp.21203–21209. 
Srivastava, N. et al., 2009. Role of H2AX in DNA damage response and human cancers. 
Mutation research, 681(2–3), pp.180–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18804552 [Accessed September 22, 2013]. 
Srivenugopal, K.S. et al., 1996. Ubiquitination-Dependent Proteolysis of O 6 -
Methylguanine-DNA Methyltransferase in Human and Murine Tumor Cells following 
Inactivation with O 6 -Benzylguanine. Biochemistry, 35, pp.1328–1334. 
Starcevic, D., Dalal, S. & Sweasy, J.B., 2004. Is There a Link Between DNA Polymerase Beta 
and Cancer? Cell Cycle, 3(8), pp.996–999. Available at: 
http://www.tandfonline.com/doi/abs/10.4161/cc.3.8.1062%5Cnhttp://www.ncbi.n
lm.nih.gov/pubmed/15280658%5Cnhttp://www.tandfonline.com/doi/abs/10.4161
/cc.3.8.1062. 
Stone, Lawrence & Aebersold, 1940. Preliminary report on the use of fast neutrons in 
treatment of malignant disease. Radiologylogy, 35, p.322. 
Strauss, P.R. et al., 1997. Substrate Binding by Human Apurinic / Apyrimidinic 
Endonuclease Indicates a Briggs-Haldane Mechanism *. , 272(2), pp.1302–1307. 
Stupp, R. et al., 2001. Current and future developments in the use of temozolomide for the 
treatment of brain tumours. The lancet oncology, 2(9), pp.552–60. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11905710. 
Stupp, R. et al., 2009. Effects of radiotherapy with concomitant and adjuvant 
temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised 
phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology, 10(5), 
pp.459–66. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19269895 
[Accessed July 11, 2014]. 
Stupp, R. et al., 2005a. Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. The New England journal of medicine, 352(10), pp.987–96. Available 
Chapter 8: References 
Natalie Mayhead - August 2018   173 
at: http://www.ncbi.nlm.nih.gov/pubmed/15758009. 
Stupp, R. et al., 2005b. Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. The New England journal of medicine, 352(10), pp.987–96. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/15758009. 
Suto, R.K. et al., 2003. Crystal Structures of Nucleosome Core Particles in Complex with 
Minor Groove DNA-binding Ligands. Journal of Molecular Biology, 326(2), pp.371–
380. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0022283602014079 
[Accessed December 28, 2013]. 
Svetlova, M.P., Solovjeva, L. V. & Tomilin, N. V., 2010. Mechanism of elimination of 
phosphorylated histone H2AX from chromatin after repair of DNA double-strand 
breaks. Mutation Research - Fundamental and Molecular Mechanisms of 
Mutagenesis, 685(1–2), pp.54–60. 
Talpaert-Borl, M. & Liuzzi, M., 1983. Reaction of apurinic/apyrimidinic sites with 
[14C]methoxyamine: A method for the quantitative assay of AP sites in DNA. 
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 740(4), 
pp.410–416. Available at: 
http://www.sciencedirect.com/science/article/pii/0167478183900891 [Accessed 
November 27, 2017]. 
Talpaert-Borlè, M., 1987. Formation, detection and repair of AP sites. Mutation Research - 
Fundamental and Molecular Mechanisms of Mutagenesis, 181(1), pp.45–56. 
Tang, J. et al., 2011. N-methylpurine DNA glycosylase and DNA polymerase B modulate 
BER inhibitor potentiation of glioma cells to temozolomide. NEURO-ONCOLOGY, 
13(5), pp.471–486. 
Taverna, P. et al., 2001. Methoxyamine potentiates DNA single strand breaks and double 
strand breaks induced by temozolomide in colon cancer cells. Mutation research, 
485(4), pp.269–81. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11585361. 
Tebbs, R.S. et al., 1999. Requirement for the Xrcc1 DNA base excision repair gene during 
early mouse development. Developmental biology, 208(1999), pp.513–529. 
Thomas, M.D.R. & Warrington, A.P., 2006. GafChromic® RTQA film for routine quality 
assurance of high-energy photon beams GafChromic R RTQA film for routine quality 
assurance of high-energy photon beams. Phys. Med. Biol. Phys. Med. Biol, 51141(51), 
pp.1439–1447. Available at: http://iopscience.iop.org/0031-9155/51/6/005. 
Thompson, L.H., 2012. Recognition, signaling, and repair of DNA double-strand breaks 
produced by ionizing radiation in mammalian cells: the molecular choreography. 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
174  Natalie Mayhead - August 2018 
Mutation research, 751(2), pp.158–246. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22743550 [Accessed July 14, 2014]. 
Vermeulen, C. et al., 2007. Role for DNA polymerase beta in response to ionizing radiation. 
DNA Repair, 6(2), pp.202–212. 
Vidal, A.E. et al., 2001. XRCC1 coordinates the initial and late stages of DNA abasic site 
repair through protein-protein interactions. EMBO Journal, 20(22), pp.6530–6539. 
Vredenburgh, J.J. et al., 2007. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma 
Multiforme. Journal of Clinical Oncology, 25(30), pp.4722–4729. Available at: 
https://doi.org/10.1200/JCO.2007.12.2440. 
Waligórski, M.P.R. et al., 2004. Cellular parameters and RBE-LET dependences for 
modelling heavy-ion radiotherapy. Radiotherapy and oncology : journal of the 
European Society for Therapeutic Radiology and Oncology, 73 Suppl 2(3), pp.S173-5. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/15971337. 
Wallace, S.S., Murphy, D.L. & Sweasy, J.B., 2013. Base Excision Repair and Cancer. Cancer 
Lett, 327(327), pp.73–89. 
Walsh, D.W.M. et al., 2017. Live cell imaging of mitochondria following targeted irradiation 
in situ reveals rapid and highly localized loss of membrane potential. Scientific 
Reports, 7(October 2016), p.46684. Available at: 
http://www.nature.com/articles/srep46684. 
Wang, D. et al., 2009. APE1 overexpression is associated with cisplatin resistance in non-
small cell lung cancer and targeted inhibition of APE1 enhances the activity of 
cisplatin in A549 cells. Lung Cancer, 66(3), pp.298–304. 
Watanabe, S. et al., 2003. Methylated DNA-binding domain 1 and methylpurine-DNA 
glycosylase link transcriptional repression and DNA repair in chromatin. Proceedings 
of the National Academy of Sciences of the United States of America, 100(22), 
pp.12859–64. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=240709&tool=pmcent
rez&rendertype=abstract. 
Weil, M.K. & Chen, A., 2012. PARP Inhibitor Treatment in Ovarian and Breast Cancer. 
National Institute of Health, 35(301), pp.1–43. 
Weiss, G.J. et al., 2010. Final results from a phase I study of oral TRC102 (methoxyamine 
HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in 
patients with refractory cancer. Journal of Clinical Oncology, 28(15_suppl), p.2576. 
Chapter 8: References 
Natalie Mayhead - August 2018   175 
Available at: https://doi.org/10.1200/jco.2010.28.15_suppl.2576. 
Wéra,  a-C. et al., 2014. Influence of the nucleus area distribution on the survival fraction 
after charged particles broad beam irradiation. Physics in medicine and biology, 
59(15), pp.4197–211. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25017303 [Accessed August 26, 2014]. 
Werbrouck, J. et al., 2013. Early biomarkers related to secondary primary cancer risk in 
radiotherapy treated prostate cancer patients: IMRT versus IMAT. Radiotherapy and 
oncology : journal of the European Society for Therapeutic Radiology and Oncology, 
pp.1–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23791364 [Accessed 
June 26, 2013]. 
Weterings, E. & van Gent, D.C., 2004. The mechanism of non-homologous end-joining: a 
synopsis of synapsis. DNA repair, 3(11), pp.1425–35. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15380098 [Accessed October 21, 2013]. 
Whittle, I.R. et al., 2010. Assessment of physiological parameters within glioblastomas in 
awake patients: a prospective clinical study. British Journal of Neurosurgery, 24(4), 
pp.447–453. Available at: 
http://www.tandfonline.com/doi/full/10.3109/02688691003746290. 
Wick, W. et al., 2012. EORTC topics in neurooncology: The long path from a focus on 
neurological complications of cancer towards molecularly defined trials and 
therapies in neurooncology. European Journal of Cancer, Supplement, 10(1), pp.20–
26. 
Wick, W. & Platten, M., 2014. Understanding and targeting alkylator resistance in 
glioblastoma. Cancer Discovery, 4(10), pp.1120–1122. 
Williams, M.V., Denekamp, J. & Fowler, J.., 1985. A review of αβ ratios for experimental 
tumors: Implications for clinical studies of altered fractionation. International Journal 
of Radiation Oncology*Biology*Physics, 11(1), pp.87–96. Available at: 
http://www.sciencedirect.com/science/article/pii/0360301685903669?via%3Dihu
b [Accessed November 16, 2017]. 
World health organisation, 2013. World Health Organisation: Cancer statistics. 
Wyatt, M.D. & Pittman, D., 2006. Methylating Agents and DNA Repair Responses: 
Methylated Bases and Sources of Strand Breaks. Chemical Research in Toxicology, 
19(4), pp.7–20. 
Xi, T., Jones, I.M. & Mohrenweiser, H.W., 2004. Many amino acid substitution variants 
identified in DNA repair genes during human population screenings are predicted to 
Modulation of the Base Excision Repair (BER) pathway in the treatment of 
glioblastoma with radiotherapy 
176  Natalie Mayhead - August 2018 
impact protein function. Genomics, 83(6), pp.970–979. 
Xiang, D.-B. et al., 2008. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA 
enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in 
vivo. Cancer gene therapy, 15(10), pp.625–635. 
Yan, L. et al., 2007. Combined treatment with temozolomide and methoxyamine: Blocking 
apurininc/pyrimidinic site repair coupled with targeting topoisomerase II?? Clinical 
Cancer Research, 13(5), pp.1532–1539. 
Yang, J. et al., 2010. Cells deficient in the base excision repair protein, DNA polymerase 
beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene, 29(3), pp.463–468. 
Yang, S. et al., 2012. Development and validation of an LC-MS/MS method for 
pharmacokinetic study of methoxyamine in phase I clinical trial. Journal of 
Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 901, 
pp.25–33. Available at: http://dx.doi.org/10.1016/j.jchromb.2012.05.036. 
Yokoya,  a. et al., 2008. DNA damage induced by the direct effect of radiation. Radiation 
Physics and Chemistry, 77(10–12), pp.1280–1285. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0969806X08001370 [Accessed August 
6, 2014]. 
Zhang, J., Stevens, M.F.G. & Bradshaw, T.D., 2012. Temozolomide: mechanisms of action, 
repair and resistance. Current molecular pharmacology, 5(1), pp.102–14. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/22122467. 
Zhang, Y. et al., 2005. Reconstitution of 5′-directed human mismatch repair in a purified 
system. Cell, 122(5), pp.693–705. 
Zhao, G. et al., 2005. Mutation of DNA polymerase β in esophageal carcinoma of different 
regions. , 11(30), pp.4618–4622. 
Zienolddiny, S. et al., 2006. Polymorphisms of DNA repair genes and risk of non-small cell 
lung cancer. Carcinogenesis, 27(3), pp.560–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16195237 [Accessed April 2, 2014]. 
Zirkle, R. & Bloom, W., 1953. Irradiation of Parts of Individual Cells. Science, 117(1), 
pp.487–493. 
 
 
